inspired patient driven science terry living parkinson disease annual report nele living lupus carola living parkinson disease letter stakeholder ii management report board director corporate governance statement business performance review operating financial review iii consolidated financial statement iv note consolidated financial statement v responsibility statement vi report statutory auditor vii abbreviated statutory financial statement ucb sa viii corporate societal responsiblity performance report neil scientist ucb slough carrie living crohn disease u c b n n u l r e p rt inspired patient driven science sten living deonna restless leg syndrome living ra rafaelle living epilepsy christer living mercedes mother parkinson disease son living epilepsy lakeisha bernadette living epilepsy living lupus vivian living osteoporosis victor living epilepsy tom living crohn disease u c b n n u l r e p rt advancing pipeline central nervous system cns phase phase phase filing neupro rotigotine advanced parkinson disease japan neupro rotigotine restless leg syndrome japan brivaracetam epilepsy pos adjunctive therapy vimpat lacosamide epilepsy pos monotherapy u vimpat lacosamide epilepsy pos monotherapy eu vimpat lacosamide epilepsy pos adjunctive therapy asia vimpat lacosamide epilepsy pos paediatric adjunctive therapy vimpat lacosamide epilepsy pgtcs adjunctive therapy cns partner japan otsuka partialonset seizure primary generalised tonic clonic seizure immunology phase phase phase filing cimzia certolizumab pegol rheumatoid arthritis japan cimzia certolizumab pegol axial spondyloarthritis cimzia certolizumab pegol psoriatic arthritis epratuzumab systemic lupus erythematosus cimzia certolizumab pegol juvenile idiopathic arthritis romosozumab sclerostin antibody postmenopausal osteoporosis cdp anticdl systemic lupus erythematosus ucb immunological disease u c b n n u l r e p rt key figure revenue rebitda core eps million million e revenue net sale rd expense ratio rd expense revenue recurring ebit rebit recurring ebitda ratio rebitda revenue net profit core eps per nondiluted share net debt ratio net debt rebitda equity ratio cash flow operating activity capital expenditure including intangible asset employee function yearend employee region yearend administration belgium north america marketing sale france total total rest world germany manufacturing italy asia pacific australia uk spain rd eu others eu others ustria bulgaria czech republic denmark finland greece hungary ireland luxembourg netherlands poland portugal romania slovakia sweden asia pacific australia australia china hongkong india japan south korea rest world brazil kazakhstan mexico norway russia switzerland turkey ukraine north america canada u u c b n n u l r e p rt milestone rd milestone cimzia rheumatoid arthritis japan filing jan psoriatic arthritis phase result feb rheumatoid arthritis start phase cearly study feb juvenile idiopathic arthritis start phase mar axial spondyloarthritis phase result apr rheumatoid arthritis japan approval dec vimpat epilepsy pgtcs adjunctive therapy phase result jan epilepsy po adjunctive therapy asia start phase nov neupro parkinson disease restless leg syndrome u approval apr parkinson disease restless leg syndrome eu approval room temperature stable patch aug parkinson disease restless leg syndrome japan approval dec romosozumab postmenopausal osteoporosis start phase apr olokizumab rheumatoid arthritis phase topline result sept financial performance billion revenue million rebitda core eps partnership ucb strengthens strategic alliance wilex jan aug ucb astellas announce agreement jointly develop commercialize cimzia japan jan ucb nodality enter multiyear strategic collaboration feb ucb oxford university announce new rd partnership mar ucb expands brazil may ucbharvard research alliance expands move forward june oct ucb newbridge pharmaceutical partner middle east african market nov biotie therapeutic reported positive phase b topline result tozadenant parkinson disease dec u c b n n u l r e p rt corporate governance gerhard mayr became chairman board may anna richo appointed executive vice president general counsel nov bob trainor executive vice president general counsel retired dec greg duncan executive vice president president north american operation left feb new organizational structure deliver superior sustainable value patient feb gerhard mayr chairman board anna richo executive vice president general counsel cimzia vimpat reaching patient living crohn reaching patient disease rheumatoid arthritis across country living epilepsy across country million net sale million net sale approval japan dec indication development filing feb indication development neupro keppra reaching patient living reaching thousand patient living parkinson disease restless leg syndrome epilepsy across country across country million net sale million net sale sale increase rest world launch u july approval japan dec u c b n n u l r e p rt letter stakeholder gerhard mayr roch doliveux chairman chief executive officer inspired patient driven science rosanne carer child epilepsy u c b n n u l r e p rt l e tt e r h e sta k e h l e r frauke living type diabetes friend jerome living epilepsy dear shareholder partner colleague living severe disease completed ucbs transformation patientcentric biopharmaceutical company thanks remarkable achievement colleague ucb expect company growth many year driven core medicine emerging market new breakthrough achieving target year ucb reached crossover point ucbs performance emerging market another key net sale new core medicine exceeded driver growth sale million versus keppra ucbs leading medicine many year previous year constant exchange rate core medicine cimzia vimpat neupro cvn acquisition majority stake meizler brazil mean achieved combined sale million touching presence major emerging market life nearly people living selected targeted ucb immunological neurological disorder overall achieved financial target revenue moreover keppra performed better expected reaching billion intense rd investment resisting generic competition europe u advance pipeline well expense launch enjoying intense growth asia driven japan neupro u resulting underlying profitability e keppra copromoted otsuka leading cns reassured recurring ebitda million net company japan medicine market profit tax million translating core exclusivity least earnings per share line stable dividend policy considers longterm potential company board director proposed gross dividend per share u c b n n u l r e p rt l e tt e r h e sta k e h l e r anne scientist ucb brainelalleud investing revenue promising pipeline new medicine strengthening pipeline ucbs financial achievement complemented phase development ucbs rich pipeline three new significant progress pipeline example potential medicine continues strengthen romozosumab neupro approved launched u sclerostin antibody potential breakthrough bone treatment parkinson disease pd restless leg loss disorder entered phase postmenopausal syndrome rls neupro also approved japan osteoporosis codeveloped partner december well cimzia first half amgen addition epratuzumab potential novel launch cimzia japan partner treatment lupus brivaracetam epilepsy astellas leading immunology company japan continued progress phase neupro marketed otsuka also differentiated cimzia label u europe early stage pipeline focus potential competitor completed phase program breakthrough offer true differentiation major new indication cimzia axial systematically discontinue project wealth spondyloarthritis well psoriatic arthritis combined quality pipeline internal external allows prevalence two disease half u make choice consequently one hand current indication decided pursue olokizumab phase hand one external program tozadenant novel oral therapy parkinson disease developed partner biotie achieved positive phase b result december u c b n n u l r e p rt l e tt e r h e sta k e h l e r christer living parkinson disease ensuring quality compliance across ucb continued operate highest broad responsibility commitment society standard quality safety compliance example embracing environmental social dimension passed inspection regulatory agency effort recognized ucb reached top critical finding identified wci world sustainable company according industry leader drug safety approach benefit corporate knight torontobased specialized medium risk governance also successfully implemented financial information product company corporate integrity agreement u second last least engagement colleague year running ucb measure annual company strengthened reputation leading wide survey continued strengthen surpassing biopharmaceutical company new corporate industry standard according survey provider societal responsibility csr strategy societal reflects u c b n n u l r e p rt l e tt e r h e sta k e h l e r neil scientist ucb slough patientcentricity valued medicine health solution make difference people living severe disease ucb entering position strength u cbs advance impressive given finally information throughout health care system force impacting global biopharmaceutical becoming transparent extent never experienced industry industry major inflection point build basis comparison insight combined technological scientific advance one hand face substantial challenge create foundation even better including expiry important patent stiffer economical healthcare people generic competition declining rd investment rising rd cost per project additionally economic new environment innovative biopharmaceutical crisis forced government europe beyond company capable rapidly harnessing tighten healthcare expenditure power contemporary technology affect industry commercial prospect could advantage complex environment company also impede patient access new medicine able provide sustainable value people developing developed country living severe disease internal capability alone partner build strategic alliance hand force demographic combine strength building unique advantage aging spendable power baby boomer power energizing technology advance inflection point new leader emerge ucb science provide unique opportunity innovative aspires one leader new biopharmaceutical biopharmaceutical company time leader focus bringing solution people consumer patient getting information suffer severe disease able share power greater accountability expected value bring patient payer u c b n n u l r e p rt l e tt e r h e sta k e h l e r implementing clear strategy carrie living crohn disease inspired patient driven science ince ucbs strategy focused research strategy focus first secondin delivering superior sustainable solution class innovative approach prioritizing project people live severe disease targeting clear proof concept clear end point two set severe disease neurological disease focus manufacturing network rd scaleup disease immune system special focus launch appropriate augment internal rheumatologic gastroenterologic disease capability using strategic partnership large area constantly strive better understand small molecule commercial phase product patient serve using contemporary science securing costeffective supply completed create unique solution efficient way deliver biotech pilot plant belgium progressing buildout commercialscale manufacturing five key enablers lie behind strategy biotech plant switzerland initially intended manufacture cimzia f ostering connectivity example connecting best university biotech company commercial strategy presence patient caregiver covering specialist physician payer patient group well payer north america europe major emerging market developing diverse connected talent focusing china india russia brazil mexico turkey ensuring compliance rule regulation collectively account pharmaceutical ruthlessly eliminating noncore activity emerging market r eaching competitive profitability second half area continue learn bestinclass decade company outside biopharma industry area innovation customer insight cost management activitybased management u c b n n u l r e p rt l e tt e r h e sta k e h l e r net sale geographical area million france germany italy north america spain uk ireland eu rest world asia japan helping thousand patient across country priority aspiring superior growth result strategy ucb aim exceed result ucb expects revenue grow biopharma industry compounded growth also expect lowsingledigit percent excluding exchange rate impact invest peer rd proportionally approximately billion recurring ebitda sale gradually reaching peer profitability million core eps range lower marketing selling expense well general based million share administrative expense peer major patent expiry many year ucb focus priority three new core medicine fueling growth plus growing cimzia vimpat neupro reach rich pipeline cutting edge science ucb patient poised build strong global presence neurology building emerging market business immunology deliver significant return shareholder thanks current performance advancing latestage pipeline growth core medicine confirm ambition bringing innovative breakthrough potential medicine reach million patient cimzia human clinical trial vimpat neupro representing peak sale least ensuring quality compliance law billion second half decade regulation improving profitability versus peer strict focus value creation activity developing passionately engaged colleague business partner u c b n n u l r e p rt l e tt e r h e sta k e h l e r people living severe disease meeting ucb employee orchestrate forum achievement past present future energy every day make difference would possible without insight life people living severe disease work patient physician payer regulator impact life know committed follow commitment colleague partner strict regulatory standard research development support shareholder leadership manufacturing distribution product board would like thank ensure meet safety quality regulatory legal environmental requirement without effort would especially like thank people live would making happen severe disease family physician payer insight feedback knowledge last least thanks go ucb board inspiration director governance experience expertise well support challenging contribution also sincerely grateful talented committed diverse team ucb employee around ucb inspired patient driven science globe human talent greatest asset committed bring superior sustainable value organization wish recognize every patient stakeholder one engaged colleague invest much sincerely roch doliveux gerhard mayr chief executive officer chairman u c b n n u l r e p rt l e tt e r h e sta k e h l e r upcoming milestone rd milestone cimzia axial spondyloarthritis filing u eu feb cimzia psoriatic arthritis filing u eu feb vimpat epilepsy po monotherapy u phase result q vimpat epilepsy po paediatric adjunctive therapy start phase h epratuzumab systemic lupus erythematosus phase result h vimpat epilepsy po monotherapy eu phase result q cimzia juvenile idiopathic arthritis phase result h brivaracetam epilepsy po adjunctive therapy phase result h vimpat epilepsy po adjunctive therapy asia phase result h romosozumab postmenopausal osteoporosis phase result end cimzia cearly rheumatoid arthritis phase result cimzia exxelerate rheumatoid arthritis phase result cvn peak sale cimzia vimpat neupro billion billion million financial guidance billion revenue million rebitda core eps u c b n n u l r e p rt ii ii management report board director corporate governance statement business performance review operating financial review corporate governance statement director auditor board director gerhard mayr chair evelyn du monceau vice chair roch doliveux executive director albrecht de graeve director arnoud de pret director harriet edelman director peter fellner director charlesantoine janssen director jeanpierre kinet director tom mckillop director norman j ornstein director bridget van rijckevorsel director inge basteleurs secretary board december statutory auditor p ricewaterhousecoopers represented permanent representative jean fossion honorary director andré jaumotte honorary chair mark eyskens honorary chair george jacob de hagen honorary chair karel boone honorary chair daniel janssen honorary deputy chair prince lorenz belgium alan blinken michel didisheim eric janssen guy keutgen paul etienne maes gaëtan van de werve jeanlouis vanherweghem honorary chairman executive committee daniel janssen p aul etienne maes george jacob de hagen u c b n n u l r e p rt ii n g e e n r e p rt f h e b ar f r e ct r belgianheadquartered company commitment committee executive committee charter highest standard corporate governance board corporate governance annually updated december director hereafter board ucb sa nv reviewed board line code hereafter ucb adopted charter corporate interpretation governance october required belgian accordance belgian company code code corporate governance first edition code following page provide factual information required article belgian company code ucb ucbs corporate governance includes change adopted belgian code corporate governance ucbs corporate governance together relevant second edition march hereafter code event took place change reference code corporate governance taking account ucbs capital shareholder structure modification specific international aspect ucb ucbs governance board committee charter corporate governance available composition main feature ucbs internal control ucb website wwwucbcominvestorsgovernance risk management system remuneration report charter describes main aspect ucbs corporate also includes explanation applicable governance including governance structure deviation code term reference board well capital share capital warrant capital ucb modified respectively ucb issued december amounted warrant represented share issued warrant expired warrant issued confer share right subscribe one ordinary share following cancellation expiration exercise part since february share capital ucb warrant warrant still exercised represented share hereafter ucb share may ucb share may registered dematerialized share request shareholder may bearer share defensive warrant also issued following decision accordance law general meeting shareholder ucb hereafter general meeting excluding preferential right loan since january shareholder longer request represented loan stock unit ucb share converted bearer ucb nominal value warrant attached share pursuant belgian law december confers right joint subscription million bearer ucb share registered custody account ordinary ucb share subscribed financière de investment account automatically converted tubize sa ucbs reference shareholder april dematerialized ucb share january january bearer ucb share deposited adhoc committee set meeting registration custody investment account meeting also appointed member committee automatically converted dematerialized ucb share committee decides predefined circumstance implementation warrant approval fully paid ucb share registered transfer warrant holder warrant may transferred prior approval board entered agreement ucb ensuring compliance registered ucb share recorded special register condition issuance exercise warrant ucb share admitted listing trading nyse euronext brussels proposed annual shareholder meeting april cancel possibility bearer share within ucb belgian code corporate governance second edition published march available website belgian corporate governance committee httpwwwcorporategovernancecommitteebe u c b n n u l r e p rt ii n g e e n r e p rt f h e b ar f r e ct r treasury share warrant may exercised adhoc committee ucb acquired sold ucb decides one predefined circumstance associated share december ucb held hostile takeover bid occurs total ucb share share assimilated security representing launch takeover bid third party judged total number ucb share hostile board ucb fipar sa affiliate indirectly controlled ucb change control ucb due transaction relating acquired ucb share ucb share ucb stock one third party carried either ucb share ucb share stock market isolation concerted ucb share ucb share manner december ucb fipar sa held total threat takeover bid operation involving ucb share share change control ucb assimilated security representing total number ucb share defensive warrant agreement holder defensive warrant ucb expire ucb sca affiliate indirectly controlled ucb april ucb share arising exercise acquired ucb share ucb share warrant issued reference market price ucb share ucb share period prior issuance december ucb sca longer hold ucb share convertible bond ucb share acquired ucb ucb fipar sa ucb sca order cover part ucbs obligation ucb issued senior unsecured bond due resulting employee stock option plan stock award aggregate principal amount million placed plan performance share plan ucb cover part institutional investor following accelerated bookbuilding ucbs obligation resulting convertible bond procedure september hereafter convertible bond extraordinary general meeting decided additional detail please refer note treasury share november attach conversion right bond according decision general meeting held convertible bond denomination november board authorized unlimited may converted december duration time accordance article section october conversion price per belgian company code dispose ucb ucb share upon receipt conversion request share outside stock exchange way sale bondholder board option sole discretion exchange contribution kind disposal ucbs best interest issue new ucb share ii authorization also cover disposal ucb share held deliver existing ucb share iii make combination direct subsidiary ucb within meaning article two option belgian company code convertible bond converted according decision meeting board new ucb share current conversion price ucb would board director ucbs direct subsidiary issue new share conversion price may authorized period five year starting revised accordance antidilution provision november acquire ucb share maximum accordance term condition bond total number ucb share exchange value case change control equivalent closing price ucb share euronext brussels day immediately preceding acquisition ucb lux sa purchased april amount plus maximum minus maximum taking million nominal convertible bond thereafter also account applicable legal requirement sold option equivalent one embedded bond ucb proposed general meeting april bond listed euro mtf market institute authorized capital luxembourg stock exchange odify modality authorization proposed general meeting april replacing limit upper limit highest allow dematerialized register bond stock exchange course day lower floor one euro renewing authorization ahead term period year starting april u c b n n u l r e p rt ii n g e e n r e p rt f h e b ar f r e ct r hareholders shareholder structure ucbs main shareholder financière de tubize sa financière de tubize act concert schwarz company listed euronext brussels hereafter financière de vermögensverwaltung gmbh co kg tubize reference shareholder holding listed table financière de tubize made transparency notification hereunder share covered agreement holding ucb september subsequent including share held financière de tubize represent notification compliance law may share capital ucb publication significant shareholding listed company financière de tubize held janssen family according article law may remainder ucb share held public accordance latest subsequent notification made compliance law may present ucb major shareholder ucb controlling major shareholder december date according notification compliance current voting law may capital share financière de tubize sa tubize october ucb sa december assimilated securities june option april ucb fipar sa december assimilated security april schwarz vermögensverwaltung gmbh co kg october tubize linked company concert excluding option december capital group company september vanguard health care fund march please see press release june option exercised would represent additional voting right information regarding assimilated security option required law tubize declared acting concert schwarz vermögensverwaltung gmbh co kg communication virtue article law april relating public takeover bid made jointly stable shareholder ucb ucb received communication made respectively november december december following shareholder acting concert virtue article law april summary since september date voting right shareholder allocated follows september december financière de tubize schwarz vermögensverwaltung gmbh co kg ucb sa ucb fipar sa total voting right voting right share ucb sa held ucb sa affiliate suspended compliance article belgian company code u c b n n u l r e p rt ii n g e e n r e p rt f h e b ar f r e ct r oard director board committee b board director composition board mandate roch doliveux albrecht de graeve independent director peter fellner expire next general meeting held april assessed potential january april composition candidate gncc proposed board board follows mandate renewed proposal submitted karel boone chair next shareholder general meeting evelyn du monceau vice chair tom mckillop reached age limit board roch doliveux executive director meeting december decided make exception albrecht de graeve director age limit article corporate governance arnoud de pret director charter tom mckillop given exceptional experience peter fellner director expertise retired ceo major pharmaceutical jeanpierre kinet director company light scientific background thomas leysen director gerhard mayr director peter fellner reelected start fourth term tom mckillop director director solely reason longer qualify norman j ornstein director independent director per applicable law gaëtan van de werve director pursuant article belgian company code bridget van rijckevorsel director ucb declares currently three female director board board member replacement alexandre van damme resigned director appointment board considered ucb via march board governance nomination compensation committee gncc systematically taking account general meeting held april enhancing diversity board includes searching thomas leysen gaëtan van de werve resigned senior female profile could add complementary value director tom mckillop reelected term board four year independent director harriet edelman charlesantoine janssen functioning board elected director term four year board met seven time attendance rate harriet edelman independent director april member follows roch doliveux executive director ucb qualify independent director gerhard mayr chair evelyn du monceau vice chair evelyn du monceau arnoud de pret bridget van rijckevorsel roch doliveux executive director charlesantoine janssen representative reference shareholder eligible albrecht de graeve qualify independent director arnoud de pret harriet edelman gerhard mayr albrecht de graeve harriet edelman peter fellner peter fellner jeanpierre kinet tom mckillop charlesantoine janssen norman ornstein meet independence criterion stipulated jeanpierre kinet belgian company code board code tom mckillop present composition board director norman j ornstein follows bridget van rijckevorsel since april first appointed end term independent board main area discussion review director office director decision ucbs strategy report gerhard mayr chair x audit committee gncc ucbs corporate evelyn du monceau governance organization risk risk management vice chair succession planning structuring ucb group roch doliveux tax strategy appointment reserved board executive director remuneration policy management financial albrecht de graeve x reporting rd debt refinancing investment program arnoud de pret business development proposal financial commercial harriet edelman x partnership license agreement divestments noncore peter fellner x activity asset report resolution proposal charlesantoine janssen shareholder published invitation general jeanpierre kinet x meeting compliance belgian company code tom mckillop x transaction contractual relationship norman j ornstein x ucb including affiliated company bridget van rijckevorsel member board giving rise conflict interest u c b n n u l r e p rt ii n g e e n r e p rt f h e b ar f r e ct r tom mckillop participate secretary four meeting partly attended discussion regarding granting exception age andré van der toorn vice president treasure risk limit stipulated article corporate management two meeting partly attended governance charter bo iversen vice president tax douglas minder director financial collaboration ifrs competence center board started induction program spread rené broekhuis vice president corporate compensation four induction session new director cover benefit one meeting entirely attended various area expertise required biopharmaceutical anna richo executive vice president deputy general company counsel partly attended robert trainor executive session legal intellectual property internal audit vice president general counsel caroline vancoillie senior quality assurance drug safety corporate health safety director reporting consolidation raf remijsen director environment hse risk management treasury corporate finance aaron bartlone senior vice president corporate sa h session finance investor information according term reference see charter session people ucb corporate governance available ucb website session global technical operation audit committee monitored financial reporting process company internal control risk management system assessment board effectiveness internal audit effectiveness board conducted internal assessment statutory audit annual consolidated account functioning well contribution success ucb independence external auditor including set strategic mission aim optimize provision additional service ucb audit composition operation board committee committee reviewed authorized fee addition well interaction ceo executive audit committee reviewed impairment corporate committee conducted chair board restructuring project equity value subsidiary chair gncc risk management including litigation tax ifrs external auditor satisfaction survey board committee governance nomination compensation committee gncc audit committee board set governance nomination board set audit committee compensation committee gncc composition composition functioning term reference april december follows accordance belgian company code composition audit committee end term independent office director april follows evelyn du monceau chair end term independent office director gerhard mayr x tom mckillop x arnoud de pret chair albrecht de graeve x majority member gncc meet gerhard mayr x independence criterion set article ter belgian company code member competency albrecht de graeve gerhard mayr fulfill expertise required matter remuneration independence criterion set article ter belgian policy required article quater belgian company code member competency company code accounting audit matter required article gncc met four time attendance rate bis belgian company code audit member committee attended committee composition complies belgian roch doliveux chair executive committee company code requiring least one member except discussing issue relating independent director code recommends majority fabrice enderlin executive vice president human resource member audit committee independent communication act secretary except case discussing issue relating ceo compensation audit committee met four time according term reference see charter attendance rate member except corporate governance available ucb website albrecht de graeve whose attendance rate gncc reviewed appointment proposal submitted external auditor attended part meeting board approval performance executive audit committee part without management presence committee member remuneration reviewed internal external auditor presence succession planning ceo member audit committee meeting attended executive committee reviewed submitted detlef thielgen executive vice president chief financial board approval remuneration policy longterm officer doug gingerella senior vice president global incentive granted company management internal audit olaf elbracht vice president reporting performance criterion grant linked consolidation three time inge basteleurs vice president legal affair secretary general acted u c b n n u l r e p rt ii n g e e n r e p rt f h e b ar f r e ct r executive committee gncc april tasked board composition executive committee supervise report governance ucb since january october composition responsible corporate governance charter executive committee follows corporate governance statement roch doliveux ceo chair executive committee scientific committee greg duncan executive vice president president june board set amongst north american operation member scientific committee assist board review quality ucb rd science competitive fabrice enderlin executive vice president corporate standing human resource communication committee member outstanding scientific ismail kola executive vice president president medical expertise following ucb newmedicines iris löwfriedrich executive vice president global project end term independent office director development chief medical officer peter fellner x mark mcdade executive vice president global operation jeanpierre kinet x jeanchristophe tellier executive vice president president european operation scientific committee met three time detlef thielgen executive vice president attendance rate member chief financial officer member scientific committee meet robert trainor executive vice president regularly executive vicepresident president general counsel december ucb newmedicines member scientific december robert trainor retired executive committee also closely involved activity ucbs vice president general counsel november scientific advisory board sab composed external anna richo joined executive committee executive leading scientific medical expert sab created vice president deputy general counsel january september executive committee critically anna richo replaced robert trainor executive review rd activity ucb provide scientific appraisal vice president general counsel strategic input best way ucb become thriving biopharmaceutical leader advise greg duncan left ucbs executive committee end executive committee strategic choice related january early stage rd scientific committee report since february composition executive board sabs appraisal ucbs research activity committee hence follows strategic orientation roch doliveux ceo chair executive committee fabrice enderlin executive vice president corporate human resource communication corporate societal responsibility ismail kola executive vice president president ucb newmedicines iris löwfriedrich executive vice president biopharma development solution chief medical officer mark mcdade executive vice president established brand solution supply anna richo executive vice president general counsel jeanchristophe tellier executive vice president biopharma brand solution detlef thielgen executive vice president chief financial officer functioning executive committee executive committee met two three day month transaction contractual relationship ucb including related company member executive committee u c b n n u l r e p rt ii n g e e n r e p rt f h e b ar f r e ct r remuneration report remuneration report describes ucbs executive remuneration nonexecutive director remuneration policy executive compensation level ucbs board member compensated service set remuneration policy form part broader cashbased compensation program level set human resource policy including performance pay set based benchmark include management talent development governance remuneration board member comparable european nomination compensation committee gncc biopharmaceutical company pay consists fixed oversees executive compensation policy plan annual retainer varying size based director committee role responsibility set forth mandate fee per meeting attended longterm corporate charter adopted board director equity incentive granted also form variable pay level pay approved ucbs global reward principle general meeting shareholder april new market assessment presented gncc accomplish company goal within highly competitive february leading new proposal global biopharma environment need qualified submitted board endorsement annual talented executive working high performance culture general assembly approval remuneration foster type culture fully engaged employee level ucb director follows critical competitive global reward program objective ucb global reward program annual fee fair equitable according market practice c hairman board recognize reward high performance v ice chair irectors link executive pay individual contribution overall success ucb board attendance fee provide strong motivation reinforcing business c hairman board per meeting strategy achievement corporate goal v ice chair per meeting enable u attract retain industry best talent irectors per meeting global level audit committee governance nomination global reward program support drive vision compensation committee annual compensation senior executive variable pay make c hairman board committee significant component total remuneration offering ember board committee variable pay program closely linked short term longterm individual company performance scientific advisory committee annual compensation development ucb ember committee remuneration policy application rule total remuneration policy remuneration member director board committee member ucb executive committee set board basis follows recommendation gncc gncc meet least twice per year time gerhard mayr chairman k arel boone ended april considers market factor affecting company current future pay practice e velyn du monceau vice chair r och doliveux executive director evaluates effectiveness remuneration policy albrecht de graeve term recognising performance determines appropriate evolution plan rnoud de pret peter fellner r eviews financial target different performance jeanpierre kinet based compensation program homas leysen ended april etermines compensation level ucbs tom mckillop management team norman j ornstein remuneration policy ensures compensation b ridget van rijckevorsel program member executive committee gaëtan van de werve ended april including equity incentive pension scheme termination arrangement fair appropriate attract retain lexandre van damme ended march motivate management team c harlesantoine janssen since april h arriet edelman since april u c b n n u l r e p rt ii n g e e n r e p rt f h e b ar f r e ct r statement remuneration policy applied reported year remuneration executive director section discusses competitive positioning strategy throughout performance period ongoing ucb adopts market operates achievement monitored moment vesting also provides overview executive compensation payout final result validated corporate structure purpose different element pay finance department final approval audit link pay performance committee addition base salary performance related incentive pay executive eligible range benchmark total reward program benefit perquisite line market compensation practice per global reward principle remuneration package intend fair appropriate attract retain ucb implemented significant change motivate management also must reasonable executive reward program introduction new view company economics relevant practice upper management compensation policy change comparable global biopharmaceutical company result ongoing drive strengthen link reward program executive contribution gncc regularly considers appropriate mix level overall success ucb change mainly impact cash equity award offer executive based variable pay scheme explained variable recommendation corporate human resource pay section department recommendation reviewed independent compensation consultant tower watson change fully aligned spirit belgian ensure market competitiveness total remuneration governance legislation therefore also european take consideration market trend affecting regulation executive compensation enable better sector market survey normally conducted every alignment executive compensation ucbs strategy year assess competitiveness compensation commitment deliver short longterm component base salary bonus longterm incentive goal performance executive data aged year describe element pay determined survey conducted based global market movement performance embedded incentivebased within executive compensation significant change element pay occur job content instance due company organization market pricing role may conducted time capture impact change executive committee compensation package composed base salary two main element b ase salary fixed element pay variable pay consisting cash bonus longterm incentive long term bonus incentive ucb benchmark executive total reward program defined comparator group international company within biopharmaceutical sector company pharmaceutical biotechnology activity benchmark take focussed approach peer company europe well benefit perquisite recognition u ucbs competitive positioning policy target median pay level comparator group element total direct compensation base salary variable pay actual compensation level individual determined according benchmark taking account performance base salary level experience relation benchmark target base salary determined based specific job comparator group monitored closely ensure dimension criterion relation level base year year robust data available view pay market typically pay role challenge industry consolidation impact stability market level base pay defined specific compensation underlying data level individual depends extent heshe impact business hisher level skill experience compensation element pay performance evolution base pay depends individual level executive compensation program based sustained performance level pay compared balance individual corporate performance market benchmark market factor inflation gncc competitiveness senior executive shortterm proposes salary increase ceo board longterm incentive take account performance ceo proposes gncc executive financial target set board committee member endorsement u c b n n u l r e p rt ii n g e e n r e p rt f h e b ar f r e ct r variable pay bonus performance year new compensation policy cash bonus designed reward performance ucbs upper management entered effect company individual time horizon one year several implication variable pay policy new part new upper management compensation policy policy ensures appropriate level reward shortterm ceo shortterm incentive bonus performance rebalancing proportion pay target reduced base pay address longterm sustainable performance executive committee member target variable pay level bonus longterm incentive align market practice lti brought closer median comparator group providing opportunity longterm incentive lti executive exceed median market level remuneration practice link significant portion company individual performance outstanding equitybased compensation midterm longterm variable pay target subject double performance company financial strategic goal performance multiplier consists corporate individual lti program benchmarked european performance multiplier mechanism guarantee strong biopharmaceutical company practice threetiered link individual contribution company performance incentive program includes stock option plan free interdependent calculation mechanism share plan stock award performance share plan delivers significant value company individual performance excellent conversely mechanism ensures new upper management compensation policy design company individual performance level result greater proportion variable pay linked lower expectation adequately reflected longterm rather shortterm performance significantly diminished value achieved relative size lti target represents value shortterm bonus performance assessment grant per new upper management corporate performance multiplier compensation policy longterm incentive target expressed percentage base pay longer fixed number corporate objective ceo set beginning share option award change made response year gncc approved board challenge maintaining appropriate competitive lti since performance year ucb adopted recurring grant size target level longterm incentive represent earnings income tax depreciation amortization base pay ceo executive rebitda preferred corporate performance metric committee member target incentive subject executive senior management corporate application double corporate individual performance multiplier defined percentage actual performance multiplier see table rebitda versus budget translated payout curve following application corporate individual ensures acceptable range performance performance multiplier resulting value translated rewarded payout curve translated payout range number longterm incentive using binomial value minimum payout threshold set award spread across existing longterm incentive performance falling threshold result program based following allocation corporate performance multiplier double multiplier mechanism design result stock option variable pay opportunity stock award individual performance multiplier performance share qualitative objective ceo proposed stock option gncc approval board director gncc proposes individual performance multiplier ceo eligibility participation stock option plan board based performance assessment end board discretion vesting period typically three year year ceo proposes gncc date grant longer depending local executive committee member endorsement legislative requirement vested stock option exercisable share price exceeds original grant discussing individual performance gncc deliberates price thus executive incentivized increase achievement financial quantitative objective share price vesting period order benefit ceo nonfinancial aspect ceo stock option u stock appreciation right executive committee evaluation includes extent granted instead stock option follow individual carried duty line vesting rule stock option plan result employee company value expected leadership behaviour receiving cash amount equal appreciation ucb criterion evaluated executive stock instead actual share stock option stock committee member appreciation right expire tenth anniversary specific business achievement date grant grant price fixed grant date strategic input vision without discount underlying ucb share price team leadership executive committee team membership impact u c b n n u l r e p rt ii n g e e n r e p rt f h e b ar f r e ct r stock award pension stock award plan provides conditional right ucb executive committee international nature common stock fulfilled upon remaining employment member participate pension plan available ucb three year grant date vesting period country contract plan varies line local three year date grant executive committee competitive legal environment member eligible participation board defined benefit plan ucb either frozen discretion executive incentivized outperform closed new entrant new executive committee biopharmaceutical market increase company share member would therefore automatically join either defined price vesting period optimize value contribution cash balance plan stock award moment vesting country delivery award may also made belgium phantom share award value based executive committee member participate cash evolution share price settled cash balance retirement benefit plan fully funded predetermined vesting date depending local ucb benefit retirement age capitalization legislative environment guaranteed rate return employer annual contribution affiliation plan ucb performance share plan contributes amount equal annual base performance share plan ensures strong link salary target bonus ucb also provides annual pay performance performance share grant guaranteed return increased belgian health ucb common stock senior executive group index minimum defined belgian certain corporate target must met time legislation maximum vesting performance criterion target defined executive committee member also participate board upon proposal gncc time ucb senior executive supplementary defined contribution grant metric used plan must address plan contribution plan twofold following requirement company contribution based actual corporate valid strategically relevant company result defined board stakeholder within influence control executive line sight company contribution equal annual basic salary measurable predictable definable robust realistic accurately measurable time horizon chief executive officer benefit individual pension promise lump sum age vesting period three year number share pension promise established roch doliveux awarded adjusted end vesting period based joined organization company performance goal actual company performance specified threshold beneficiary benefit retirement based average annual leaf prior vesting share awarded basic salary last five year would actuarially maximum award capped original grant reduced ceo leave retirement country delivery award may also u made phantom share depending local member participate ucb retirement saving legislative environment plan plan composed qualified nonqualified component ucbs total contribution plan range annual pay based age contribution irs limit made qualified part plan contribution irs limit made nonqualified component pensionable compensation level contribution limited executive committee member also participate deferred compensation plan fully funded employee participant contribute individual basis defer salary bonus germany executive committee member covered closed defined benefit pension plan plan promise pension case retirement disability death benefit case retirement disability amount last annual base salary retirement disability u c b n n u l r e p rt ii n g e e n r e p rt f h e b ar f r e ct r remuneration element remuneration policy member executive committee also typically gncc carefully monitor impact new entitled participate international healthcare plan upper management compensation scheme would executive life insurance available senior make necessary adjustment based overall executive executive committee member also provided effectiveness policy certain executive perquisite company car benefit kind element disclosed compensation section compensation executive committee executive committee remuneration policy member executive committee extensively described ucb charter chairman executive committee corporate governance available chief executive officer ucb website remuneration chairman executive committee ceo roch doliveux composed termination arrangement abovementioned element base salary shortterm given international character executive incentive longterm incentive committee well dispersal various activity addition director fee board member across different geography member agreement ucb sa remuneration benefit granted governed different legal jurisdiction directly indirectly chairman executive executive committee termination agreement committee ceo ucb affiliate exception jeanchristophe tellier anna richo amount signed entry force belgian b ase salary earned corporate governance law april limit level termination indemnity hortterm incentive bonus paid relating financial year service contract established roch doliveux provides case termination eligible longterm incentive number ucb share option lump sum equal month actual base compensation see section plus actual average variable compensation relating ther component remuneration cost three previous year case termination due change pension insurance coverage monetary value control lump sum equal month fringe benefit amount includes ismail kola hold belgian employment contract retirement benefit based service cost termination clause would entitle based performance external benchmark severance payment month base salary bonus inflation board approved salary increase case contract terminated company case ceo new annual base salary march change control ucb payment would equivalent month base salary bonus ceo total compensation base salary bonus lti fabrice enderlin detlef thielgen specific amount excluding pension contribution termination provision belgian contract benefit represents decrease value case termination local employment law compared line deployment new practice would apply compensation policy notably reduced target cash bonus iris löwfriedrich german employment agreement provides minimum six month notice caring entrepreneurship fund termination indemnity equal one year base salary roch doliveux continued contribute portion bonus overall would represent month compensation fund set part termination package king baudouin foundation caring entrepreneurship robert trainor mark mcdade hold fund focus supporting entrepreneurship field u employment agreement clause included health wellness agreement specifying termination payment month base salary bonus involuntary termination agreement company case change control jeanchristophe tellier greg duncan anna richo covered u employment agreement clause allowing severance payment equal month base salary bonus involuntary termination employment agreement case change control ucb u c b n n u l r e p rt ii n g e e n r e p rt f h e b ar f r e ct r member executive committee amount compensation stated reflects longterm incentive number ucb share option amount executive committee member earned see section based effective period service executive ther component remuneration cost committee member see section composition pension insurance coverage monetary value executive committee fringe benefit amount includes remuneration benefit granted directly retirement benefit based service cost indirectly global basis member aggregated executive committee compensation base executive committee company affiliate salary bonus lti amount belonging group amount excluding pension contribution benefit b ase salary earned noted one new member joined executive committee hortterm incentive bonus paid relating financial year longterm incentive lti granted binomial binomial value binomial value value stock performance performance total binomial stock option stock option stock award award share share value lti roch doliveux ismail kola robert trainor iris löwfriedrich fabrice enderlin detlef thielgen greg duncan jeanchristophe tellier mark mcdade anna richo number right acquire one ucb share price april march january march roch doliveux fabrice enderlin detlef thielgen ismail kola value stock option calculated based binomial methodology defined tower watson number ucb share phantom share delivered free vesting period three year still employed ucb value stock award calculated based binomial methodology per share award defined tower watson number ucb share phantom share delivered free vesting period three year still employed ucb upon fulfilment predefined performance condition value performance share calculated based binomial methodology per performance share defined tower watson robert trainor granted phantom stock award ucb share december addition grant april binomial valuation objective technique pricing longterm incentive determines fair value stock price life longterm incentive november anna richo granted signon stock award ucb share share delivered november november u c b n n u l r e p rt ii n g e e n r e p rt f h e b ar f r e ct r longterm incentive vesting schedule showing longterm incentive granted executive committee member previous year reported previous annual report vested calendar year accumulated information table detail longterm incentive granted stock option stock awards performance shares number vested number total value total value exercised exercised number vested upon vesting number vested upon vesting roch doliveux greg duncan detlef thielgen mark mcdade fabrice enderlin iris löwfriedrich robert trainor ismail kola based decision taken gncc february upon vesting stock award performance share ucb deliver number share cash order cover tax social security liability due beneficiary award jeanchristophe tellier ismail kola joined ucb lti grant addition greg duncan became member executive committee lti vesting stock option granted iris löwfriedrich april vested april exercise price eur stock appreciation right granted robert trainor greg duncan mark mcdade april vested april exercise price stock option granted roch doliveux detlef thielgen fabrice enderlin april vested january exercise price fabrice enderlin detlef thielgen exercised stock option granted april exercise price eur greg duncan exercised stock appreciation right granted april exercise price eur upon vesting ucb share value represents market value share delivered vesting date determined average high low price ucb share date addition vesting grant robert trainor stock award including phantom award granted performance share outstanding subject accelerated vesting date retirement per plan rule section internal revenue code award subject deferral delivered december ismail kola granted signon phantom stock award delivery share payment cash amount december ucb share value december longterm incentive grant ucbs policy grant number longterm incentive defined policy actual grant value known based corporate individual performance april based share price day multiplier attributed performance year grant found number option award granted made april following close performance april resulting grant value reported year grant size based valuation share price annual report stock option stock award performance share roch doliveux fabrice enderlin ismail kola iris löwfriedrich mark mcdade detlef thielgen anna richo jeanchristophe tellier u c b n n u l r e p rt ii n g e e n r e p rt f h e b ar f r e ct r feature ucbs internal control risk management system internal control board ucbs governing body one role reliable data result properly stated provide entrepreneurial leadership ucb within accordance requirement framework prudent effective control enables procedure coordinated global internal risk assessed managed ucb management audit function advance issuance halfyear responsible establishing maintaining adequate internal annual account result procedure reviewed control provide reasonable assurance regarding reporting consolidation team well finance achievement objective reliable nature financial legal department external auditor appropriate information compliance relevant law regulation followup potential issue identified performed performing internal control process within ucb consideration adjustment reported financial information efficient manner disclosure evaluated audit committee assist board responsibility result procedure reviewed ceo monitoring management ucb ucb group cfo subsequently audit committee whole effectiveness ucbs overall internal prior publication account control process overall financial reporting process external auditor global internal audit function ucb update business plan annual basis effectiveness prepares detailed annual budget financial year considered approved board management global internal audit function provides independent reporting system place providing management objective assurance activity designed evaluate add financial operational performance measurement value improve ucbs internal control operation indicator management account prepared monthly bringing systematic disciplined approach evaluation cover major area business variance recommending enhancement ucbs governance plan previous forecast analyzed explained compliance risk management internal control process acted timely manner addition regular board global internal audit group undertakes audit plan discussion meeting held least monthly financial compliance operational audit review executive committee discus performance specific reviewed approved audit committee project discussed required information covering relevant company activity program includes system developed support ucbs long term objective independent review system internal control managed professionally staffed information risk management finding status corrective management team action taken address regularly reported writing executive committee status completion audit plan well summary risk management finding status corrective action reported global risk management policy applicable whole writing audit committee four time per year ucb group affiliate worldwide describes ucbs ucb adopted formal procedure focused internal commitment provide effective risk management system control financial reporting referred across ucb order minimize exposure risk transparency directive process process intended could threaten corporate objective help minimize risk selective disclosure help ensure board responsible approving ucb group material information disclosure made ucb strategy goal objective overseeing investor creditor regulator accurate complete establishment implementation review ucb timely fairly present ucbs condition help ensure group risk management system adequate disclosure material financial nonfinancial information significant event transaction risk board assisted audit committee responsibility appreciation risk risk process consists number activity identified key management audit committee examines regular contributor internal control process includes basis area risk could significantly affect ucb executive committee member required certify group financial situation reputation monitor writing understand complied overall risk management process ucb ucbs requirement related financial reporting process including providing reasonable assurance effective corporate risk management committee consisting efficient operation reliable financial information executive committee member senior management compliance law regulation promote representative business function reporting understanding broad range potential issue executive committee provides strategic leadership detailed checklist provided complete endorses corporate risk assessment prioritization assist certification addition detailed process drive establishment risk mitigation plan worldwide review sale credit account receivables within business function operation supported inventory trade inventory accrual provision global risk management system effectively efficiently reserve performed finance director assess report mitigate manage actual potential risk individual business unit required acknowledge exposure chair corporate risk management writing financial reporting area based committee report directly ceo provides periodic u c b n n u l r e p rt ii n g e e n r e p rt f h e b ar f r e ct r status update directly executive committee risk management strategy objective global annual basis audit committee well internal audit function responsible independently board regularly reviewing well validating risk management process ucb jointly agreeing business executive committee responsible implementing function action mitigate control assessed risk rivate investment transaction trading ucb share p board approved dealing code prevent insider board designated robert trainor executive trading offence market abuse particularly vice president general counsel june period preceding publication result information anna richo executive vice president general counsel would likely significant effect price january insider trading compliance officer whose ucb share price share issued duty responsibility defined dealing code company targeted planned operation document dealing code establishes list key employee reviewed updated board december director inform compliance officer dealing code establishes rule director executive transaction ucb share intend make management key employee prohibit account code fully compliance directive dealing ucb share financial instrument issued ec insider dealing market manipulation company designated period preceding belgian law august supervision announcement financial result socalled closed financial sector financial service period prohibits trading ucb share dealing code available ucb website socalled special closed period person wwwucbcominvestorsgovernanceinsidertrading soon possession privileged information external audit general meeting held april reappointed pwc appointed external auditor affiliate pricewaterhousecoopers hereafter pwc external ucb group worldwide auditor ucb legal term three year fee paid ucb auditor amounted permanent representative designated pwc ucb belgium jean fossion audit audit related nonaudit related total pwc belgium pwc outside belgium total u c b n n u l r e p rt ii n g e e n r e p rt f h e b ar f r e ct r nformation requested article royal decree november following element may impact event set abovementioned notification benefit takeover bid see section candidate presented approval ucbs capital structure date capital ucb fully paid indication different class share class share right obligation attached holder security percentage total special control right share capital represents description right december security february capital company amounted represented system control employee share par value fully paid share scheme control share entitled right right exercised directly different class share see section employee system restriction either legal prescribed article restriction either legal association transfer prescribed article security association voting right restriction transfer security apply existing ucb share entitle holder thereof vote fully paid share according article ucbs article general meeting association hereafter article association follows article article association ucb share give right one vote fully paid share registered may transferred prior agreement board director person entity acquires subscribes beneficial ownership share whether registered capital b shareholder holding share fully paid wish company conferring right vote obliged transfer part shareholding notify intention declare within period required law number share registered letter board director indicating name purchased subscribed together total number candidate approved number share offered share held number total exceeds proportion sale price proposed term sale total voting right exercisable possible board director may registered letter oppose reduction general meeting shareholder sale within month notification presenting another procedure followed time person candidate purchaser selling shareholder candidate obliged make initial declaration mentioned increase proposed board right preemption voting strength subsequently share offered sale unless proposed seller withdraws additional total voting right acquired defined sale within day following sale share voting right fall one limit specified notification right preemption exercisable unit price occur according modality described legislation corresponding lower two following amount applicable disclosure large shareholding issuer average closing price ucb ordinary share whose security admitted trading regulated market continuous trading market euronext brussels failure respect statutory requirement penalized stock exchange working day preceding notification manner laid article company code preceding paragraph reduced amount still noone may general meeting shareholder cast greater paid number vote relating share unit price offered third party proposed approval accordance paragraph declared holding least twenty day date meeting abovementioned notification board director shall taken notification exercise right preemption treasury share ucb share held ucb direct name account purchasing candidate indirect affiliate law voting right presented board price payable within proposed general meeting april month notification without prejudice favorable financial instrument whatever nature granting condition offered third party presented approval owner thereof right acquire initiative c board reply within period month ucb share exceeding threshold would notification set first paragraph subsection b trigger notification requirement sale may take place condition less favorable u c b n n u l r e p rt ii n g e e n r e p rt f h e b ar f r e ct r agreement shareholder large majority director nonexecutive known ucb may board member result restriction transfer least three nonexecutive director independent security exercise accordance legal criterion adopted voting right board agreement ucb aware expired n single director group director may dominate terminated decisionmaking ucb knowledge content written composition board guarantee diversity agreement might result restriction transfer contribution experience knowledge ability required security exercise voting right ucbs specialist international activity c andidates fully available carry function rule governing appointment take five directorship listed company replacement board member gncc gather information allowing board ensure article association company criterion set met time company shall managed board director appointment renewal term office least three member whether shareholder appointed new directorship appointment gncc performs four year general meeting shareholder assessment existing required ability knowledge time subject dismissal general meeting shareholder experience board profile ideal candidate retiring director eligible reelection period office drawn basis assessment proposed retiring director reappointed cease immediately board discussion definition closing ordinary general meeting shareholder profile established gncc selects candidate general meeting shareholder shall determine fixed fit profile consultation board member variable remuneration director value including chair executive committee possibly attendance voucher charged operating expense using recruitment firm recommendation final candidate made gncc board board decides general meeting decides simple majority vote proposal submitted shareholder approval matter candidate proposed board selection process ruled company charter appointment reference shareholder representative corporate governance follows board vicechair present candidate chosen reference shareholder board consultation gncc dialogue board member composition board director duration mandate age limit composition director appointed general meeting shareholder fouryear term term may renewed board opinion number ten fifteen member appropriate efficient decisionmaking moreover age limit seventy stipulated director one hand contribution experience knowledge shall give hisher current term day annual general different field hand number also allows meeting shareholder following hisher seventieth birthday change board composition managed without board may propose exception rule undue disruption way within provision law article association ucb board shall procedure appointment renewal term composed least three member general meeting process appointment reelection director run shareholder decides number director upon proposal board strives maintain optimum level ability board experience within ucb board large majority board member proposal appointment renewal resignation possible nonexecutive director retirement director examined board based curriculum vitae director directorship candidate recommendation gncc available consultation ucbs website curriculum gncc assesses director candidate vitae mention director directorship reelection next general meeting shareholder listed company commitment effectiveness make recommendation board regarding reelection appointment director special attention given evaluation chair director appointed general meeting board chairman board committee shareholder following proposal board upon recommendation gncc assessment conducted chair board chair gncc meeting director proposing candidate general meeting shareholder capacity director case may chair board take particular account following criterion member board committee chair board assessment conducted chair gncc senior independent director chair gncc assessment conducted chair board senior u c b n n u l r e p rt ii n g e e n r e p rt f h e b ar f r e ct r independent director session based questionnaire cover director role governance company board ucbs governing body effectiveness board amongst others evaluate commitment contribution constructive power take decision matter involvement discussion decisionmaking law expressly attribute general meeting shareholder board act collegially feedback given gncc report board make recommendation proposed reelection role responsibility functioning board determined ucbs article association term board submits general meeting shareholder reference board board committee proposal concerning appointment renewal resignation described charter possible retirement director proposal communicated general meeting shareholder part among matter may law take decision agenda relevant shareholder meeting board reserved key area delegated wide power administration executive committee see point general meeting shareholder resolve proposal board area majority vote opt create management committee sense article belgian company code since preferred event vacancy term board empowered permanently delegate power granted law fill post allow decision ratified next general representation ucb general meeting shareholder board role provide entrepreneurial leadership ucb proposal appointment state whether candidate within framework prudent effective control proposed executive director define term proposed enables risk assessed managed board set ucbs mandate ie four year accordance strategic aim ensures necessary financial human article association indicate place useful resource place ucb meet objective review information relation professional qualification management performance board set ucbs value candidate addition main function directorship standard ensures obligation shareholder candidate may obtained consulted others understood met take collegiate responsibility board also indicates whether candidate meet sound exercise authority power independence criterion particular stipulated power board reserved concern mainly article ter company code fact director following end also receives information order qualify independent may hold mandate required relation three consecutive term maximum twelve year case director meet independence definition ucbs mission value strategy risk tolerance criterion proposal submitted general meeting key policy shareholder acknowledge independent character monitoring proposal appointment available ucbs website management performance implementation wwwucbcom company strategy effectiveness board committee performance external auditor b rule governing amendment ucbs article association appointment removal rule governing amendment article among member chair board association set belgian law decision amend consultation board member conducted chair article association made general governance nomination compensation committee meeting majority vote cast provided gncc least share capital ucb present among member chair member represented meeting audit committee gncc member attendance quorum met first extraordinary scientific committee general meeting second general meeting convened chair executive committee following proposal decide without attendance quorum gncc member executive committee following proposal power board member gncc recommendation chair particular power issue buy executive committee back share person major external body person power board defined belgian law outside ucb requested represent ucb certain article association subsidiary recommendation chair term reference board responsibility executive committee board reserved described r eviews succession planning chair executive charter corporate governance company follows committee executive committee member proposed gncc endorsement appointment removal senior u c b n n u l r e p rt ii n g e e n r e p rt f h e b ar f r e ct r executive recommendation chair significant agreement executive committee ucb party take effect alter terminate upon change e nsure integrity timely disclosure financial control ucb following takeover statement ucb group ucb material bid effect thereof except financial nonfinancial information shareholder nature financial market disclosure would seriously approve framework internal control risk prejudicial ucbthis exception management set executive management shall apply ucb controlled internal audit direct access specifically obliged disclose audit committee information basis legal requirement preparation general meeting shareholder decision proposed considered meeting c onvertible bond ucb sa amount million fixed rate senior unsecured e xecutive management structure general organization convertible security issued september ucb ucb group state case change control approval annual budget including rd program concept defined term condition capital plan increase overall annual budget approved general meeting held including rd program capital plan november bondholder right require issuer redeem bondholder bond longterm major finance operation r etail bond ucb sa amount million c reating establishing closing settling transferring fixed rate senior unsecured security issued subsidiary branch production location major division november state case change exceeding value million control concept defined term allotment merger division purchase sale pledging condition approved general instrument share value exceeding million meeting held november bondholder involving third party right require issuer redeem bondholder bond purchase sale pledging property asset value exceeding million lease period exceeding institutional bond ucb sa amount nine year aggregate amount expenditure million fixed rate senior unsecured security exceeding million issued december state case change control concept defined term condition plan grant stock term condition approved stock option employee general meeting held april bondholder informed end every semester right require issuer redeem charitable donation excess ytd bondholder bond single beneficiary facility agreement amount million request chair executive committee amongst others ucb sa commerzbank board may also asked pronounce event ag fortis bank sanv mizuho corporate diverging opinion among majority member bank nederland nv joint coordinator mandated executive committee chair lead arranger book runner royal bank scotland nv belgium branch ing belgium sanv kbc bank nv bank tokyomitsubishi ufj ltd authorization shareholder exists date barclays capital dnb bank asa sumitomo allowing board issue new ucb share mitsui banking corporation mandated lead arranger dated november amended restated according decision general meeting held november october change november board board director control clause approved general meeting direct subsidiary authorized period held april five year starting november acquire share ucb maximum issued share exchange hybrid bond ucb amount million fixed value equivalent closing price ucb share tofloating rate perpetual subordinated security issued euronext brussels day immediately preceding march include h stepup change acquisition plus minus maximum taking also control term condition state account applicable legal requirement case change control concept defined term condition applicable interest rate warrant see section increased base point unless ucb elect reimburse predefined condition event hostile bond point change control clause takeover exercised abovementioned adhoc approved general meeting april committee decides facility agreement amount million ucb lux sa borrower ucb sa promoter guarantor european investment bank dated may change control clause approved general meeting april u c b n n u l r e p rt ii n g e e n r e p rt f h e b ar f r e ct r ucb stock award performance share plan agreement ucb ucb share granted annually ucb certain board member employee employee according grade performance criterion providing compensation vest according rule plan three year board member resign made upon condition beneficiary remains continuous redundant without valid reason employment ucb group employment employee cease takeover bid also vest upon change control merger f detail see section main contractual december following number stock award term hiring termination arrangement performance share outstanding ceo member executive committee stock award vest agreement provide specific compensation board member case termination takeover bid performance share vest addition executive committee member identified section seven employee u benefit change control clause executive committee change control clause guarantee termination member contract described compensation employment employee cease remuneration report section takeover bid application article belgian company code excerpt minute meeting board held board director established article march company code applicable operation board discussed recommendation present governance nomination compensation committee relating executive committee member ceo b aron karel boone chair bonus performance base salary c ountess evelyn du monceau vice chair march lti grant resolved r roch doliveux executive director bonus lti grant approved proposed b aron albrecht de graeve director r peter fellner director financial consequence company cost p rofessor jeanpierre kinet director company ir thomas mckillop director c eo bonus target individual r gerhard mayr director performance r norman j ornstein director c ount arnoud de pret director c eo base salary increase r alexandre van damme director c eo lti stock option year month r bridget van rijckevorsel director vesting stock award year vesting psp mr gaëtan van de werve director year vesting cost ucb vesting r thomas leysen director difference might exist purchase price share company exercise price attendance determined accordance condition stipulated plan rule mr inge basteleurs secretary general board discussed recommendation governance nomination compensation committee prior discussion decision board director lti program resolved following concerning following item resulting governance nomination compensation committee approval ucb stock option pproval executive committee ceo bonus plan performance base salary march present operation designed past lti grant promote shareholding approximately employee pproval stock option plan ucb group within company including executive director member executive pproval stock award plan committee financially encourage pproval performance share plan continuing involve success company make aware value roch doliveux executive director stated direct ucb share market whilst adhering rule financial interest implementation said decision governing insider information accordance article company code director withdrew meeting order attend discussion board director concerning issue participate vote u c b n n u l r e p rt ii n g e e n r e p rt f h e b ar f r e ct r financial consequence operation ucb performance share plan reserved senior company basically consist difference executive exceeded expectation might exist purchase price share considered top performer including executive company price resale share director member executive committee concerned beneficiary exercising option proposed governance nomination compensation accordance condition stipulated plan rule committee reason grant line remuneration policy beneficiary distribution board director approved intended provide long term incentive vesting linked recommendation governance nomination condition beneficiary remains employed within compensation committee concerning rule group least three year grant date pre stock option allocation basis job category defined target achieved ucb group payout level responsibility thus number vary granted amount depending option shall allocated employee level achievement performance condition ucb group estimate take account employee hired promoted eligible level financial consequence operation company january april basically consist value ucb share time vesting b stock appreciation right sar u ucb ucb performance share plan two metric grant sars rather stock option u approved recommendation governance sar plan follows rule ucb stock option nomination compensation committee board plan difference instead granting real april vesting plan adjusted net profit share participant provides ability tax beating consensus revenue benefit appreciation value ucb stock distribution board director approved appreciation paid cash moment exercise recommendation governance nomination c etting exercise price exercise price compensation committee concerning rule option lowest two following amount free share grant basis job category level average closing price calendar day responsibility thus number share shall preceding offer march allocated senior executive within group final closing price day preceding amount known april case new offer march recruit psps share shall allocated payout ranging depending meeting performance u cb determine different exercise price condition set board director final amount eligible employee subject legislation requires known april case new recruit different exercise price order benefit reduced taxation allocation stock award e vesting stock option vesting period performance share exceptional year date grant except country circumstance allowed less favorable accordance measure concurrent creation approval ucb stock award incentive stock pool board approved allocate year share allocation stock plan ucb performance exceptional circumstance beneficiary identified share plan executive committee senior executive ucb stock award plan reserved senior grant approved executive committee executive including executive director member governance nomination compensation committee executive committee proposed gncc informed yearend designed promote shareholding among category personnel ucb group within company delegating power financially encourage continuing involve success company make aware board decided delegate power chairman value ucb share market whilst adhering executive committee company currently rule governing insider information line roch doliveux senior executive vice president remuneration policy beneficiary intended fabrice enderlin acting individually right sub provide long term incentive free share grant linked delegate order ensure execution decision condition beneficiary remains employed within taken specifically finalize rule regulation group end vesting period ie normally issue documentation beneficiary three year grant date financial consequence exercise procedure operation company basically consist value ucb share time vesting u c b n n u l r e p rt ii n g e e n r e p rt f h e b ar f r e ct r pplication article section belgian company code deviation code principle guideline secretary board principle anna richo joined executive committee report general counsel instead chairman november advice governance board jointly constant basis monitor nomination compensation committee based corporate governance compliance ucb alignment previously existing departure payment executive committee member board principle tom mckillop join discussion director granted anna richo departure payment board director december decided eighteen month grant exception age limit article corporate governance charter u c b n n u l r e p rt ii n g e e n r e p rt f h e b ar f r e ct r business performance review business performance review operating financial review based consolidated financial statement ucb group company prepared accordance ifrs separate statutory financial statement ucb sa prepared accordance belgian generally accepted accounting principle together report board director general assembly shareholder well auditor report filed national bank belgium within statutory period available request website key highlight revenue increased million net sale went due solid performance three core product cimzia vimpat neupro strong keppra sale japan resistance generic erosion europe partially offset generic competition mature product portfolio royalty income fee result lower biotechnology ip revenue increased due new milestone partially offset lower contract manufacturing sale recurring ebitda reached million compared million reflecting revenue increase offset launch expense cimzia vimpat neupro rd investment n et profit increased million million reflecting strong revenue lower nonrecurring higher financing expense core eps increased per share terry living parkinson disease due rounding financial data may add table included management report u c b n n u l r e p rt ii n g e e n r e p rt f h e b ar f r e ct r actual variance million actual rate cst rate revenue net sale royalty income fee revenue gross profit marketing selling expense research development expense general administrative expense operating income expense recurring ebit rebit non recurring income expense ebit operating profit net financial expense profit income tax income tax expense credit profit continuing operation profit loss discontinuing operation net profit attributable ucb shareholder attributable noncontrolling interest na na recurring ebitda capital expenditure including intangible asset na net financial debt na cash flow operating activity na weighted average number share non diluted na eps per weighted average number share non diluted core eps per weighted average number share non diluted key event number key event affected eptember new pilot biotechnology plant affect ucb financially ucbs brainelalleud site belgium plant focus developing ucbs molecule research clinical trial manufacturing process designed optimised important agreement initiative move development full scale industrial production facility include multiple fermentation reactor ecember biotie therapy reported positive well integrated laboratory topline result phase b study evaluating adenosine aa antagonist tozadenant syn june october ucbharvard research parkinson disease pd ucb hold biotie alliance expands move forward ucb licence exclusive worldwide right tozadenant launched second third collaborative research project phase development commercialization ucb harvard build upon innovative research currently analyzing data full detail decision alliance signed second research project development expected first quarter aim driving translation developing small molecule compound induction autophagy potential application treatment neurodegenerative disease n ovember exemed pharmaceutical acquires third focused human microbiome develop new ucbs indian production facility vapi ucbs vapi therapeutic application immunology plant currently focus production packaging distribution ucb mature drug mainly ay ucb expands brazil ucb meizler indian market exemed pharmaceutical continue biopharma privatelyowned brazilian pharmaceutical activity also planning bring new business company announced signed agreement site ucb acquires meizler biopharma part partnership ucb bring part mature n ovember exclusive partnership agreement new medicine meizler biopharmas portfolio newbridge pharmaceutical several middle commercialization brazil east african market make ucbs core product cimzia vimpat neupro available patient u c b n n u l r e p rt ii n g e e n r e p rt f h e b ar f r e ct r pril convertible bond ucb purchased seizure fully controlled despite current treatment million par value outstanding convertible concomitant antiepileptic drug enrolment trial bond million convertible bond issued plan due external competition market ucb sa september clinical trial patient design reason patient currently levetiracetam excluded first result expected arch collaboration university h brivaracetam present opportunity oxford see investment gbp million extend ucbs leadership within epilepsy providing new project field translational medicine better treatment challenging disease f ebruary ucb nodality enter ucb new drug candidate innovative multiyear strategic collaboration utilize mechanism action preandpost synaptic inhibitor nodalitys proprietary single cell network profiling ppsi developed treatment drug scnp technology assist development several refractory epilepsy singledose multipledose phase ucb compound field immunology study completed satisfactorily however january ucb astellas announce development molecule continue agreement jointly develop commercialize cimzia japan following decision otsuka immunology pharmaceutical discontinue collaboration december cimzia certolizumab pegol immunology ucb astellas agreed codevelop approved japan treatment adult patient copromote cimzia certolizumab pegol japan rheumatoid arthritis ra following submission january august strategic alliance marketing authorisation japanese ministry wilex strengthened ucb exercised health labour welfare mhlw january subscription oversubscription right issuance ucb astellas pharma inc agreed codevelop new share wilex ag munich germany company copromote cimzia japan specializing development drug diagnostic february april phase trial cimzia agent cancer ucb acquired additional share psoriatic arthritis psa axial spondyloarthritis wilex total holding axspa including ankylosing spondylitis reported first positive result submission u eu regulatory authority followed november december regulatory update pipeline progress accepted filing u eu regulatory authority february central nervous system cns march cimzia phase program juvenile november ucb started new phase clinical idiopathic arthritis jia started scheduled u trial vimpat lacosamide asia designed first result expected second half investigate efficacy safety lacosamide adjunctive september ucb announced topline phase therapy adult patient partialonset seizure initial result olokizumab rheumatoid arthritis study result phase study expected first met primary endpoint demonstrating significant half reduction disease activity score week however u european monotherapy phase program current data suggest sufficient differentiation vimpat partialonset seizure track potential versus tocilizumab ucb progress first result expected second quarter program internally phase exploring fourth quarter respectively option olokizumab including partnering vimpat openlabel pilot phase study adjunctive therapy primary generalised tonicclonic seizure april romosozumab sclerostin antibody also known pgtcs reported positive result january discussion cdp amg phase clinical trial started regulatory agency move phase development treatment postmenopausal osteoporosis pmo pgtcs ongoing initial result phase program expected paediatric phase program due start first end half e xpanding pipeline ucb initiated phase study n eupro rotigotine received u regulatory approval assess ucb new mechanism action april since july room temperature stable patch treatment immunological disease available u early advanced parkinson clinical development project immunology disease pd well restless leg syndrome rls namely phase program cimzia exxelerate august room temperature stable patch approved cearly epratuzumab systemic lupus eu early advanced pd well rls erythematosus sle also cdp sle december neupro approved japan phase advancing parkinson disease restless leg syndrome ucbs cns partner otsuka pharmaceutical exclusive right february ucb partner amgen inc developing marketing neupro japan announced pursue phase clinical trial program cdp amg acceleration fracture healing phase study evaluating brivaracetam adjunctive based evaluation currently available phase therapy treatment partial onsetseizures result accelerated fracture healing study general adult epilepsy ongoing study evaluates regulatory guidance fracture healing program efficacy safety brivaracetam mgday compared placebo adjunctive treatment adult epilepsy patient partial onset u c b n n u l r e p rt ii n g e e n r e p rt f h e b ar f r e ct r operating financial review scope change result divestment remaining nonpharma activity ie film september surface specialty february ucb report result activity part profit discontinued operation recurring nonrecurring transaction decision onetime nature affect ucbs result shown separately nonrecurring item besides ebit earnings interest tax operating profit line recurring ebit rebit recurring operating profit reflecting ongoing profitability company biopharmaceutical activity included recurring ebit equal line operating profit impairment restructuring income expense reported consolidated financial statement core eps core net profit net profit attributable ucb shareholder adjusted aftertax impact nonrecurring item financial oneoffs tax contribution discontinued operation net amortization linked sale per nondilutive weighted average number share core product core product ucbs newly launched medicine cimzia vimpat neupro one ucbs priority growth three product including continued launch new indication carola living parkinson disease due rounding financial data may add table included management report consolidated financial statement first financial statement group early adopted ia r financials restated ia r always applied u c b n n u l r e p rt ii n g e e n r e p rt f h e b ar f r e ct r et sale product total net sale amount n million higher period actual variance million actual rate cst rate core product cimzia vimpat neupro product keppra including keppra xr zyrtec including zyrtecd cirrus xyzal omeprazole metadate cd nootropil total net sale core product cimzia certolizumab pegol moderately severely xyzal levocetirizine allergy reported net sale active rheumatoid arthritis ra crohn disease cd million mainly due growing market share available u switzerland brazil russia argentina japan offset generic competition european market chile mexico reached net sale million omeprazole generic product hyperacidity disease increase million reached net sale million compared million vimpat lacosamide epilepsy addon therapy last year treatment partialonset seizure showed million net metadate cd methylphenidate hci attention deficit sale hyperactivity disorder reported net sale million neupro rotigotine parkinson disease pd restless u increase despite generic launch leg syndrome rls net sale increased million september million plus nootropil piracetam cognitive disorder saw decrease net sale million million product product net sale mature product remained stable keppra levetiracetam epilepsy reported net sale million million keppra xr u lower last year net sale decreased due postpatent erosion europe partially compensated increase rest world mainly due e keppra japan zyrtec cetirizine including zyrtecdcirrus allergy decreased net sale million due generic competition u c b n n u l r e p rt ii n g e e n r e p rt f h e b ar f r e ct r net sale product million million cns cns immunology allergy immunology allergy et sale geographical area n north america net sale repor ted ucb reached europe net sale reached million million increase year cimzia net sale increased million constant currency cimzia patient suffering million antiepileptic drug vimpat crohn disease cd rheumatoid ar thritis ra increased million neupro treatment net sale increased million anti parkinson disease restless leg syndrome reached epileptic drug vimpat available addon therapy net sale million increase yearover treatment par tialonset seizure achieved net sale year keppra net sale decreased represented million bringing neupro million due generic competition allergy drug u market second half net sale reached xyzal zyrtec decreased total level million keppra franchise amounted million million due generic competition nootropil yearoveryear including decrease decreased million net sale product related keppra xr venlafaxine xr reached net sale contributed million reduction versus million tussionex hydorcodone plistirex previous year chlorpheniramine polistirex net sale amounted million rest world net sale amounted due fur ther generic competition net sale million increase mainly related growth product reached million asia including e keppra japan zyrtec xyzal constant rate contributed million million japan market leading e keppra grew yearoveryear three new core product cimzia vimpat neupro available patient region contributed million net sale geographical area million million france france germany germany italy italy north america north america spain spain ukireland ukireland rest world europe rest world japan europe asia japan asia u c b n n u l r e p rt ii n g e e n r e p rt f h e b ar f r e ct r actual actual rate constant rate million million million net sale north america core product cimzia vimpat neupro product keppra including keppra xr venlafaxine xr tussionex net sale europe core product cimzia vimpat neupro product keppra xyzal zyrtec including cirrus nootropil net sale rest world core product cimzia vimpat neupro product zyrtec including cirrus keppra xyzal nootropil unallocated total net sale royalty income fee actual variance million actual rate cst rate biotechnology ip toviaz zyrtec u royalty income fee royalty income fee amounted million u royalty income received overthecounter sale million compared period remained stable amounted million last year biotechnology intellectual property ip decreased royalty income decreased million million due expiration patent royalty million paid pfizer overactive bladder treatment toviaz fesoterodine went million zyrtec u c b n n u l r e p rt ii n g e e n r e p rt f h e b ar f r e ct r revenue actual variance million actual rate cst rate contract manufacturing sale astellas otsuka provas profit sharing xyzal milestone profit sharing revenue revenue amounted million neupro new partner jointly develop million commercialize cimzia japan astellas contract manufacturing sale decreased million profit sharing agreement novartis provas lower compared period last year contract jalra icandra germany represents million manufacturing sale major part related agreement gsk announced xyzal milestone profit sharing otsukarelated revenue pertains million mainly related received sale reimbursement rd expense milestone recognised milestone japanese market part agreement entered otsuka ucb codevelop e keppra cimzia japan since early collaboration otsuka focus e keppra gross profit actual variance million actual rate cst rate revenue net sale royalty income fee revenue cost sale cost sale product service royalty expense amortization intangible asset linked sale gross profit product service net royalty income amortization intangible asset linked sale gross profit million higher following royalty expense royalty increased million increase revenue million due higher royalty relating launched product cimzia vimpat neupro cost sale three component cost sale partially offset decrease biotechnology ip product service royalty expense amortization venlafaxine xr royalty expense intangible asset linked sale cost sale product service cost sale product service increased million million net sale million net sale due product mix u c b n n u l r e p rt ii n g e e n r e p rt f h e b ar f r e ct r actual variance million actual rate cst rate biotechnology ip royalty expense amortization intangible asset linked sale stream trade name etc amortization expense ifrs business combination ucb reflected intangible asset product already balance sheet significant amount intangible asset relating launched amounted million million celltech schwarz pharma acquisition inprocess lower compared mainly due expiration research development manufacturing knowhow royalty writedown period certain intangible asset ecurring ebit recurring ebitda r actual variance million actual rate cst rate revenue net sale royalty income fee revenue gross profit marketing selling expense research development expense general administrative expense operating income expense total operating expense recurring ebit rebit add amortization intangible asset add depreciation charge recurring ebitda rebitda operating expense encompassing marketing selling recurring ebit million due higher expense research development expense general operating expense administrative expense operating income total amortization intangible asset product related expense reached million higher last went million million year reflecting mainly due end usefull life certain million higher marketing selling expense driven intangible asset launch neupro u july epreciation charge amounted million continued launch e keppra japan regional expansion cimzia vimpat neupro recurring ebitda million compared reflecting higher revenue contrasted higher million higher research development expense operating expense due ongoing launch activity reflecting well advanced latestage clinical development ucbs core product major region well e keppra including project last development phase high rd expense due late stage pipeline progressing phase phase well cvn lifecycle management million higher general administrative expense million decrease operating incomeexpenses mainly related due reimbursement expense reoccur u c b n n u l r e p rt ii n g e e n r e p rt f h e b ar f r e ct r et profit core eps n actual variance million actual rate cst rate recurring ebit impairment charge restructuring expense gain disposal non recurring income expense total non recurring income expense ebit operating profit net financial expense profit income tax income tax expense credit profit continuing operation profit discontinued operation net profit net profit attributable ucb shareholder aftertax nonrecurring item financial oneoffs profit discontinued operation tax oneoffs amortization intangible linked sale tax amortization intangible core net profit attributable ucb shareholder weighted average number share na core eps attributable ucb shareholder total nonrecurring incomeexpenses amounted net financial expense increased million million pretax expense compared million pre million million including million tax expense nonrecurring item include oneoff loss debt extinguishment related convertible impairment nonfinancial asset result bond million writeoff wilex investment yearly impairment testing restructuring expense related average tax rate recurring activity shape reorganization support function severance compared period last year cost gain divestment primary care market low income tax rate arising year due u australia expense related litigation recognition previously unrecognized tax loss optimization civil investigate demand october significant proportion loss arising higher tax united state department justice united jurisdiction nonrecurring item lead tax credit state attorney office eastern district pennsylvania million compared tax credit million issued civil investigative demand ucb inc relating includes oneoff tax income due release price reporting cimzia u federal government liability longer required sale marketing cimzia u company cooperated fully investigation september net profit amount million million government concluded investigation without million attributable ucb imposing fine penalty taking action shareholder million noncontrolling interest company net profit attributable ucb shareholder adjusted nonrecurring item included impairment charge aftertax impact nonrecurring item financial million mainly related syn oneoffs aftertax contribution discontinued optimization manufacturing facility million operation net amortization linked sale give rise restructuring expense include primarily new organization core net profit million higher european operation nonrecurring core eps attributable ucb shareholder expense composed u million restructuring amounted compared per nondilutive epratuzumab licence agreement immunomedics weighted average number share ucb additional amortizationdepreciation u c b n n u l r e p rt ii n g e e n r e p rt f h e b ar f r e ct r capital expenditure tangible capital expenditure resulting ucb noncurrent liability increase noncurrent liability biopharmaceutical activity amounted million million million mainly related compared million capital increase long term debt employee benefit expenditure related mainly new biotech pilot decrease deferred tax liability plant brainelalleud belgium biotech plant current liability increase current liability bulle switzerland million million result share swap acquisition intangible asset reached million transaction million ucb share total amount versus million software development cost million increase short term bank loan milestone incurred collaboration agreement net debt net debt increased million inlicencing deal million end december million addition foreseen agreement ucb end december underlying profitability offset lonza manufacturing lonza pegylated antibody dividend payment result fragmentbased bulk active ucb participated shareholder perpetual bond prefinancing related capital expenditure depreciation charge investment recognized cost good sold added back recurring ebitda cash flow statement calculation purpose evolution cash flow generated biopharmaceuticals balance sheet activity affected following cash flow operating activity amounted million compared million stem intense intangible asset intangible asset decreased focus improving working capital million million december million december includes ongoing cash flow investing activity show outflow amortization intangible asset million mainly million compared million related acquisition celltech schwarz pharma result higher spending tangible intangible impact yearly impairment testing million asset acquisition meizler biopharma decreasing u dollar increasing british pound brazil acquisition schwarz pharma zuhai company ltd pr china goodwill goodwill amount million million increase december december cash flow financing activity outflow reflecting acquisition meizler biopharma brazil partially million includes repurchase convertible offset impact decreasing u dollar bond dividend paid ucb shareholder increasing british pound shareholder perpetual subordinated bond compensated higher borrowing noncurrent asset noncurrent asset increased million mainly driven investment biotech plant deferred tax related recognition outlook employee benefit decrease interest rate derivative ucb expects financial result driven current asset increase million continued growth cimzia vimpat neupro december million december emerging market partially offset postexclusivity expiry stem increase cimzia neupro inventory erosion keppra higher cash due focus working capital monetization unrealized gain derivative revenue anticipated grow lowsingledigit percent excluding exchange rate impact approximately shareholder equity ucbs shareholder equity billion million decreased million december december important recurring ebitda expected approximately change stem net profit noncontrolling interest million million comprehensive income million core earnings per share expected corresponding including change related ia revised range based million cumulative translation adjustment dividend share outstanding payment million u c b n n u l r e p rt ii n g e e n r e p rt f h e b ar f r e ct r iii iii consolidat ed f inancial tatem ents consolidated income statement consolidated statement comprehensive income consolidated statement financial position consolidated statement cash flow consolidated statement change equity consolidated income statement year ended december note restated million continuing operation net sale royalty revenue revenue cost sale gross profit marketing selling expense research development expense general administrative expense operating income expense operating profit impairment restructuring income expense impairment nonfinancial asset restructuring expense income expense operating profit financial income financing cost profit loss income tax income tax expense credit profit loss continuing operation discontinued operation profit loss discontinued operation profit attributable equity holder ucb sa noncontrolling interest basic earnings per share continuing operation discontinued operation total basic earnings per share diluted earnings per share continuing operation discontinued operation total diluted earnings per share consolidated statement comprehensive income year ended december note restated million profit period comprehensive income net gain loss available sale financial asset exchange difference translation foreign operation effective portion gain loss cash flow hedge net gain loss hedge net investment foreign operation remeasurment defined benefit obligation income tax relating component comprehensive income comprehensive income loss period total comprehensive income period attributable equity holder ucb sa noncontrolling interest total comprehensive income period u c b n n u l r e p rt iii c n l e f n n c l tat e e n consolidated statement financial position st jan year ended december note restated restated million asset noncurrent asset intangible asset goodwill property plant equipment deferred income tax asset investment associate financial asset including derivative financial instrument total noncurrent asset current asset inventory trade receivables income tax receivables financial asset including derivative financial instrument cash cash equivalent asset disposal group classified held sale total current asset total asset equity liability equity capital reserve attributable ucb shareholder noncontrolling interest total equity noncurrent liability borrowing bond financial liability including derivative financial instrument deferred income tax liability employee benefit provision trade liability total noncurrent liability current liability borrowing financial liability including derivative financial instrument provision trade liability income tax payable liability disposal group classified held sale total current liability total liability total equity liability u c b n n u l r e p rt iii c n l e f n n c l tat e e n consolidated statement cash flow year ended december note restated million profit year attributable ucb shareholder noncontrolling interest adjustment profit loss discontinued operation adjustment noncash transaction adjustment item disclose separately operating cash flow adjustment item disclose investing financing cash flow change working capital cash flow generated operation tax paid period net cash flow generated operating activity acquisition intangible asset acquisition property plant equipment acquisition subsidiary net cash acquired acquisition investment subtotal acquisition proceeds sale intangible asset proceeds sale property plant equipment proceeds sale business unit net cash disposed proceeds sale investment dividend received subtotal disposal net cash flow used investing activity proceeds issuance perpetual subordinated bond repayment bond proceeds borrowing repayment borrowing payment finance lease liability acquisition issuance treasury share dividend paid ucb shareholder net dividend paid share interest received interest paid net cash flow used financing activity cash discontinued operation net increase decrease cash cash equivalent net cash cash equivalent beginning period effect exchange rate fluctuation net cash cash equivalent end period cash cash equivalent bank overdraft u c b n n u l r e p rt iii c n l e f n n c l tat e e n consolidated statement change equity million attributed equity holder ucb sa cumulative translation total stockholder retained earnings cash flow hedge share capital available sale noncontrolling treasury share net investment reserve share premium financial asset hybrid capital adjustment interest equity hedge total balance january profit period comprehensive income loss total comprehensive income dividend sharebased payment transfer reserve treasury share equity component linked convertible bond put call option noncontrolling interest dividend shareholder perpetual subordinated bond business combination balance december restated million attributed equity holder ucb sa cumulative translation total stockholder retained earnings cash flow hedge share capital available sale noncontrolling treasury share net investment reserve share premium financial asset hybrid capital adjustment interest equity hedge total balance january effect early adoption ia r note restated profit period comprehensive income loss total comprehensive income dividend sharebased payment transfer reserve treasury share issuance perpetual subordinated bond dividend shareholder perpetual subordinated bond balance december restated u c b n n u l r e p rt iii c n l e f n n c l tat e e n iv iv note consolidated financial statement general information summary significant accounting policy critical judgement accounting estimate financial risk management segment reporting business combination discontinued operation revenue operating expense nature employee benefit expense operating income expense impairment nonfinancial asset restructuring expense income expense financial income financing cost income tax expense credit component comprehensive income intangible asset goodwill property plant equipment financial asset inventory trade receivables cash cash equivalent capital reserve sharebased payment borrowing bond financial liability deferred tax asset liabilities employee benefit provision trade liability note consolidated statement cash flow financial instrument category derivative financial instrument earnings per share dividend per share commitment contingency related party transaction event balance sheet date ucb company general information ucb sa ucb company subsidiary ucb sa parent company limited liability company together group global biopharmaceutical company incorporated domiciled belgium focused severe disease two therapeutic area namely registered office allée de la recherche b central nervous system disorder immunology brussels belgium ucb sa listed euronext brussels consolidated financial statement company stock exchange year ended december comprise board director approved consolidated financial company subsidiary within group ucb statement statutory financial statement ucb pharma sa wholly owned subsidiary branch sa issue february shareholder uk integrated account requested approve statutory financial statement ucb sa annual meeting april summary significant accounting policy principal accounting policy applied preparation hanges accounting c consolidated financial statement set policy consistently applied year policy disclosure presented unless otherwise stated new amended standard adopted basis preparation group current year group early adopted amendment ia revised june consolidated financial statement company endorsed european union june hereafter prepared accordance international financial ia r group applied ia r retrospectively reporting standard ifrs ifric interpretation accordance transitional provision set adopted use european union ifrss issued ia transitional provision international accounting standard board iasb impact future period opening statement financial effective time preparing consolidated financial position earliest comparative period presented statement adopted use european union january restated endorsement procedure established european commission amendment ia change accounting defined benefit plan termination benefit significant consolidated financial statement prepared change relates accounting change defined benefit using historical cost convention except certain item obligation plan asset amendment require including available sale financial asset derivative financial recognition change defined benefit obligation fair instrument liability cashsettled share based value plan asset occur hence eliminate payment arrangement measured fair value corridor approach permitted previous version preparation consolidated financial statement ia accelerate recognition past service cost conformity ifrs requires use certain critical actuarial gain loss recognized immediately accounting estimate also requires management exercise comprehensive income order net pension judgement process applying group accounting asset liability recognized consolidated statement policy area involving higher degree judgement financial position reflect full value plan deficit complexity area assumption estimate surplus furthermore interest cost expected return significant consolidated financial statement plan asset used previous version ia disclosed note replaced netinterest amount ia r calculated applying discount rate net defined necessary comparative reclassified benefit liability asset ia r introduces certain change order enhance interperiod comparability information presentation defined benefit cost including presented current prior year extensive disclosure u c b n n u l r e p rt iv n e h e c n l e f n n c l stat e e n impact early application ia r consolidated financial statement group adjusted opening equity january first financial statement group early figure restated ia r adopted ia r revised standard adopted always applied retrospectively accordance ia consequently million net employee benefit obligation net deferred tax liability equity balance reported january effect early application ia r recorded comprehensive income retained earnings restated balance january balance reported december effect early application ia r opening balance movement year recorded comprehensive income currency translation adjustment income statement restated balance december effect consolidated income statement follows million decrease employee benefit expense social tax increase income tax expense increase profit year effect consolidated statement comprehensive income follows million remeasurement defined benefit obligation income tax decrease comprehensive income decrease total comprehensive income year ifrss ifric interpretation effective first time financial year beginning january material impact group ew standard interpretation yet adopted n following new standard amendment existing liability part fair value change due entity standard interpretation issued credit risk recorded comprehensive income effective financial year beginning january rather income statement unless creates early adopted accounting mismatch group yet assess ifrs full impact intends adopt ifrs later r financial instrument address classification accounting period beginning january measurement recognition financial asset group also consider impact remaining phase financial liability ifrs issued november ifrs completed board october replaces part ia relate classification measurement financial instrument r consolidated financial statement effective ifrs requires financial asset classified two january latest build existing principle measurement category measured fair value identifying concept control determining measured amortized cost determination factor whether entity included within made initial recognition classification depends consolidated financial statement parent company entity business model managing financial standard provides additional guidance assist instrument contractual cash flow characteristic determination control difficult assess instrument financial liability standard retains group currently assessing ifrs full impact ia requirement main change r joint arrangement effective january case fair value option taken financial latest ifrs seek provide user financial u c b n n u l r e p rt iv n e h e c n l e f n n c l stat e e n statement greater clarity entity involvement goodwill initially measured excess aggregate joint arrangement requiring entity recognize consideration transferred fair value non contractual right obligation arising joint controlling interest net identifiable asset acquired arrangement participates independently liability assumed consideration lower arrangement legal structure two fair value net asset subsidiary acquired form joint arrangement ifrs joint operation difference recognized profit loss joint venture group currently evaluating intercompany transaction balance unrealized gain impact standard transaction group company eliminated r disclosure interest entity effective unrealized loss also eliminated unless transaction january latest ifrs includes provides evidence impairment asset transferred disclosure requirement form interest accounting policy subsidiary changed entity including joint arrangement associate special necessary ensure consistency policy adopted purpose vehicle balance sheet vehicle group group currently evaluating impact standard r fair value measurement aim improve change ownership interest consistency reduce complexity providing precise subsidiary without change definition fair value single source fair value control measurement disclosure requirement use across group treat transaction noncontrolling interest ifrss requirement largely aligned result loss control transaction ifrs u gaap extend use fair value equity owner group purchase non accounting provide guidance controlling interest difference consideration applied use already required permitted paid relevant share acquired carrying value standard within ifrss u gaap group net asset subsidiary recorded equity gain currently evaluating impact standard loss disposal noncontrolling interest also ifrss ifric interpretation recorded equity yet effective would expected material impact group disposal subsidiary group cease control retained interest consolidation entity remeasured fair value change carrying amount recognized profit loss fair value subsidiary initial carrying amount purpose subsequently accounting retained interest associate joint subsidiary entity including special purpose entity venture financial asset addition amount previously group power govern financial recognized comprehensive income respect operating policy generally accompanying shareholding entity accounted group directly disposed one half voting right existence related asset liability may mean amount effect potential voting right currently exercisable previously recognized comprehensive income convertible considered assessing whether group reclassified profit loss control another entity subsidiary fully consolidated date control transferred group associate deconsolidated date control cease associate entity group group u acquisition method accounting significant influence control generally accompanying account business combination consideration shareholding voting right transferred acquisition subsidiary fair value investment associate accounted using equity asset transferred liability incurred equity method accounting initially recognized cost interest issued group consideration transferred carrying amount increased decreased recognize includes fair value asset liability resulting investor share profit loss investee contingent consideration agreement acquisitionrelated date acquisition group investment associate cost expensed incurred identifiable asset acquired includes goodwill identified acquisition liability contingent liability assumed business combination measured initially fair value ownership interest associate reduced acquisition date acquisitionbyacquisition basis significant influence retained proportionate share group recognises noncontrolling interest amount previously recognized comprehensive acquiree either fair value noncontrolling interest income classified profit loss appropriate proportionate share acquirees net asset group share associate postacquisition profit contingent consideration transferred group loss recognized income statement share recognized fair value acquisition date subsequent postacquisition movement comprehensive income change fair value contigent consideration recognized comprehensive income corresponding deemed asset liability recognized accordance adjustment carrying amount investment ia either profit loss change cumulative postacquisition movement adjusted comprehensive income contingent consideration carrying amount investment group classified equity remeasured subsequent share loss associate equal exceeds interest settlement accounted within equity associate including unsecured receivables u c b n n u l r e p rt iv n e h e c n l e f n n c l stat e e n group recognize loss unless incurred change fair value monetary security denominated obligation made payment behalf associate foreign currency classified available sale analysed translation difference resulting change unrealized gain transaction group amortized cost security change associate eliminated extent group interest carrying amount security translation difference related associate unrealized loss also eliminated unless change amortized cost recognized profit transaction provides evidence impairment loss change carrying amount recognized asset transferred accounting policy associate comprehensive income changed necessary ensure consistency policy adopted group translation difference nonmonetary financial asset liability reported part fair value gain loss dilution gain loss arising investment associate recognized income statement translation difference nonmonetary financial asset equity classified available sale included available sale reserve comprehensive income segment reporting group company group activity one segment biopharmaceuticals result financial position group entity significant class business either none currency hyperinflationary singularly aggregate chief operating decision economy functional currency different maker executive committee review presentation currency translated presentation operating result operating plan make resource currency follows allocation decision companywide basis therefore ucb operates one segment ssets liability balance sheet presented translated closing rate date balance sheet oreign currency f income expense income statement translated average exchange rate unless average translation reasonable approximation cumulative effect rate prevailing transaction date case following important exchange rate used income expense translated rate date preparing consolidated financial statement transaction resulting exchange difference recognized comprehensive income referred cumulative closing rate average rate translation adjustment consolidation exchange difference arising usd translation net investment foreign operation borrowing currency instrument designated jpy hedge investment taken gbp comprehensive income foreign operation partially chf wholly disposed sold exchange difference recorded equity recognized income statement part gain loss sale closing rate represent spot rate goodwill fair value adjustment arising acquisition december december foreign entity treated asset liability foreign entity translated closing rate functional presentation currency item included individual financial statement revenue group entity measured using currency primary economic environment entity operates functional currency consolidated financial statement revenue recognized probable future economic presented euro functional currency benefit associated transaction flow entity company presentation currency group benefit measured reliably amount revenue considered reliably measured transaction balance contingency relating sale resolved revenue represents fair value consideration foreign currency transaction translated received receivable sale good ordinary functional currency using exchange rate prevailing course group activity revenue shown net date transaction foreign exchange gain value added tax return rebate trade discount cash loss resulting settlement transaction discount related medicaid medicare u translation yearend exchange rate monetary similar programme country asset liability denominated foreign currency recognized income statement except deferred comprehensive income qualifying cash flow hedge qualifying net investment hedge u c b n n u l r e p rt iv n e h e c n l e f n n c l stat e e n net sale research development revenue sale good recognized internallygenerated intangible significant risk reward ownership good asset research development transferred buyer expenditure group retains neither continuing managerial internal research development cost expensed involvement degree usually associated incurred due long development period significant ownership effective control good sold uncertainty related development new product amount revenue measured reliably risk related outcome clinical trial well likelihood regulatory approval probable economic benefit associated concluded group internal development cost transaction flow entity general qualify capitalization intangible asset cost incurred incurred respect transaction measured reliably acquired intangible asset estimate expected sale return chargebacks granted inprocess research development project acquired via government agency wholesaler managed care business combination right acquired via either customer deducted revenue time related licensing arrangement separate purchase capitalized revenue recorded incentive offered intangible asset estimate calculated basis intangible asset amortized straightline basis historical experience specific term estimated useful life moment individual agreement available use royalty income mpairment royalty recognized accrual basis accordance substance relevant agreement nonfinancial asset revenue reporting date group review carrying amount intangible asset goodwill property plant revenue comprises revenue generated equipment determine whether indication licensing profitsharing agreement well contract impairment indication exists recoverable manufacturing agreement revenue recognized amount asset estimated order determine earned related service performed extent impairment loss irrespective whether indication impairment impairment assessment group receives third party upfront milestone intangible yet available use goodwill carried similar payment related sale outlicensing annually asset amortized impairment product revenue associated performance milestone loss recognized amount asset carrying recognized based upon achievement milestone amount exceeds recoverable amount event event substantive objectively determinable represents important point development life possible estimate recoverable amount cycle pharmaceutical product upfront payment individual asset group estimate recoverable license fee subsequent deliverable amount cashgenerating unit cgu asset initially reported deferred income recognized belongs recoverable amount higher asset fair revenue earned period development value less cost sell value use determine value collaboration manufacturing obligation use group u estimate future cash flow generated asset cgu using method interest income used initial measurement asset cgu basis mediumterm plan business activity interest recognized time proportion basis take estimated cash flow discounted using appropriate rate account effective yield asset reflects current market assessment time value money risk specific asset cgu dividend income impairment loss recognized directly income statement impairment nonfinancial asset dividend recognized shareholder right caption nonfinancial asset goodwill receive payment established suffered impairment reviewed possible reversal impairment reporting date reversal cost sale impairment recognized income statement impairment loss reversed extent asset carrying amount exceed carrying amount cost sale includes primarily direct production cost would determined net depreciation related production overhead amortization amortization impairment loss recognized related intangible asset well service rendered startup impairment loss goodwill never reversed cost expensed incurred royalty expense directly intangible asset assessed impairment compound linked good sold included cost good sold compound basis u c b n n u l r e p rt iv n e h e c n l e f n n c l stat e e n estructuring expense r intangible asset income expense patent license trademark expense made group order better intangible asset positioned face economic environment patent license trademark intangible asset operates presented income statement collectively referred intangible asset shown restructuring expense historical cost intangible asset acquired business gain loss arising upon sale intangible asset combination recognized fair value acquisition date property plant equipment well increase intangible asset except goodwill amortized reversal provision litigation tax litigation useful life straightline basis moment litigation related discontinued operation presented available use ie regulatory approval income statement income expense obtained estimated useful life based lower contract life economic useful life income tax year intangible asset except goodwill considered finite economic useful life therefore intangible asset indefinite life identified tax expense period comprises current deferred income tax tax recognized income computer software statement except extent relates item recognized comprehensive income directly acquired computer software license capitalized equity case tax also recognized basis cost incurred acquire bring use comprehensive income directly equity respectively specific software cost amortized estimated useful life year straightline basis current income tax charge calculated basis tax law enacted substantively enacted balance sheet date country company subsidiary goodwill operate generate taxable income deferred income tax recognized using liability method goodwill arises acquisition subsidiary associate temporary difference arising carrying joint venture represents excess amount asset liability consolidated financial consideration transferred group interest statement corresponding tax base used net fair value net identifiable asset liability computation taxable profit contingent liability acquiree fair value deferred income tax liability generally recognized noncontrolling interest acquiree goodwill initially taxable temporary difference deferred income recognized asset cost subsequently carried tax asset recognized extent probable cost less accumulated impairment loss goodwill related future taxable profit available acquisition subsidiary presented separately deductible temporary difference carried forward tax credit face balance sheet whereas goodwill arising carried forward loss utilized deferred income tax upon acquisition associated company included accounted arises initial recognition investment associated company goodwill initial recognition asset liability ucb operates one segment one cash generating transaction business combination unit purpose impairment testing time transaction affect neither accounting taxable profit goodwill considered indefinite life tested impairment annually whenever indication carrying amount deferred income tax asset may impaired comparing carrying amount reviewed balance sheet date reduced recoverable amount recoverable amount extent longer probable sufficient taxable cashgenerating unit less carrying amount profit available allow part asset unit impairment loss allocated first reduce recovered carrying amount goodwill allocated unit deferred income tax calculated tax rate asset unit pro rata basis expected apply period liability settled carrying amount asset unit impairment loss asset realized deferred tax asset liability goodwill reversed discounted disposal subsidiary joint venture attributable deferred tax asset liability offset amount goodwill included determination legally enforceable right offset current tax liability profit loss disposal entity asset deferred income tax relate event fair value identifiable asset taxable entity taxation authority liability contingent liability exceeds cost management periodically evaluates position taken tax business combination excess remaining reassessment return respect situation applicable tax recognized directly profit loss regulation subject interpretation establishes provision appropriate basis amount expected paid tax authority u c b n n u l r e p rt iv n e h e c n l e f n n c l stat e e n roperty plant p lease equipment property plant equipment carried cost less lease classified finance lease term accumulated depreciation impairment loss except lease transfer substantially risk reward property plant equipment construction ownership lessee lease classified carried cost less accumulated impairment loss operating lease cost includes directly attributable cost bringing asset working condition intended use finance lease purchased software integral functionality asset held finance lease recognized asset related equipment capitalized part equipment group lower fair value present value minimum lease payment less cumulative borrowing cost directly attributable acquisition depreciation impairment loss corresponding construction production qualifying asset capitalized liability lessor included balance sheet part cost asset obligation finance lease subsequent cost included asset carrying amount lease payment apportioned finance charge recognized separate asset appropriate reduction lease obligation achieve constant probable future economic benefit associated rate interest remaining balance liability item flow group cost item finance charge recognized income statement measured reliably repair maintenance expensed incurred depreciable amount leased asset allocated accounting period period expected use land depreciated systematic basis consistent depreciation policy depreciation calculated using straightline method group adopts depreciable asset owned allocate cost asset land property reasonable cer tainty group obtain construction residual value ownership end lease term period estimated useful life depreciation commences expected use useful life asset otherwise asset ready used asset depreciated shor ter lease term residual value useful life asset useful life reviewed least financial yearend expectation differ previous estimate change operating lease isare accounted change accounting estimate accordance ia accounting policy change lease payment operating lease recognized accounting estimate error income statement straightline basis term relevant lease benefit received receivable following useful life applicable main property incentive enter operating lease also spread plant equipment category straightline basis lease term b uildings year achinery year financial asset laboratory equipment year p rototype equipment year classification furniture fixture year group classifies financial asset following category fair value profit loss loan vehicle year receivables available sale classification depends c omputer equipment year purpose financial asset acquired sset held finance lease shorter asset useful management determines classification financial asset life leasing term initial recognition gain loss disposal determined comparing proceeds disposal carrying amount financial asset fair value recognized income expense income profit loss statement instrument classified fair value profit loss investment property indicative land building held held trading designated upon initial earn rental asset initially carried cost recognition financial asset designated fair value depreciated straightline basis estimated profit loss group manages investment useful life underlying useful life correspond make purchase sale decision based selfused tangible asset given insignificant amount fair value accordance group financial market investment property separately presented risk management policy derivative financial instrument balance sheet also categorized held trading unless designated hedge u c b n n u l r e p rt iv n e h e c n l e f n n c l stat e e n loan receivables loan receivables nonderivative financial asset criterion group u determine fixed determinable payment quoted objective evidence impairment loss include active market included current asset except ignificant financial difficulty issuer obligor maturity greater month balance sheet date classified noncurrent asset group breach contract default delinquency loan receivables comprise trade receivables interest principal payment cash cash equivalent balance sheet group economic legal reason relating borrower financial difficulty granting borrower available sale financial asset concession lender would otherwise consider available sale financial asset nonderivative financial becomes probable borrower enter asset either designated category bankruptcy financial reorganization classified category included disappearance active market financial noncurrent asset unless management intends dispose asset financial difficulty investment within month balance sheet date bservable data indicating measurable recognition measurement decrease estimated future cash flow group first assesses whether objective evidence regular purchase sale financial asset recognized impairment exists trade date date group commits purchase sell asset investment initially recognized loan receivables category amount loss fair value plus transaction cost financial asset measured difference asset carrying carried fair value profit loss financial asset amount present value estimated future cash fair value profit loss initially recognized fair flow excluding future credit loss value transaction cost expensed income incurred discounted financial asset original effective statement financial asset derecognized right interest rate carrying amount asset reduced receive cash flow investment expired amount loss recognized consolidated transferred group transferred income statement loan heldtomaturity investment substantially risk reward ownership available variable interest rate discount rate measuring sale financial asset financial asset fair value impairment loss current effective interest rate profit loss subsequently carried fair value loan determined contract practical expedient receivables carried amortized cost using effective group may measure impairment basis interest method less impairment loss instrument fair value using observable market price fair value listed investment based current bid subsequent period amount impairment loss price market financial asset active decrease decrease related objectively unlisted security group establishes fair value using event occurring impairment recognized valuation technique improvement debtor credit rating reversal previously recognized impairment loss recognized gain loss arising change fair value consolidated income statement financial asset fair value profit loss category recognized income statement period arise gain loss arising change asset classified available sale fair value available sale financial asset group assesses end reporting period recognized directly comprehensive income whether objective evidence financial asset disposal impairment availableforsale financial asset group financial asset impaired debt security cumulative gain loss deferred equity group u criterion referred case recycled income statement equity investment classified available sale significant prolonged decline fair value security mpairment cost also evidence asset impaired evidence exists available sale financial asset financial asset cumulative loss measured difference acquisition cost current fair value less impairment asset carried amortized cost loss financial asset previously recognized profit loss removed equity recognized profit group assesses end reporting period loss impairment loss recognized consolidated income whether objective evidence financial asset statement equity instrument reversed group financial asset impaired financial asset consolidated income statement subsequent period group financial asset impaired impairment loss fair value debt instrument classified available incurred objective evidence impairment sale increase increase objectively related result one event occurred initial event occurring impairment loss recognized recognition asset loss event loss event profit loss impairment loss reversed event impact estimated future cash flow consolidated income statement financial asset group financial asset reliably estimated u c b n n u l r e p rt iv n e h e c n l e f n n c l stat e e n erivative financial cash flow hedge forecast transaction subsequently instrument result recognition financial asset financial liability associated gain loss recognized hedging activity directly equity reclassified income statement period period asset acquired group u derivative financial instrument hedge liability assumed affect income statement exposure foreign exchange interest rate risk arising cash flow hedge relationship discontinued prospectively operational financing investment activity hedge fails effectiveness test hedging instrument group engage speculative transaction sold terminated exercised management revoke derivative financial instrument initially recorded fair designation forecasted transaction longer highly value attributable transaction cost recognized probable forecasted transaction longer highly income statement incurred derivative financial probable still expected occur hedging gain instrument subsequently remeasured fair value loss previously deferred equity remain equity transaction affect profit loss method recognising resulting gain loss depends whether derivative financial instrument forecasted transaction longer expected designated hedging instrument nature occur gain loss released immediately item hedged group designates derivative financial income statement instrument either cash flow hedge fair value hedge net investment hedge fair value hedge group document inception transaction change fair value derivative financial instrument relationship hedging instrument hedged designated qualify fair value hedge item well risk management objective strategy recorded income statement together change undertaking various hedging transaction group fair value hedged asset liability also document assessment hedge inception attributable hedged risk ongoing basis whether derivative financial instrument used hedging transaction highly effective offsetting change fair value cash flow net investment hedge hedged item hedge net investment foreign operation full fair value hedging derivative financial instrument accounted similarly cash flow hedge gain loss classified noncurrent asset liability remaining hedging instrument relating effective portion hedged item month current asset hedge recognized comprehensive income liability remaining maturity hedged item less gain loss relating ineffective portion recognized month immediately income statement within financial income gain loss accumulated equity recycled embedded derivative financial instrument separated income statement foreign operation partially host contract accounted separately disposed sold economic characteristic risk host contract embedded derivative financial instrument closely related separate instrument term derivative financial instrument embedded derivative financial instrument would meet qualify hedge accounting definition derivative financial instrument certain derivative financial instrument qualify combined instrument measured fair value hedge accounting change fair value derivative profit loss financial instrument qualify hedge accounting recognized immediately income statement within cash flow hedge financial income effective portion change fair value derivative financial instrument designated qualify inventory cash flow hedge recognized comprehensive income gain loss relating ineffective portion recognized immediately income statement within raw material consumables good purchased resale financial income valued lower cost net realisable value cash flow hedge firm commitment forecasted cost determined using weighted average cost method transaction result recognition nonfinancial cost work progress finished good comprises asset nonfinancial liability time asset cost conversion cost incurred bringing liability recognized associated gain loss inventory present location condition derivative financial instrument previously conversion cost include cost production recognized equity included initial measurement related fixed variable production overhead cost asset liability including depreciation charge net realisable value represents estimated selling price less estimated cost completion cost incurred marketing selling distribution u c b n n u l r e p rt iv n e h e c n l e f n n c l stat e e n trade receivables hybrid capital bond condition hybrid capital issued satisfy trade receivables recognized initially fair value criterion stipulated ia financial instrument subsequently measured amortized cost using effective presentation instrument accounted equity interest rate method less provision impairment instrument group hybrid capital classified equity interest cash cash equivalent reflected dividend shareholder statement change equity cash cash equivalent comprise cash hand demand deposit shortterm highly liquid bond borrowing investment original maturity three month less bank overdraft bank overdraft shown within bond borrowing overdraft initially measured fair borrowing current liability balance sheet value net transaction cost incurred subsequently measured amortized cost using effective interest oncurrent asset n rate method difference proceeds net transaction cost settlement redemption disposal group held borrowing recognized term borrowing sale discontinued accordance group accounting policy operation borrowing classified current liability unless group unconditional right defer settlement liability least month balance sheet date discontinued operation component company either disposed classified held sale represents major separate line business ompound financial c geographical area operation part single coordinated plan dispose subsidiary acquired instrument exclusively view resale compound financial instrument issued group noncurrent asset disposal group classified comprise convertible bond converted held sale carrying amount recovered ordinary share option issuer number principally sale transaction sale considered share issued vary change fair highly probable noncurrent asset disposal group value past due existence option measured lower carrying amount fair value issuer redeem cash convertible bond less cost sell carrying amount recovered separated debt derivative component principally sale transaction rather continuing use impairment loss upon initial classification upon initial recognition bond fair value debt held sale recognized income statement component determined based present value noncurrent asset classified held sale neither contractually determined stream cash flow discounted depreciated amortized rate interest applied time market instrument comparable credit status providing substantially cash flow term share capital without conversion option subsequent initial recognition debt component ordinary share measured based amortized cost using effective interest method ordinary share classified equity incremental cost directly attributable issue new share option remainder proceeds allocated shown equity deduction net tax proceeds conversion option recognized within derivative company issue preference mandatory subsequent initial recognition derivative component redeemable preference share measured fair value gain loss upon measurement recognized income statement treasury share result board decision revoke ucbs right related cash settlement option derivative group company purchase company component reclassified equity based fair value equity share capital treasury share consideration date revocation equity component paid including attributable direct cost net income remeasured subsequent initial recognition except tax deducted equity attributable conversion expiry company equity holder share cancelled reissued share subsequently reissued transaction cost directly attributable bond consideration received net directly attributable offering incremental included calculation incremental transaction cost related income tax amor tized cost using effective interest method effect included equity attributable company amor tized income statement life equity holder instrument u c b n n u l r e p rt iv n e h e c n l e f n n c l stat e e n trade payable asset excluding interest recognized immediately statement financial position charge credit comprehensive income period occur trade payable initially measured fair value remeasurement recorded comprehensive income subsequently measured amortized cost using effective recycled however entity may transfer amount interest method recognized comprehensive income within equity past service cost recognized profit loss period plan amendment netinterest calculated applying employee benefit discount rate net defined benefit liability asset defined benefit cost split three category pension obligation ervice cost pastservice cost gain loss curtailment settlement group operates various postemployment scheme including defined benefit defined contribution n etinterest expense income pension plan r emeasurement defined contribution plan pension plan group present first two component defined group pay fixed contribution separate entity benefit cost line item employee benefit expense legal constructive obligation pay consolidated income statement nature expense contribution event fund hold aggregation curtailment gain loss accounted sufficient asset pay employee benefit relating pastservice cost remeasurements recorded employee service current prior period comprehensive income obligation contribution defined contribution pension plan recognized employee benefit expense consolidated income statement due prepaid postretirement employee benefit contribution recognized asset extent group company provide postretirement healthcare cash refund reduction future payment available benefit retiree group net obligation typically defined benefit plan define amount pension amount future benefit employee earned benefit employee receive retirement usually return service current prior period dependent one factor age year expected cost benefit accrued period service compensation liability recognized employment using methodology used defined consolidated statement financial position respect benefit plan defined benefit pension plan present value defined benefit obligation less fair value plan asset termination benefit surplus resulting calculation limited present value economic benefit available form termination benefit payable employment refund plan reduction future contribution terminated normal retirement date plan employee accepts voluntary redundancy exchange benefit group recognises termination benefit defined benefit obligation calculated independent demonstrably committed either terminating actuary using projected unit credit method full employment current employee according detailed actuarial valuation based updated personnel information formal plan without possibility withdrawal providing performed least every three year additionally termination benefit result offer made encourage net fluctuation recognized balance sheet voluntary redundancy benefit falling due one year next due plan circumstance month balance sheet date discounted present significant membership change modification plan etc value full actuarial valuation also required year full actuarial valuation required projection known rollforwards previous year updated profitsharing bonus plan assumption discount rate salary increase turnover used group recognises liability expense rollforward valuation individual employee bonus profitsharing based formula take data last full valuation date used taking consideration profit attributable company account assumption salary increase possibly shareholder certain adjustment group recognises turnover valuation measure liability provision contractually obliged applicable balance sheet date december market past practice created constructive obligation value retirement plan asset also established reliable estimate obligation made reported date regardless whether full roll forward valuation performed sharebased payment present value defined benefit obligation determined discounting estimated future cash outflow group operates several equitysettled cashsettled using yield high quality corporate bond sharebased compensation plan maturity date approximating term related group fair value employee service received exchange obligation denominated currency grant stock option recognized expense benefit expected paid total amount expensed determined reference remeasurement comprising actuarial gain loss fair value stock option granted excluding effect asset ceiling applicable return plan impact nonmarket service performance vesting u c b n n u l r e p rt iv n e h e c n l e f n n c l stat e e n condition example profitability remaining employee provision entity specified time period nonmarket vesting condition included provision recognized balance sheet assumption number option expected vest total amount expensed recognized present obligation legal constructive vesting period period specified result past event vesting condition satisfied probable outflow resource embodying fair value stock option plan measured economic benefit required settle obligation grant date using blackscholes valuation model take account expected life cancellation rate reliable estimate made amount option balance sheet date entity revise obligation estimate number option expected vest recognises impact revision original estimate amount recognized provision best estimate income statement corresponding expenditure required settle present obligation adjustment equity balance sheet date provision measured present value expenditure expected required proceeds received net directly attributable settle obligation using discount rate reflects current transaction cost credited share capital nominal value market assessment time value money risk share premium option exercised specific obligation increase provision due fair value amount payable employee respect passage time recognized interest expense share appreciation right settled cash restructuring provision recognized group recognized expense corresponding increase detailed formal plan raised valid expectation liability period employee become affected carry restructuring unconditionally entitled payment liability remeasured starting implement plan announcing main balance sheet date settlement date feature affected change fair value liability recognized personnel expense income statement critical judgement accounting estimate estimate judgement continuously evaluated ritical accounting c based historical experience factor including expectation future event believed estimate assumption reasonable circumstance preparation financial statement conformity ifrs adopted use european union requires ritical judgement c management make estimate assumption affect applying group reported amount asset liability disclosure contingent asset liability date financial accounting policy statement reported amount revenue expense reporting period revenue recognition management base estimate historical experience nature group business many sale various assumption reasonable transaction simple structure circumstance result form basis making reported amount revenue expense may sale agreement may consist multiple arrangement readily apparent source actual result occurring different time group definition equal estimate estimate also party outlicensing agreement involve assumption reviewed periodically effect upfront milestone payment may occur several revision reflected financial statement period year involve certain future obligation revenue determined necessary recognized significant risk reward ownership transferred group retain continuing managerial involvement effective sale allowance control good sold obligation group accrual expected sale return charge fulfilled might result cash receipt initially back rebate including u medicaid drug recognized deferred income released income rebate program u federal medicare program subsequent accounting period based different similar rebate country estimate based condition specified agreement analysis existing contractual obligation legislation historical trend group experience assessment u c b n n u l r e p rt iv n e h e c n l e f n n c l stat e e n management total accrual item group applied following key assumption adequate based upon currently available information value use calculation required impairment testing interpretation relevant regulation deduction intangible asset goodwill yearend based management estimate actual deduction growth rate terminal value might differ estimate difference could impact accrual recognized balance sheet future iscount rate respect goodwill period consequently level sale recognized intangible related marketed product income statement future period often time iscount rate respect intangible related lag several month recording estimate pipeline product final accounting sale allowance general discount rebate deduction shown invoice since cash flow also take account tax expense accounted immediate deduction gross posttax discount rate used impairment testing sale income statement sale return charge management estimate use posttax discount back rebate discount mentioned rate approximates result using pretax rate applied invoice estimated deducted sale presented pretax cash flow balance sheet appropriate accrual account deducted sale environmental provision intangible asset goodwill group provision environmental remediation cost disclosed note significant group intangible asset carrying amount element environmental provision consist cost million note goodwill carrying amount fully clean refurbish contaminated site treat million note intangible asset amortized contamination certain site mainly related useful life straightline basis discontinued chemical film activity group moment available use ie regulatory approval obtained future remediation expense affected number uncertainty include amongst others detection management estimate useful life acquired previously unknown contaminated site method inprogress rd compound equates period extent remediation percentage waste attributable compound benefit patent protection data group financial capability exclusivity intangible asset acquired potentially responsible party given inherent difficulty business combination comprises compound estimating liability area cannot guaranteed marketed patent protection data additional cost incurred beyond amount exclusivity exists management estimate useful life currently accrued effect resolution environmental equates period compound realize matter result operation cannot predicted due substantially cash contribution uncertainty concerning amount timing intangible asset goodwill regularly reviewed future expenditure result future operation impairment whenever indication change arise could impact provision recognized impairment might exist intangible asset yet balance sheet future available use goodwill subject least annual impairment testing employee benefit assess impairment estimate made group currently many defined benefit plan future cash flow expected result use disclosed note calculation asset asset eventual disposal estimated cash flow liability related plan based upon statistical adjusted present value using appropriate actuarial assumption particular case discount rate reflects risk uncertainty present value defined benefit obligation associated forecasted cash flow impacted assumption discount rate used arrive actual outcome could vary significantly estimate present value future pension liability assumption discounted future cash flow factor entrance future increase salary benefit absence competition technical obsolescence lower furthermore group u statisticallybased assumption expected right could result shortened useful life covering area future withdrawal participant impairment plan estimate life expectancy actuarial assumption used might differ materially actual result due change market economic condition higher lower employee turnover longer shorter life span participant change factor assessed difference could impact asset liability recognized balance sheet future period u c b n n u l r e p rt iv n e h e c n l e f n n c l stat e e n financial risk management group exposed various financial risk arising market risk underlying operation corporate finance activity financial risk market risk including currency risk market risk risk change market price interest risk price risk credit risk liquidity risk foreign exchange rate interest rate equity price affect group income statement value note present information group exposure holding financial instrument objective market risk abovementioned risk group policy process management manage control market risk exposure managing risk group management capital group enters derivative financial instrument risk management carried group treasury also incurs financial liability order manage market risk department policy approved financial risk possible group seek apply hedge accounting management committee frmc order manage volatility income statement frmc established includes chief group policy practice enter derivative financial officer head accounting reporting transaction speculative purpose consolidation department financial control department internal audit department tax department treasury foreign exchange risk risk department group operates across world exposed frmc responsible movement foreign currency affecting net income r eviewing result ucb risk assessment financial position expressed euro group actively monitor currency exposure appropriate pproval recommended risk management strategy enters transaction aim preserving value onitoring compliance financial market risk asset anticipated transaction group u management policy forward contract foreign exchange option cross currency swap hedge certain committed anticipated pproval policy change foreign exchange flow financing transaction r eporting audit committee instrument purchased hedge transaction exposure group financial risk management policy established primarily denominated u dollar gb pound japanese yen frmc need identify analyse risk faced swiss franc currency group group set appropriate risk limit control important exposure group financial risk management monitor risk adherence limit risk management policy hedge period minimum maximum policy reviewed frmc semiannual basis month anticipated cash flow primarily derived reflect change market condition group activity sale royalty outlicensing revenue provided natural hedge exist group certain investment foreign operation whose net asset exposed foreign currency translation risk currency exposure arising net asset group foreign operation u managed borrowing denominated u dollar provides economic hedge currency exposure arising net asset group foreign operation switzerland uk managed forward contract group investment subsidiary hedged mean borrowing forward contract currency considered material longterm neutral effect translation exposure arising consolidation foreign currency denominated financial statement group foreign subsidiary shown cumulative translation adjustment group consolidated statement change equity u c b n n u l r e p rt iv n e h e c n l e f n n c l stat e e n effect currency fluctuation december euro strengthened weakened following currency variable held constant impact equity posttax profit forth year would follows change rate impact strenghtening impact equity income statement million weakening eur loss gain loss gain december usd gbp chf change rate impact strenghtening impact equity income statement million weakening eur loss gain loss gain december usd gbp chf group policy practice enter derivative transaction speculative purpose interest rate risk effect interest rate fluctuation change interest rate may cause variation interest basis point increase interest rate balance income expense resulting interestbearing asset sheet date would increased equity million liability addition affect market value million basis point decrease interest rate certain financial asset liability instrument described would decreased equity million million following section market risk financial asset basis point increase interest rate balance sheet interest rate group major debt instrument date would increased profit loss million fixed floating described note group u million basis point decrease interest interest rate derivative manage interest rate risk rate would decreased profit loss million described note million change profit loss group designates derivative financial instrument would result change fair value cash flow interest rate swap hedging instrument fair value interest rate derivative designated foreign currency hedge fixed rate financial asset liability denominated floating rate liability group derivative financial instrument hedged item qualify hedge accounting well inefficient accounted fair value profit loss por tion fair value hedge designated por tion fixed rate borrowing group retail bond change fair value resulting interest rate institutional eurobond derivative designated euro denominated floating rate liability group highly probable future cash flow fixed rate debt instrument issued accounted equity ia change fair value resulting interest rate derivative designated foreign currency denominated floating rate liability group accounted profit loss consequence underlying future cash flow result derivative instrument qualifying accounting change fair value equity ia u c b n n u l r e p rt iv n e h e c n l e f n n c l stat e e n market price risk change market value certain financial asset exposure financial asset credit risk derivative financial instrument affect income controlled setting policy limiting credit exposure financial position group financial longterm asset high quality counterparties regular review credit rating held contractual purpose marketable setting defined limit individual counterparty security held mainly regulatory purpose risk criterion set group treasury investment policy loss value managed review prior investing based generally considered high quality long term credit continuous monitoring performance investment rating year credit default swap rate change risk profile appropriate reduce exposure netting agreement investment equity bond debenture fixed isda international swap derivative income instrument entered basis guideline association master agreement signed respective regard liquidity credit rating counterparties maximum exposure credit risk resulting financial activity without considering netting amount subject market price risk rather immaterial agreement equal carrying amount financial asset therefore impact equity income statement plus positive fair value derivative instrument reasonable change market price risk assumed negligible similar group purchased treasury liquidity risk share well american style call option providing right purchase share ucb sa liquidity risk risk group able accounted equity issued convertible meet financial obligation fall due group bond maturing group repurchased million approach managing liquidity ensure far equity component linked possible always sufficient liquidity meet convertible bond amount million million liability due normal circumstance without net tax result ucbs decision revoke cash incurring unacceptable loss risking damage settlement option linked convertible bond group reputation group maintains sufficient reserve cash credit risk readily realisable marketable security meet liquidity requirement time addition group certain unutilized revolving committed facility disposal credit risk arises possibility counterparty transaction may unable unwilling meet balance sheet date group following obligation causing financial loss group trade source liquidity available receivables subject policy active risk management c ash cash equivalent note focus assessment country risk credit million million availability ongoing credit evaluation account monitoring procedure certain concentration within trade arketable nonequity security note receivables counterparty credit risk particularly million million u due sale via wholesaler note u nutilized committed facility note credit exposure critical country certain southern million million european country group obtained credit insurance existing billion syndicated committed revolving credit u group entered trade receivable facility group maturing undrawn per end financing agreement qualifies derecognition according million bilateral committed credit facility term condition agreement ucb drawn milion per end linearly degressive retain nonpayment late payment risk relating transferred trade receivables u c b n n u l r e p rt iv n e h e c n l e f n n c l stat e e n table analysis contractual maturity group maturity date excluding impact netting amount financial liability relevant maturity grouping based mentioned respect financial derivative remaining period balance sheet date contractual indicative contractual undiscounted cash flow contrac tual cash less million note total flow year year year year december bank borrowing debenture short term loan finance lease liability convertible bond retail bond institutional eurobond trade liability bank overdraft interest rate swap put call option noncontrolling interest forward exchange contract used hedging purpose outflow inflow forward exchange contract derivative financial instrument fair value profit loss outflow inflow december bank borrowing debenture short term loan finance lease liability convertible bond retail bond institutional eurobond trade liability bank overdraft interest rate swap forward exchange contract used hedging purpose outflow inflow forward exchange contract derivative financial instrument fair value profit loss outflow inflow u c b n n u l r e p rt iv n e h e c n l e f n n c l stat e e n capital risk management group policy respect managing capital safeguard group ability continue going concern order provide return shareholder benefit patient reduce group external debt order obtain capital structure consistent others industry million restated total borrowing note bond note less cash cash equivalent note available sale debt security note cash collateral related financial lease obligation net debt total equity total financial capital gearing ratio fair value estimation fair value financial instrument traded active market carrying amount less impairment provision trade available sale financial asset based quoted receivables trade payable assumed approximate market price balance sheet date fair value fair value financial liability disclosure purpose estimated discounting future fair value financial instrument traded contractual cash flow current market interest rate active market determined using established valuation available group similar financial instrument technique option pricing model estimated discounted value cash flow group u variety fair value hierarchy method make assumption based market condition existing balance sheet date effective january group adopted amendment ifrs financial instrument measured quoted market price used longterm debt balance sheet fair value amendment requires technique estimated discounted cash flow used disclosure fair value measurement level following determine fair value remaining financial instrument fair value measurement hierarchy fair value interest rate swap calculated present value estimated future cash flow fair level quoted unadjusted price active market value forward exchange contract determined using identical asset liability discounted value exchanged amount currency level technique input converted prevailing spot rate balance sheet date significant effect recorded fair value observable either directly indirectly level technique use input significant effect recorded fair value based observable market data u c b n n u l r e p rt iv n e h e c n l e f n n c l stat e e n financial asset measured fair value million level level level total december financial asset available sale asset note quoted equity security quoted debt security derivative financial asset note forward foreign exchange contract cash flow hedge forward exchange contract fair value profit loss interest rate derivative cash flow hedge interest rate derivative fair value profit loss million level level level total december financial asset available sale asset note quoted equity security quoted debt security derivative financial asset note forward foreign exchange contract cash flow hedge forward exchange contract fair value profit loss interest rate derivative cash flow hedge interest rate derivative fair value profit loss financial liability measured fair value million level level level total december financial liability derivative financial liability note forward foreign exchange contract cash flow hedge forward exchange contract fair value profit loss interest rate derivative cash flow hedge interest rate derivative fair value profit loss put call option noncontrolling interest million level level level total december financial liability derivative financial liability note forward foreign exchange contract cash flow hedge forward exchange contract fair value profit loss interest rate derivative cash flow hedge interest rate derivative fair value profit loss put call option noncontrolling interest reporting period ending december transfer level level fair value measurement transfer level fair value measurement u c b n n u l r e p rt iv n e h e c n l e f n n c l stat e e n segment reporting group activity one segment biopharmaceuticals operating result operating plan make resource allocation decision companywide basis therefore ucb significant class business either operates one segment enterprisewide disclosure singularly aggregate chief operating decision product sale geographic area revenue major maker executive committee review customer presented product sale information net sale consist following million cimzia vimpat neupro keppra includ keppra xr zyrtec includ zyrtecd cirrus xyzal omeprazole metadate cd nootropil venlafaxine xr tussionex product total net sale geographic information table show sale geographic market customer located million north america germany france italy spain uk ireland belgium country total net sale table illustrates property plant equipment geographic market asset located million north america switzerland germany france spain uk ireland belgium country total u c b n n u l r e p rt iv n e h e c n l e f n n c l stat e e n nformation major customer ucb customer individually account u sale wholesaler accounted total net sale end approximately u sale business combination meizler biopharma may ucb acquired issued immunology ucb bring part mature new outstanding share meizler biopharma meizler medicine meizlers portfolio commercialisation privatelyowned brazilian pharmaceutical company brazil based ucbs control board director purchase price equal u million million minus management ucb fully consolidated meizler meizlers net debt adjustment net debt total purchase price allocated preliminary finalised time financial statement net tangible intangible asset based upon historic published term deal purchase book value may set forth excess price may increased u million certain cash purchase price preliminary net tangible contingent payment purchase agreement also grant asset intangible asset recorded goodwill selling shareholder put option exercisable company expects continue obtain information remaining share meizler grant measurement period one year acquisition ucb call option providing right purchase selling date assist determining fair value net asset shareholder remaining share meizler note acquired acquisition date noncontrolling interest exercise price based multiple ebitda amount contingent consideration put result preceding year call option remaining share meizler meizler privatelyheld brazilian pharmaceutical company estimated value recorded december founded based outside sao paulo yet finalised subject change could team employee commercializes portfolio significant preliminary purchase price allocation inlicensed specialty product brazilian market covering meizler follows different therapeutic area including central nervous system million acquisition date cash consideration recognised amount identifiable asset acquired liability assumed provisional fair value noncurrent asset current asset noncurrent liability current liability total identifiable net asset goodwill income statement year includes net sale loss million million respectively meizler business combination effected january ucbs net sale loss would million million respectively u c b n n u l r e p rt iv n e h e c n l e f n n c l stat e e n discontinued operation profit discontinued operation million environmental claim site ucb retained profit million arose mainly termination liability settled past month well tax liability partial reversal provision related unwinding discount rate legacy film chemical activity including termination revenue million revenue generated mean profitsharing agreement upfront payment milestone payment reimbursement contract manufacturing revenue total revenue revenue generated profitsharing agreement stella jointly development commercialization relates primarily following item cimzia japan r evenue copromotion provas jalra ilestone payment due agreement actient icandra germany novartis pharmaceutical r evenue copromotion xyzal u gsk xyzal japan sale milestone sanofi revenue contract manufacturing activity mainly linked toll manufacturing agreement entered ucb received milestone payment gsk shire well contract manufacturing revenue reimbursement different party mainly earned product related actient pharmaceutical tsuka codevelopment e keppra neupro japan agreement delsym operating expense nature table illustrates certain item expense recognized income statement using classification based nature within group million note restated employee benefit expense depreciation property plant equipment amortization intangible asset impairment nonfinancial asset total u c b n n u l r e p rt iv n e h e c n l e f n n c l stat e e n employee benefit expense million note restated wage salary social security cost postemployment benefit defined benefit plan postemployment benefit defined contribution plan sharebased payment employee director insurance employee benefit total employee benefit expense total employee benefit expense allocated discontinued operation employee benefit consist along functional line within income statement except mainly termination benefit severance payment case discontinued operation longterm shortterm disability benefit included relevant determination profit headcount december hourly paid monthly paid management total information regarding postemployment benefit sharebased payment found note operating income expense operating income expense amounted million million consists mainly amortization nonproduction related intangible asset million million reversal provision million million impairment reversal impairment respect trade receivables tangible fixed asset million million reimbursement third party development expense incurred group million million grant received million expense related health care reform u u c b n n u l r e p rt iv n e h e c n l e f n n c l stat e e n impairment nonfinancial asset review recoverable amount group asset impairment charge related group property resulted recognition impairment charge amounting plant equipment certain administrative building million million manufacturing facility amounted million million trademark patent licence impairment charge amount million million impairment reasonably possible change key assumption respect intangible asset million management based determination asset recoverable amount would cause asset carrying amount result yearly impairment testing additional exceed recoverable amount impairment charge million trademark patent licence recognized million restructuring expense restructuring expense december amount function severance cost restructuring million million related expense mainly related new organization shape restructuring cost reorganization support european operation income expense income amounted million expense october united state department justice million comprised following item united state attorney office eastern district pennsylvania issued civil investigative demand ther income million compared ucb inc relating price reporting cimzia million divestment primary care u federal government sale marketing market u australia cimzia u company cooperated fully ther expense amounted million investigation september government million mainly relate concluded investigation without imposing fine penalty taking action company patent infringment suit aaipharma ucb optimization ucb company structure u sale omeprazole product hatchwaxman patent infringement suit ucb million expense related mallinkckrodt u filed anda restructuring epratuzumab license agreement metadate cd paragraph iv certification immunomedics ucb immunomedics received patent infringement suit u apotex nonrefundable cash payment totalling u million upon ucb sale univasc uniretic execution amendment additional amortization moexipril product depreciation government concluded investigation without imposing fine penalty taking action company u c b n n u l r e p rt iv n e h e c n l e f n n c l stat e e n financial income financing cost net financing cost year amounted million million breakdown financing cost financial income follows financing cost million interest expense convertible bond retail bond institutional eurobond borrowing interest expense related interest rate derivative financial charge finance lease impairment equity security net fair value loss foreign exchange derivative net foreign exchange loss net financial income expense loss debt extinguishment total financing cost financial income million interest income bank deposit interest rate derivative dividend income net gain interest rate derivative net fair value gain foreign exchange derivative net foreign exchange gain total financial income impairment equity security related investment wilex note april ucb purchased million par value outstanding convertible bond loss debt extinguishment million note u c b n n u l r e p rt iv n e h e c n l e f n n c l stat e e n income tax expense credit million restated current income tax deferred income tax total income tax expense credit group operates internationally implying subject weighted average tax rate applicable profit loss income tax many different tax jurisdiction consolidated company income tax expense group profit tax income tax recognized income statement differs theoretical amount would arise using detailed follows million restated profit loss tax income tax expense credit calculated domestic tax rate applicable respective country theoretical income tax rate reported current income tax reported deferred income tax total reported tax charge credit effective income tax rate difference theoretical reported tax expense nondeductible tax purpose nontaxable income increase decrease tax provision effect previously unrecognized tax loss used period tax credit variation tax rate tax rate effect current tax adjustment related prior year deferred tax adjustment related prior year effect unused tax credit tax loss recognized deferred tax withholding tax tax total income tax expense credit low theoretical income tax rate arising year due significant proportion loss arising higher tax jurisdiction effective tax rate remains low due continued recognition previously unrecognized tax loss u c b n n u l r e p rt iv n e h e c n l e f n n c l stat e e n component comprehensive income million restated available sale financial asset gain loss arising year less reclassification adjustment gain loss included income statement cashflow hedge gain loss arising year less reclassification adjustment gain loss included income statement net investment hedge gain loss arising year less reclassification adjustment gain loss included income statement remeasurement defined benefit obligation gain loss arising year less reclassification adjustment gain loss included income statement u c b n n u l r e p rt iv n e h e c n l e f n n c l stat e e n intangible asset trademark patent million licence total gross carrying amount january addition disposal transfer one heading another business combination effect movement exchange rate gross carrying amount december accumulated amortization impairment loss january amortization charge year disposal impairment loss recognized income statement transfer one heading another transfer asset held sale effect movement exchange rate accumulated amortization impairment loss december net carrying amount december trademark patent million licence total gross carrying amount january addition disposal transfer one heading another transfer asset held sale effect movement exchange rate gross carrying amount december accumulated amortization impairment loss january amortization charge year disposal impairment loss recognized income statement transfer one heading another transfer asset held sale effect movement exchange rate accumulated amortization impairment loss december net carrying amount december group amortises intangible asset amortization year group recognized total impairment intangible asset allocated cost sale intangible charge million million related yearly asset related compound amortization impairment testing impairment charge detailed charge related software allocated function note presented income statement use software caption impairment nonfinancial asset majority group intangible asset arose intangible asset includes software process previous acquisition group acquired development project major part milestone intangible asset totalling million million incurred collaboration agreement addition related mainly milestone incurred collaboration agreement inlicencing deal addition software capitalized eligible software development cost u c b n n u l r e p rt iv n e h e c n l e f n n c l stat e e n goodwill million cost january acquisition effect movement exchange rate net book value december group test goodwill impairment reporting significant change key assumption date frequently indication goodwill comparing might impaired purpose impairment testing cash flow beyond projected forecasted period terminal group operates one segment biopharma value extrapolated using estimated growth rate one single cash generating unit cgu represents growth rate exceed longterm lowest level goodwill monitored average growth rate relevant territory recoverable amount cgu determined based cgu operates valueinuse calculation methodology applied group revenue expense eur performing impairment testing modified usd based country following important exchange rate compared used preparing future cash flow key assumption calculation performed based cash flow usd projection derived financials underlying gbp strategic plan approved management covering period jpy year given nature industry longterm chf projection used fully model appropriate product lifecycles based patent expiry therapeutic area longterm projection based past starting risk free short term libor eur month performance management expectation market long term eu generic government bond year development adjusted specific risk include discount rate applied determined based revenue growth rate newly launched product weighted average cost capital dcf model including year benchmark cost debt equity adjusted probability reaching commercial stage new reflect specific asset country risk associated product indication cgu given industry group used discount rate probability success future product launch marketed product pipeline expected date thereof product discount rate reviewed least annually postpatent expiry erosion since aftertax cash flow incorporated calculation valueinuse cgu posttax discount rate used order remain consistent use posttax discount rate approximates result using pretax rate applied pretax cash flow tax rate used sensitivity analysis based management assessed reasonable change key assumption determination recoverable amount would cause carrying value cgu materially exceed recoverable amount information purpose sensitivity analysis using perpetual growth rate combined overall discount rate discount rate would result impairment goodwill u c b n n u l r e p rt iv n e h e c n l e f n n c l stat e e n property plant equipment office computer equipment million land plant vehicle asset building machinery construction total gross carrying amount january addition disposal transfer one heading another business combination effect movement exchange rate gross carrying amount december accumulated depreciation january depreciation charge year impairment charge disposal transfer one heading another business combination effect movement exchange rate accumulated depreciation december net carrying amount december office computer equipment million land plant vehicle asset building machinery construction total gross carrying amount january addition disposal transfer one heading another transfer asset held sale effect movement exchange rate gross carrying amount december accumulated depreciation january depreciation charge year impairment charge disposal transfer one heading another transfer asset held sale effect movement exchange rate accumulated depreciation december net carrying amount december none group property plant equipment subject plant equipment impairment charge detailed restriction title property plant note presented income statement equipment pledged security liability caption impairment nonfinancial asset group acquired property plant capitalized borrowing cost equipment totalling million million month capitalized borrowing cost addition related mainly investment amounted million million construction biological pilot plant brainelalleud belgium biological plant bulle switzerland leased asset supporting new product delivery device well improvement replacement capital expenditure ucb lease building office equipment number finance lease agreement carrying value leased year group recognized total impairment building million million charge million million property u c b n n u l r e p rt iv n e h e c n l e f n n c l stat e e n financial asset noncurrent financial asset million available sale financial asset refer cash deposit derivative financial instrument note loan granted third party reimbursement right respect german defined benefit plan financial asset total financial asset year end current financial asset million clinical trial material available sale financial asset refer derivative financial instrument note total financial asset year end available sale financial asset current noncurrent available sale financial asset comprise following million equity security debt security total available sale financial asset year end movement carrying value available sale financial asset follows million equity debt equity debt security security security security january addition disposal revaluation equity gain loss reclassified equity income statement impairment charge note december u c b n n u l r e p rt iv n e h e c n l e f n n c l stat e e n group investment listed debt security mainly january ucb participated capital increase issued european government well financial partially participated august capital increase institution bond classified available wilex consequently ucbs stake wilex decreased sale measured fair value fair value listed material decrease fair debt security determined reference published price value investment led impairment million quotation active market thru profit loss million note financial asset include investment wilex biotie september ucb participated biotie therapy therapy classified available sale ucb capital increase ucbs stake decreased significant influence measured fair value decrease fair value related investment upon initial recognition amount million december recognized comprehensive income refer note none financial asset either past due year end inventory million raw material consumables work progress finished good good purchased resale inventory cost inventory recognized expense included cost sale amounted million million inventory pledged security inventory stated net realisable value writedown inventory amounted million million included cost sale total inventory increased million mainly related buildup cimzia neupro stock u c b n n u l r e p rt iv n e h e c n l e f n n c l stat e e n trade receivables million trade receivables less provision impairment trade receivables net vat receivable interest receivables prepaid expense accrued income receivables royalty receivables trade receivables carrying amount trade receivables concentration credit risk respect approximates fair value respect trade trade receivables credit exposure critical receivables fair value estimated carrying country southern european country amount less provision impairment group obtained credit insurance group cooperates receivables carrying value approximates fair value given dedicated wholesaler certain country largest shortterm maturity amount outstanding trade receivable single customer mckesson corp u aging analysis group trade receivables yearend follows gross gross carrying carrying million amount impairment amount impairment past due past due less one month past due one month three month past due three month six month past due six month one year past due one year total based historical default rate group belief concern outstanding provision impairment necessary respect trade balance balance sheet date receivables past due past due one month movement provision impairment respect trade receivables shown million balance january impairment charge recognized income statement utilization reversal provision impairment effect movement exchange rate balance december class within trade receivables contain impaired asset u c b n n u l r e p rt iv n e h e c n l e f n n c l stat e e n carrying amount group trade receivables denominated following currency million eur usd jpy gbp currency trade receivables maximum exposure credit risk reporting date fair value class receivable mentioned group hold collateral security cash cash equivalent million shortterm bank deposit cash bank hand cash cash equivalent bank overdraft note cash cash equivalent less bank overdraft reported cash flow statement capital reserve hare capital share premium issued share capital company amounted first call date interest floating month million million represented euribor bps bond listed share share company luxembourg stock exchange share without par value december perpetual subordinated bond qualify equity share registered instrument group ia financial instrument bearer dematerialized share holder ucb share presentation due entitled receive dividend declared also entitled one vote per share shareholder meeting bond perpetual maturity company authorized unissued capital subordinated cb may elect defer interest payment mandatory u december share premium reserve amounted payment event occurred previous month million million junior security repurchase redemption parity junior security ybrid capital h accordingly interest presented interest expense income statement accounted corresponding accounting dividend shareholder march ucb sa completed placement within statement change equity transaction million perpetual subordinated bond bond cost deducted hybrid capital taking tax issued offer investor coupon effect account per annum first five year bond maturity date however ucb right hybrid capital amounted million december redeem bond th anniversary million dividend shareholder perpetual issue march quarter thereafter subordinated bond presented retained earnings u c b n n u l r e p rt iv n e h e c n l e f n n c l stat e e n reasury share ifrs acquisition value surplus arose schwarz pharma business combination million million group acquired thru ucb sa ucb fipar sa equity component linked convertible bond treasury share total amount million million million net tax result issued treasury share total amount ucbs decision revoke cash settlement option linked million net disposal treasury share convertible bond refer note net amount million remeasurement value defined benefit obligation group retained treasury share million million million related share swap deal december treasury share acquired put call option related meizler biopharma order honour exercise share option share million award granted board director certain purchase remaining noncontrolling interest category employee ucb fipar ucb sa schwarz pharma zuhai company ltd million right resell share later date group purchased call option ucb share total premium million umulative translation c adjustment ther reserve cumulative translation adjustment reserve represents cumulative currency translation difference relating reserve amounted million million consolidation group company use functional consists following item currency euro sharebased payment group operates several equitybased cash option become exercisable vesting period based compensation plan including share option plan three year except eligible employee subject share appreciation right plan share award plan legislation requires longer vesting period order performance share plan compensate employee benefit reduced taxation employee leaf service rendered group option usually lapse upon expiry period six month option lapse case death share option plan share award plan retirement case involuntary termination tax performance share plan equitysettled whereas share paid upon grant group obligation appreciation right plan cashsettled plan besides repurchase settle option cash plan group also operates employee share purchase plan uk u reload feature option transferable except case death share appreciation right sars plan similar hare option plan characteristic share option plan except share appreciation reserved ucb employee u plan cash settled share option granted u option holder right plan transformed sars except three employee since eligible u employee remuneration committee granted option ucb sa granted sars share executive committee member senior executive senior middle management ucb group exercise price granted option hare award plan plan equal lowest following two value average closing price ucb share remuneration committee granted free ucb sa share euronext brussels day preceding offer executive committee member senior executive free share service condition attached closing price ucb share euronext brussels whereby beneficiary required remain service day grant three year post grant date share award lapse upon leaving different exercise price determined eligible group except upon leaving retirement death employee subject legislation requires different case vest immediately beneficiary exercise price order benefit reduced taxation entitled dividend vesting period u c b n n u l r e p rt iv n e h e c n l e f n n c l stat e e n erformance share plan p limit placed employee participation plan follows b etween participant compensation remuneration committee granted performance share executive committee member senior executive u per year per participant achieved outstanding performance performance aximum u million total ownership u share conditional beneficiary completing three employee form share plan rolling period year service vesting period also subject month fulfilment certain company performance condition december plan participant performance share lapse upon leaving group except specific vesting condition share upon leaving retirement death case vest based payment expense incurred plan immaterial immediately beneficiary entitled dividend vesting period hare saving plan p hantom share option uk share award purpose plan encourage holding ucb performance share plan share employee uk participant save certain portion salary payroll deduction ucb group also phantom share option phantom share match every share bought participant free award performance phantom share plan collectively share share held account employee name referred phantom plan phantom plan apply independent company act trustee certain employee employment contract employee contribution plan limited lower certain affiliate group governed similar rule group share option share award participant compensation performance share plan except settlement gbp per year per participant december plan participant mployee share purchase e sharebased payment expense incurred plan u plan immaterial plan intended provide employee ucb affiliate harebased u opportunity purchase common share group share acquired discount payment expense funded ucb employee save defined percentage salary payroll deduction share purchased total sharebased payment expense incurred aftertax employee contribution share held group amounted million million independent third party banking institution account included relevant functional line within employee name income statement follows million cost sale marketing selling expense research development expense general administrative expense operating expense total operating expense equitysettled share option plan share award plan performance share plan cashsettled share appreciation right plan phantom share option share award performance share plan u c b n n u l r e p rt iv n e h e c n l e f n n c l stat e e n share option plan movement number share option outstanding related weighted average exercise price december weighted weighted weighted average number weighted average number average exercise share average exercise share fair value price option fair value price option outstanding january new option granted option forfeited option exercised option expired outstanding december number option fully vested january december share option outstanding december following last exercise date exercise price last exercise date range exercise price number share option april may april august march march march march march march march march total outstanding weighted average fair value share option granted volatility determined primarily reference historically observed share price ucb last five year probability early exercise reflected fair value determined based black expected life option expected forfeiture rate scholes valuation model based actual turnover employee category eligible stock option compensation significant assumption used measurement fair value share option share price grant date weighted average exercise price expected volatility expected option life year expected dividend yield risk free interest rate expected annual forfeiture rate u c b n n u l r e p rt iv n e h e c n l e f n n c l stat e e n hare appreciation right sars plan movement sars model input blackscholes model fair value liability december found table remeasured reporting date fair value sars grant date determined using outstanding right january new right granted right forfeited right exercised outstanding right december significant assumption used measurement fair value share appreciation right share price year end exercise price expected volatility expected option life year expected dividend yield risk free interest rate expected annual forfeiture rate share award plan sharebased payment expense related share beneficiary entitled dividend award spread vesting period three year vesting period movement number share award outstanding december follows number weighted average number weighted average share fair value share fair value outstanding january new share award granted award forfeited award vested paid outstanding december performance share plan movement number performance share outstanding december follows number weighted average number weighted average share fair value share fair value outstanding january new performance share granted performance share forfeited performance share vested outstanding december u c b n n u l r e p rt iv n e h e c n l e f n n c l stat e e n option granted november according transitional provision included ifrs ordinary share warrant expired option granted november yet vested warrant issued confer right january amortized income statement subscribe one ordinary share following cancellation expiration exercise part warrant respectively ucb issued warrant still exercised february subscription right warrant subscribe one movement number option warrant accounted ifrs described follows number weighted average number weighted average share fair value share fair value outstanding january option forfeited option exercised option expired outstanding december borrowing carrying amount fair value borrowing follows carrying amount fair value million noncurrent bank borrowing longterm loan finance lease total noncurrent borrowing current bank overdraft current portion bank borrowing debenture shortterm loan finance lease total current borrowing total borrowing borrowing since bank borrowing floating interest rate reset every six month carrying amount bank borrowing equates fair value respect december group weighted average interest current borrowing carrying amount approximate rate prior hedging floating fair value effect discounting considered interest rate payment subject designated cash flow insignificant hedge fixed interest rate payment subject ucb draw million billion designated fair value hedge thereby fixing weighted syndicated revolving facility expires october average interest rate group post hedging fee paid arrangement group access certain committed bond note amended facility agreement noncommitted bilateral credit facility well belgian amortized life instrument commercial paper market respect may ucb entered year floating rate bullet loan agreement applicable hedge accounting fair value european investment bank eib amount noncurrent borrowing determined based million present value payment associated debt instrument using applicable yield curve ucb credit please refer note maturity analysis group spread various different currency borrowing excluding financial liability u c b n n u l r e p rt iv n e h e c n l e f n n c l stat e e n carrying amount group borrowing denominated following currency million eur usd total interest bearing loan currency bank overdraft eur debenture short term loan eur debenture short term loan usd debenture short term loan finance lease liability eur total borrowing finance lease liability minimum lease payment million amount payable finance lease year less year year year present value finance lease liability less amount due settlement within month amount due settlement month management considers carrying value group finance lease liability approximate fair value bond carrying amount fair value bond follows carrying amount fair value coupon maturity million rate date noncurrent convertible bond retail bond institutional eurobond total noncurrent bond convertible bond fair value debt component based present value contractually determined stream cash flow discounted rate interest applied september ucb issued senior unsecured time market instrument comparable credit convertible bond amounting million closing status providing substantially cash flow date transaction october bond term without conversion option mature october ie year duration residual amount difference total gross convertible bond issued redeemed proceeds bond issuance fair value debt principal amount bear coupon component attributed fair value derivative payable semiannually arrears conversion price component result board decision revoke set bondholder right convert ucbs right related cash settlement option bond new existing option derivative component reclassified equity based company share company fair value date revocation refer note u c b n n u l r e p rt iv n e h e c n l e f n n c l stat e e n april ucb purchased million par value interest rate amortized expected life outstanding convertible bond total proceed instrument ie year bond listed million total carrying value amounted million luxembourg stock exchange led loss extinguishment million note fair value debt component convertible million reduction fair value option bond december amounted million recognized equity million fair value determined december debt component measured third party financial institution based amortized cost using effective interest rate convertible bond recognized statement financial per annum accordance ia remaining position calculated follows transaction cost included calculation effective million balance january effective interest expense note nominal interest accrued yet due nominal interest accrual previous period paid current period interest paid unamortized transaction cost upon initial recognition amortization charge period repurchase convertible bond balance december retail bond institutional eurobond october ucb completed public offering december ucb completed offering million fixed rate bond due aimed million senior unsecured bond due aimed retail investor retail bond redeemed institutional investor bond issued principal amount carry coupon redeemed principal amount per annum effective interest rate per bond carry coupon per annum annum bond listed luxembourg effective interest rate per annum bond stock exchange listed luxembourg stock exchange carrying amount retail bond december carrying amount institutional eurobond amounted million million group december amounted million designates derivative financial instrument fair value million group designates derivative financial hedge retail bond increase carrying instrument fair value hedge institutional amount retail bond fully attributable change eurobond increase carrying amount fair value hedged portion retail bond institutional eurobond fully attributable change almost fully offset change fair value fair value hedged portion institutional eurobond corresponding derivative financial instrument almost fully offset change fair value corresponding derivative financial instrument financial liability carrying amount fair value million noncurrent derivative financial instrument note total noncurrent financial liability current derivative financial instrument note financial liability total current financial liability total financial liability financial liability include share swap transaction million ucb share otc amounted million note u c b n n u l r e p rt iv n e h e c n l e f n n c l stat e e n deferred tax asset liability ecognized deferred tax asset liability r million restated intangible asset property plant equipment inventory trade receivables employee benefit provision shortterm liability tax loss unused tax credit total net deferred tax asset liability unused tax loss amount expiry date unused tax loss deferred tax asset recognized balance sheet detailed million expiry date year less year year year year without expiration unutilized tax loss emporary difference emporary difference deferred tax deferred tax liability recognized asset recognized deferred tax liability recognized taxable deferred tax asset recognized temporary difference temporary difference arising investment subsidiary carried forward represent income likely realized unrecognized deferred tax liability amount foreseeable future deferred tax asset amounting approximately million million million million respect unutilized tax credit intangible asset recognized view uncertain character recovery deferred tax directly recognized equity million restated deferred tax recognized oci effective portion change fair value cash flow hedge deferred tax liability convertible bond deferred tax directly recognized equity u c b n n u l r e p rt iv n e h e c n l e f n n c l stat e e n employee benefit ucb early adopted amendment ia consolidated statement financial position independent revised june consequence retrospective actuary assess main plan annually application ia r opening closing statement since group analysis value risk balance financial position earliest comparative period sheet profit loss account linked defined benefit restated note plan target risk level term one year consolidated balance sheet profit loss value risk measure employee covered retirement benefit plan defined annually based ucb risk tolerance threshold sponsored group company nature plan varies according legal regulation fiscal requirement ucb main risk linked defined benefit obligation economic condition country employee discount rate inflation longevity majority employed group operates defined contribution risk lay within uk belgium germany u plan defined benefit plan noted longevity considered risk plan belgium benefit either paid lump sum defined contribution plan externalised paid annuity last year ucb implemented major derisking project uk u postemployment benefit plan classified defined contribution plan group pay fixed contribution uk investment decision known buyin separate fund third party financial institution implemented ucb british scheme buyin secured legal constructive obligation pay benefit pensioner dependant deferred member contribution therefore asset liability recognized scheme december june group balance sheet respect plan apart scheme closed future accrual remaining regular prepayment accrual contribution active member transferred celltech pension life assurance scheme december pension defined benefit plan board finally secured benefit small number pensioner deferred member left service december june group operates several defined benefit plan ucb also carried enhanced transfer value benefit granted include mainly pension benefit jubilee exercise uk celltech pension life assurance premium termination indemnity benefit scheme deferred member offered granted according local market practice regulation enhancement transfer value transferred plan either unfunded funded via outside scheme total approximately gbp million liability pension fund insurance company partially funded member transferred scheme plan asset plan held separately fund u ucb implemented lump sum window exercise control trustee plan unfunded exercise deferred member notably major defined benefit plan germany offered transfer benefit scheme liability obligation recorded group balance end exercise resulted approximately sheet funded plan group liable deficit u million liability around deferred fair value plan asset present liability transferring scheme value benefit obligation accordingly liability asset plan overfunded recorded group amount recognized consolidated statement financial position arising group obligation respect defined benefit plan follows million restated present value defined benefit obligation fair value plan asset funded status deficit surplus effect asset ceiling net liability arising defined benefit obligation add liability respect cash settled share based payment note total employee benefit liability portion recognized noncurrent liability portion recognized noncurrent asset u c b n n u l r e p rt iv n e h e c n l e f n n c l stat e e n movement present value defined benefit obligation current year follows million restated january current service cost interest expense remeasurement gain loss effect change demographic assumption effect change financial assumption effect experience adjustment past service cost gain loss settlement effect change foreign exchange rate benefit payment plan benefit payment employer settlement payment plan participant contribution effect business combination disposal december movement fair value plan asset current year follows million restated january interest income remeasurement gain loss return plan asset excl interest income change asset ceiling excl interest income effect change foreign exchange rate plan participant contribution employer contribution benefit payment plan benefit payment employer settlement payment expense tax premium paid effect business combination disposal december fair value plan asset amount million million expected eliminated million representing estimated remaining average service period current defined benefit obligation total deficit million membership amount recognized consolidated income statement consolidated statement comprehensive income respect defined benefit plan follows million restated total service cost incl gain loss settlement net interest cost remeasurement long term benefit administrative expense tax component defined benefit cost recorded income statement remeasurements gain loss effect change demographic assumption effect change financial assumption effect experience adjustment return plan asset excl interest income change asset ceiling excl interest income component defined benefit cost recorded oci total component defined benefit cost u c b n n u l r e p rt iv n e h e c n l e f n n c l stat e e n total service cost net interest expense remeasurement net defined benefit liability remeasurement long term benfits administrative included statement comprehensive income part expense tax year included employee comprehensive income benefit expense consolidated income statement split recognized expense functional line follows million restated cost sale marketing selling expense research development expense general administrative expense income expense total actual return plan asset million million actual return reimbursement right million million major category plan asset end reporting period follows million restated cash cash equivalent equity instrument europe u rest world debt instrument corporate bond government bond property qualifying insurance policy investment fund total virtually equity debt instrument quoted asset held fund contain direct price active market property classified investment ucb group share property occupied level instrument based definition ifrs fair asset used group though value measurement exclude ucb share included mutual investment fund type investment principal weighted average actuarial assumption used purpose actuarial valuation follows eurozone uk u discount rate inflation na na na na u c b n n u l r e p rt iv n e h e c n l e f n n c l stat e e n significant actuarial assumption determination average duration benefit obligation end defined obligation discount rate inflation reporting period year year sensitivity analysis determined based number subdivided duration related reasonably possible change assumption occurring eurozone year year end reporting period uk year year f discount rate would basis point higher lower defined benefit obligation would decrease u year year million increase million ther year year assumption held constant group expects make contribution million f inflation rate would increase decrease basis defined benefit plan next financial year point defined benefit obligation would increase million decrease million year alm assetliability matching study assumption held constant performed consequence strategic investment policy analysed term riskandreturn reality one might expect interrelationship profile investment contribution policy integrated assumption especially discount rate expected within study main strategic choice formulated salary increase depends certain extent actuarial technical policy document fund expected inflation rate analysis abstract interdependence assumption sset mix based equity instrument debt instrument investment property group subsidiary fund cost entitlement expected earned yearly basis employee pay fixed interest rate sensitivity caused duration percentage pensionable salary residual contribution defined benefit obligation reduced including back service payment paid entity use debt instrument combination interest group funding requirement based local actuarial rate swap measurement framework framework discount rate aintaining equity buffer give assurance set risk free rate furthermore premium determined asset sufficient within next month current salary base additional liability stemming past service due salary increase backservice liability paid immediately fund apart paying cost entitlement group subsidiary liable pay additional contribution case fund hold sufficient asset case fund take measure restore solvency reduction entitlement plan member provision movement provision disclosed million environment restructuring tax total january business combination arising year unused amount reversed transfer one heading another effect movement exchange rate utilized year december noncurrent portion current portion total provision u c b n n u l r e p rt iv n e h e c n l e f n n c l stat e e n environmental provision tax provision ucb past retained certain environmental tax provision recorded group considers liability associated acquisition probable tax position taken unlikely sustained schwarz pharma divestiture surface specialty challenged tax authority assessment done latter relates divested site ucb provision individually resulting provision retained full responsibility accordance contractual group best estimate expected exposure event term agreed upon cytec industry inc tax authority challenge part provision related surface specialty business reversed provision restructuring provision provision relate mainly litigation product liability note restructuring provision utilized mainly provision litigation comprise mainly provision view shape programme announced august litigation ucb subsidiary might severance cost hand main defendant claim previous employee ucb increase provision includes increase shape provision restructuring support function product liability provision relate risk related severance cost normal course business group might liable selling kind drug assessment per formed respect mentioned risk together group legal adviser expert different domain trade liability oncurrent trade liability n million gsk sumitomo japan gsk japan switzerland payable noncurrent liability collaboration agreement total noncurrent trade liability urrent trade liability c million trade payable tax payable income tax payroll social security liability payable deferred income linked collaboration agreement deferred income royalty payable dividend shareholder perpetual subordinated bond rebate discount payable accrued interest accrued expense total current trade liability vast majority trade liability classified current consequently carrying amount total trade liability assumed reasonable approximation fair value u c b n n u l r e p rt iv n e h e c n l e f n n c l stat e e n note consolidated statement cash flow cash flow statement identifies operating investing effect noncash transaction depreciation financing activity period amortization impairment loss provision markto market etc variance working capital ucb u indirect method operating cash flow net profit loss adjusted item income expense associated investing financing cash flow million note restated adjustment noncash transaction depreciation amortization impairment reversal charge equity settled share based payment expense noncash transaction income statement adjustment ia unrealized exchange gain loss change provision employee benefit change inventory bad debt provision adjustment item disclose separately operating cash flow tax charge period adjustment item disclose investing financing cash flow gain loss disposal fixed asset dividend income expense interest income charge change working capital inventory movement per consolidated b trade receivables asset movement per consolidated b trade payable movement per consolidated b appears consolidated balance sheet corrected noncash items change inventory bad debt provision disclosed separately operating cash flow change interest receivable payable disclosed separately operating cash flow change dividend receivable disclosed separately investing cash flow change dividend payable disclosed separately financing cash flow change payable balance disclosed cash flow discontinued operation currency translation adjustment appears consolidated cash flow statement noncash item mainly linked transfer one heading another noncash movement linked affiliate revaluation fx currency movement linked entry exit consolidation scope merge entity u c b n n u l r e p rt iv n e h e c n l e f n n c l stat e e n financial instrument category million asset fair value december derivative loan profit used available asset per balance sheet note receivables loss hedging sale total financial asset asset excl derivative financial instrument derivative financial asset trade receivables including prepaid expense cash cash equivalent total million liability fair value financial december derivative liability profit used amortized liability per balance sheet note loss hedging cost total borrowing bond derivative financial liability trade liability financial liability excl derivative financial instrument total million asset fair value december derivative loan profit used available asset per balance sheet note receivables loss hedging sale total financial asset asset excl derivative financial instrument derivative financial asset trade receivables including prepaid expense cash cash equivalent total million liability fair value financial december derivative liability profit used amortized liability per balance sheet loss hedging cost total borrowing bond derivative financial liability trade liability financial liability excl derivative financial instrument total u c b n n u l r e p rt iv n e h e c n l e f n n c l stat e e n derivative financial instrument million asset liability forward foreign exchange contract cash flow hedge forward foreign exchange contract fair value profit loss interest rate derivative cash flow hedge interest rate derivative fair value profit loss put call option noncontrolling interest total noncurrent note current note full fair value hedging derivative classified million deferred tax included equity noncurrent asset liability remaining maturity respect contract gain loss recycled hedged item month current profit loss period hedged asset liability maturity hedged item less forecast transaction affect profit loss month ineffective portion recognized profit loss cash flow hedge entered group arises cash flow hedge amount million assessed highly effective december million net unrealized gain million net unrealized loss oreign currency derivative f group policy respect use financial group entered several forward foreign exchange derivative contract described note financial contract order hedge portion highly probable risk management future sale royalty income expected occur fair value foreign currency derivative contract follows million asset liability usd gbp eur pln mxn jpy chf currency total foreign currency derivative foreign currency derivative maturity analysis noted million year less year beyond year total foreign currency derivative net asset net liability u c b n n u l r e p rt iv n e h e c n l e f n n c l stat e e n following table show split foreign currency derivative currency denomination currency sold view december notional amount million usd gbp eur jpy chf currency total forward contract currency swap option collar total interest rate derivative group u various interest rate derivative contract characteristic aligned fixed rate bond manage exposure interest rate movement outstanding interest rate derivative contract borrowing repricing date amortization follows plus nominal margin value point contract average rate payer contract type million payer receiver receiver period floating interest receipt irs usd usd libor month irs usd usd libor month irs usd usd libor month irs usd usd libor month irs usd usd libor month irs usd usd libor month irs eur euribor month irs eur euribor month irs usd usd libor month irs usd usd libor month irs usd usd libor month irs eur euribor month ccirs usd usd libor month euribor month irs eur euribor month irs eur euribor month ccirs usd usd libor month euribor month ccirs usd usd libor month euribor month ccirs usd usd libor month euribor month ccirs usd usd libor month euribor month ccirs usd usd libor month euribor month irs eur euribor month edge net investment h erivative linked foreign entity convertible bond company entered loan agreement result decision ucb revoke cash partly designated hedge net investment settlement option linked convertible bond group u operation following internal corporate fair value derivative component linked restructuring net investment hedge relationship convertible bond reclassified equity million terminated december tax million net tax refer note unrealized cumulative foreign exchange gain million reported separate component equity net investment hedge unrealized gain remain equity recycled profit loss group longer hold underlying usd asset u c b n n u l r e p rt iv n e h e c n l e f n n c l stat e e n earnings per share change group accounting policy year following table summarises effect early described detail note extent application ia revised basic change impact result repor ted diluted earnings per share impact amount repor ted earnings per share increase decrease profit year attributable owner group million note increase decrease basic earnings per share increase decrease diluted earnings per share basic earnings per share restated continuing operation discontinued operation basic earnings per share basic earnings per share calculated dividing profit excluding ordinary share purchased company held attributable shareholder company weighted treasury share average number ordinary share issue year diluted earnings per share restated continuing operation discontinued operation diluted earning per share diluted earnings per share calculated adjusting would lead reduction interest expense reversal weighted average number ordinary share outstanding mark market adjustment related derivative assume conversion dilutive potential ordinary share financial liability share option calculation done determine number share could potential dilutive effect arise convertible debt acquired fair value determined average annual instrument employee stock option plan market share price company share outstanding instrument converted u c b n n u l r e p rt iv n e h e c n l e f n n c l stat e e n earnings calculation basic diluted earnings per share attributable ordinary equity holder parent based following data basic million restated profit loss continuing operation attributable shareholder ucb sa profit loss discontinued operation profit attributable shareholder ucb sa diluted million restated profit loss continuing operation attributable shareholder ucb sa adjusted interest expense convertible debt net tax profit loss continuing operation used determine diluted eps profit loss discontinued operation adjusted profit attributable shareholder ucb sa number share thousand share restated weighted average number ordinary share basic earnings per share adjusted warrant assumed conversion convertible debt weighted average number ordinary share diluted earnings per share april group issued stock loan note therefore contingently issuable share dilutive represented loan stock unit nominal value effect december december defensive warrant attached taken account calculation diluted defensive warrant confers right holder earnings per share subscribe one share newly issued ucb sa note share related convertible debt dilutive ucb share might result exercise impact december warrant issued reference market price period prior issue dividend per share gross dividend paid million proposed annual general million per share million per meeting shareholder april share respectively accordance ia event reporting period dividend respect year ended december proposed dividend recognized liability per share amounting total dividend yearend u c b n n u l r e p rt iv n e h e c n l e f n n c l stat e e n commitment contingency perating lease commitment future aggregate minimum lease payment noncancellable operating lease follows million less one year one five year five year total group number noncancellable operating lease switzerland construction pilot plant belgium began primarily related company car office space may expected completed mid pilot plant financed partially government assistance lease cover initial period three five year lease well loan december ucb initiated project payment increased annually reflect market rental build inhouse biotech manufacturing capacity bulle none lease include contingent rental switzerland order meet rising future demand million million recognized expense cimzia new manufacturing plant operational income statement respect operating lease requires investment million ucb entered longterm development agreement capital commitment various pharmaceutical clinical trial operator private equity company collaboration agreement include milestone payment dependent successful december group committed spend clinical development meeting specified sale target million million mainly respect table set maximum would paid capital expenditure construction biological milestone however unlikely achieved excludes pilot plant braine belgium biological plant bulle variable royalty payment based unit sale million less one year one five year five year total amount riskadjusted discounted philadelphia atlantic city litigation involve timing payment based group current best claim injury resulting alleged failure warn estimate achievement relevant milestone risk associated use metoclopramide week vast majority claim involve alleged injury sustained result use generic guarantee metoclopramide number legal issue court awaiting decision could impact timing outcome resolution case currently guarantee arising normal course business case scheduled trial early expected result material financial loss predict certainty outcome litigation company belief meritorious defense contingent liability pending claim furthermore group entered various agreement order conduct activity provide potential group continues actively involved litigation contingent liability financial arrangement claim investigation ongoing matter could result walloon region amounting million liability civil criminal penalty loss product exclusivity million manufacturing capacity arrangement cost fine expense associated finding sandoz amounting million elapsed adverse ucbs interest anticipated material liability arise ucb continues defendant reglan contingent liability provided product liability case case largely note material liability consolidated three different jurisdiction san francisco u c b n n u l r e p rt iv n e h e c n l e f n n c l stat e e n related party transaction ntragroup sale efensive warrant service financial year ended december april general meeting shareholder resolved intraucb group transaction carried based issue stock loan represented loan stock unit assessment mutual economic benefit party nominal value defensive involved applicable condition established warrant attached defensive warrant accordance criterion arm length negotiation defensive warrant confers right holder fair dealing view creating value subscribe one share newly issued ucb sa loan entire ucb group condition governing intraucb subscribed financière de tubize holder group transaction similar condition governing defensive warrant entered agreement thirdparty transaction ucb sa comply term condition relating regard sale intermediary finished product issue exercise defensive warrant criterion accompanied principle increasing mentioned general meeting shareholder party respective production cost arm length also resolved create ad hoc committee decide profit margin regard intraucb group service predefined circumstance implementation rendered criterion accompanied principle defensive measure transfer defensive warrant charging fee sufficient cover party respective defensive warrant may exercised specific incurred cost arm length markup intragroup circumstance existence must assessed transaction carried within ucb group constitute adhoc committee standard transaction biopharmaceutical group transaction include purchase sale intermediary aunch takeover bid third party considered l finished medical product deposit loan ucb group hostile board director affiliate well centralized function activity carried odification control ucb group due ucb group order optimize operation transaction relating ucb share one third economy scale scope party carried either stock market whether concerted fashion inancial transaction f threat takeover bid operation involving related party modification control ucb group ucb sa affiliate defensive warrant agreement holder defensive warrant ucb sa expire april ucb share resulting exercise financial transaction related party warrant issued reference market price affiliate ucb sa period prior issuance ey management compensation k key management compensation disclosed comprises committee portion year exercised compensation recognized income statement mandate member board director executive million shortterm employee benefit termination benefit postemployment benefit sharebased payment total key management compensation shortterm employee benefit include salary including social share explained note termination security contribution bonus earned year car benefit contain compensated amount including benefit leasing allowance applicable sharebased kind deferred compensation compensation includes amortization vesting loan granted company period fair value equity instrument granted subsidiary group director officer comprises share option share award performance group guarantee given respect hereto u c b n n u l r e p rt iv n e h e c n l e f n n c l stat e e n hareholders shareholder structure ucbs main shareholder financière de tubize sa financière de tubize held janssen family company listed euronext brussels hereafter financière de remainder ucb share held public tubize reference shareholder accordance latest subsequent notification made financière de tubize made transparency notification compliance law may present ucb holding ucb september subsequent major shareholding notification compliance law may publication significant shareholding listed company according article law may financière de tubize act concert schwarz vermögensverwaltung gmbh holding listed table hereunder share covered agreement including share held financière de tubize represent share capital ucb ucb controlling major shareholding december date according notification compliance current voting law may capital share financière de tubize sa tubize october ucb sa december assimilated securities june option april ucb fipar sa december assimilated security april schwarz vermögensverwaltung gmbh october tubize linked company concert excluding option december capital group company september vanguard health care fund march please see press release june option exercised would represent additional voting right information regarding assimilated securitiesoptions required law tubize declared acting concert schwarz vermögensverwaltung gmbh co kg u c b n n u l r e p rt iv n e h e c n l e f n n c l stat e e n event balance sheet date event balance sheet date ucb company fully consolidated name office holding parent australia ucb australia pty ltd level malvern road malvern victoria viking trading co ltd austria ucb pharma gesellschaft mbh geis elbergstrasse wien ucb finance nv belgium ucb fipar sa allée de la recherche brussels ucb belgium sa fin ucb sa allée de la recherche brussels ucb pharma sa ucb belgium sa allée de la recherche brussels ucb pharma sa ucb pharma sa allée de la recherche brussels ucb sa sifar sa allée de la recherche brussels ucb finance nv brazil ucb farma brasil ltda rue sete de setembro sala rio de janerio ucb sa meizler ucb alameda araguaia tamboré barueri sao paulo ucb farma brasil ltda bulgaria ucb bulgaria eood lyubata str fl apt lozenetz sofia ucb sa canada ucb canada inc winston park drive suite lhr oakville ucb holding inc china ucb trading shanghai co ltd room fu te xi yi road shanghai waigaoqiao ucb sa free trade zone ucb pharma hong kong ltd unit f south tower world finance center ucb pharma gmbh gateway harbour city hong kong schwarz pharma zuhai company ltd block changsa industrial zone qianshan district ucb pharma gmbh zhuhai guangdong province czech republic ucb sro thámova praha ucb sa denmark ucb nordic arne jacobsen alle copenhagen ucb finance nv finland ucb pharma oy finland itsehallintokuja espoo ucb finance nv france ucb pharma sa rue detienne dorves colombes ucb sa u c b n n u l r e p rt iv n e h e c n l e f n n c l stat e e n name office holding parent germany ucb pharma gmbh alfred nobel strasse monheim rhein ucb gmbh ucb gmbh alfred nobel strasse monheim rhein ucb finance nv ucb bioscience gmbh alfrednobelstrasse monheim rhein ucb pharma gmbh sanol gmbh alfrednobelstrasse monheim rhein ucb pharma gmbh greece ucb ae agiou dimitriou street alimos athens ucb sa hungary ucb hungary ltd obuda gate building arpád fejedelem ùtja budapest ucb sa india ucb india private ltd peninsula tower peninsula corporate park ucb sa ganpatrao kadam marg lower parel mumbai unimediflex private ltd peninsula tower peninsula corporate park ucb sa ganpatrao kadam marg lower parel mumbai ireland ucb pharma ireland ltd united drug house magna drive magna business park ucb sa city west road dublin celltech pharma ireland united drug house magna drive magna business park ucb ltd city west road dublin ucb manufacturing ireland ltd shannon industrial estate shannon county clare ucb pharma gmbh kremers urban kudco ireland ltd shannon industrial estate shannon county clare pharmaceutical inc italy ucb pharma spa via gadames milano viking trading co ltd japan ucb japan co ltd shinjuku grand tower nishishinjuku shinjuku tokyo ucb sa luxembourg société financière ucb sa rue eugène ruppert luxembourg ucb sa ucb lux sa rue eugène ruppert luxembourg ucb sa ucb sca rue eugène ruppert luxembourg ucb lux sa mexico ucb de mexico sa de cv homero fl col chapultepec morale ucb sa mexico df vedim sa de cv homero fl col chapultepec morale mexico df sifar sa netherlands ucb finance nv lage mosten nk breda ucb sa ucb pharma bv netherlands lage mosten nk breda ucb finance nv norway ucb pharma grini naeringspark b osteras baerum ucb finance nv poland vedim sp zoo ul kruczkowskiego warszawa sifar sa ucb pharma sp zoo ul kruczkowskiego warszawa ucb sa u c b n n u l r e p rt iv n e h e c n l e f n n c l stat e e n name office holding parent portugal ucb pharma produtos farmaceuticos lda ed amelia piso sala quinta da fonte vedim pharma sa paço de arcos vedim pharma prod quimicos e farma lda ed amelia piso sala quinta da fonte ucb pharma produtos paço de arcos farmaceuticos lda romania ucb pharma romania srl banu antonache th fl district bucharest ucb sa russia ucb pharma llc shturvaluaya bldg moscow ucb sa ucb pharma logistics llc perevedenovky pereulok bldg moscow ucb sa south korea korea ucb co ltd th floor grace tower teheranro seoul ucb sa spain vedim pharma sa paseo de la castellana planta madrid ucb sa ucb pharma sa paseo de la castellana planta madrid vedim pharma sa sweden ucb pharma ab sweden stureplan c van stockholm ucb finance nv switzerland ucb farchim sa ag ltd zi de planchy chemin de croix blanche bulle ucb investissements sa ucb investissements sa zi de planchy chemin de croix blanche bulle ucb finance nv doutors réassurance sa zi de planchy chemin de croix blanche bulle ucb investissements sa ucbpharma ag zi de planchy chemin de croix blanche bulle ucb investissements sa medeva pharma suisse sa chemin de croix blanche bulle ucb investissements sa turkey ucb pharma rüzgarlibahçe cumhuriyet caddesi gerçekler sitesi bblok kat ucb lux sa kavacik beykoz istanbul melusin ilac maddeleri pazarlama tl rüzgarlibahçe cumhuriyet caddesi gerçekler ucb pharma gmbh sitesi bblok kat kavacik beykoz istanbul u c b n n u l r e p rt iv n e h e c n l e f n n c l stat e e n name office holding parent uk fipar bath road sl slough berkshire ucb investment ltd ucb fipar ltd sub ucb inc bath road sl slough berkshire ucb inc fipar uk ltd sub ucb fipar ltd bath road sl slough berkshire ucb fipar ltd ucb investment ltd bath road sl slough berkshire ucb lux sa viking trading co ltd bath road sl slough berkshire ucb investment ltd vedim ltd bath road sl slough berkshire ucb investment ltd ucb watford ltd bath road sl slough berkshire ucb investment ltd celltech group ltd bath road sl slough berkshire ucb lux sa celltech rd ltd bath road sl slough berkshire celltech group ltd ucb ireland bath road sl slough berkshire ucb lux sa celltech japan ltd bath road sl slough berkshire celltech rd ltd celltech ltd bath road sl slough berkshire medeva ltd chiroscience group ltd bath road sl slough berkshire ucb investment ltd chiroscience rd ltd bath road sl slough berkshire ucb investment ltd darwin discovery ltd bath road sl slough berkshire ucb investment ltd medeva ltd bath road sl slough berkshire ucb investment ltd ucb pharma ltd bath road sl slough berkshire evans healthcare ltd evans healthcare ltd bath road sl slough berkshire medeva ltd medeva international ltd bath road sl slough berkshire ucb investment ltd celltech pharma europe ltd bath road sl slough berkshire ucb investment ltd international medication system uk ltd bath road sl slough berkshire ucb pharma gmbh oxford glycosciences bath road sl slough berkshire ucb investment ltd oxford glycosciences uk ltd bath road sl slough berkshire oxford glycosciences oxford glycosciences confirmant ltd bath road sl slough berkshire uk ltd schwarz pharma ltd bath road sl slough berkshire celltech group ltd u ucb holding inc corporation trust center orange street wilmington ucb finance nv delaware fipar u inc corporation trust center orange street wilmington fipar uk ltd delaware ucb inc corporation trust center orange street wilmington delaware ucb holding inc ucb bioscience inc corporation trust center orange street wilmington ucb inc delaware ucb pharco inc delaware avenue th floor wilmington delaware ucb inc celltech u llc corporation trust center orange street wilmington medeva ltd delaware ucb manufacturing inc corporation trust center orange street ucb inc wilmington delaware ucb technology inc c corporation system eight avenue ny new york ucb manufacturing inc upstate pharma llc c corporation system eight avenue ny new york ucb inc kremers urban pharmaceutical inc e ohio street suite indianapolis ucb manufacturing inc u c b n n u l r e p rt iv n e h e c n l e f n n c l stat e e n v v responsibili ty statement responsibility statement hereby confirm best knowledge consolidated financial statement december prepared accordance international financial reporting standard ifrs adopted european union legal requirement applicable belgium give true fair view asset liability financial position profit loss company undertaking included consolidation whole management report includes fair review development performance business position company undertaking included consolidation taken whole together description principal risk uncertainty face signed roch doliveux ceo detlef thielgen cfo behalf board director roch doliveux detlef thielgen chief executive officer chief financial officer vi vi report stat uto ry auditor neil scientist ucb slough statutory auditor report general shareholder meeting consolidated account company ucb sanv year ended december accordance legal requirement report financial statement order design audit procedure performance mandate statutory auditor report appropriate circumstance includes report consolidated financial statement purpose expressing opinion effectiveness year ended december defined well group internal control audit also includes evaluating report legal regulatory requirement appropriateness accounting policy used reasonableness accounting estimate made board director well evaluating overall presentation report consolidated financial consolidated financial statement obtained statement company official board director explanation audited consolidated financial statement information necessary performing audit ucb sanv company subsidiary jointly believe audit evidence obtained group prepared accordance international sufficient appropriate provide basis opinion financial reporting standard adopted european union legal regulatory requirement unmodified opinion applicable belgium consolidated financial statement comprise consolidated statement financial position opinion consolidated financial statement set consolidated income statement consolidated statement forth page give true fair view comprehensive income consolidated statement group net equity consolidated financial position change equity consolidated statement cash flow december consolidated financial december year ended performance consolidated cash flow year related note comprising summary significant accounting ended accordance international financial reporting policy explanatory information total standard adopted european union consolidated statement financial position amount legal regulatory requirement applicable belgium eur million consolidated income statement show profit year group share eur million report legal regulatory requirement board director responsibility preparation consolidated financial statement board director responsible preparation content management report board company board director responsible director consolidated financial statement preparation fair presentation consolidated financial statement accordance international financial framework mandate responsibility verify reporting standard adopted european union compliance certain legal regulatory requirement legal regulatory requirement applicable basis provide following additional statement belgium internal control board modify opinion consolidated director determines necessary enable preparation financial statement consolidated financial statement free material management report board director misstatement whether due fraud error consolidated financial statement set forth page includes information required law consistent statutory auditor responsibility consolidated financial statement however responsibility express opinion unable comment description principal risk consolidated financial statement based audit uncertainty group facing conducted audit accordance international standard financial situation foreseeable evolution significant auditing standard require comply influence certain fact future development ethical requirement plan perform audit obtain nevertheless confirm matter disclosed reasonable assurance whether consolidated financial present obvious inconsistency information statement free material misstatement became aware performance mandate audit involves performing procedure obtain brussels february audit evidence amount disclosure consolidated financial statement procedure selected statutory auditor pricewaterhousecoopers reviseurs depend statutory auditor judgment including dentreprises bedrijfsrevisoren assessment risk material misstatement represented consolidated financial statement whether due fraud error making risk assessment statutory auditor considers internal control relevant jean fossion group preparation fair presentation consolidated bedrijfsrevisor vii vii abbreviated statutory financial statement ucb sa introduction accordance belgian company code accordance legislation separate financial decided present abbreviated version statutory statement together management report financial statement ucb sa board director general assembly shareholder well auditor report filed national statutory financial statement ucb sa bank belgium within statutory period prepared accordance belgian generally accepted accounting principle document available website wwwucbcom simple request addressed noted consolidated financial statement presented present true fair view ucb sa financial position performance ucb group corporate communication allée de la recherche statutory auditor issued unqualified audit opinion b brussels belgium certify nonconsolidated financial statement ucb sa year ended december give true fair view financial position result ucb sa accordance legal regulatory disposition balance sheet million december december asset formation expense intangible asset tangible asset financial asset fixed asset amount receivable one year amount receivable within one year less shortterm investment cash bank hand deferred charge accrued income current asset total asset liability capital share premium reserve profit brought forward equity provision provision deferred tax amount payable one year amount payable within one year less accrued charge deferred income current liability total liability income statement million december december operating income operating charge operating result financial income financial charge financial result operating result income tax exceptional income exceptional charge exceptional result profit income tax income tax profit year available appropriation appropriation account million december december profit period available appropriation profit brought forward previous year profit appropriated legal reserve reserve appropriation capital reserve profit carried forward result carried forward dividend profit distributed proposed allocation profit approved total gross dividend fixed proposed allocation profit approved taking account tax regulation total net dividend withholding tax per share fixed activity ucb sa generated net profit board director proposes pay gross dividend million income tax taking account holder ucb share profit brought forward million amount available total dividend distribution million dividend distribution million proposal approved company shareholder meeting april net dividend per issued share capital ucb sa represented share payable may delivery share without par value per coupon nr attached company bearer share december capital increase march share without par value share order honour exercise share option share award granted board director certain category employee u c b n n u l r e p rt vii bbr e v e tat u ry f n n c l tat e e n f u c b summary significant accounting principle board director made following decision inancial asset f accordance article royal decree january implementing company code shareholding valued accordance proportion held shareholder fund company ntangible asset concerned shareholding included scope consolidation valued cost specific writedown made whenever valuation made research development cost capitalised year show permanent loss value intangible asset purchase cost capitalised cost entirely depreciated year difference actual amount depreciation taken receivables liability year gross amount capitalised treated writeback depreciation exceptional income shown book value receivables straightline depreciation rate applied written repayment due entirely cost based threeyear life considering pro partly uncertain doubtful rata temporis depreciation purchase price patent license similar item either accordance prudent assessment economic life intangible ssets commitment asset minimum rate equal asset required handle patent process fixed period expressed foreign depreciation lower five year considering pro currency rata temporis foreign currency transaction accounted exchange rate prevailing date transaction angible asset nonmonetary asset liability intangible tangible asset shareholding denominated foreign currency tangible asset purchased third party translated foreign exchange rate prevailing date included balance sheet purchase price asset transaction monetary asset liability denominated manufactured company valued cost foreign currency translated balance sheet date purchase price cost depreciated straightline rate realised exchange difference foreign currency basis considering pro rata temporis depreciation rate transaction recognised income statement follows nonrealised exchange loss whilst nonrealised exchange administrative building profit included accrued charge deferred income balance sheet industrial building tool rovisions p furniture office machinery vehicle risk born company subject computer equipment office machine provision reviewed year accordance rule prudence good faith sincerity provision recorded prototype equipment normal value u c b n n u l r e p rt vii bbr e v e tat u ry f n n c l tat e e n f u c b viii viii corporate societal responsiblity performance report csr activity materiality stakeholder dialogue global reporting initiative gri indicator global reporting initiative disclosure human resource environmental data scope reporting principle assurance report christer living parkinson disease csr activity background introduction fourth corporate societal responsibility csr ucb defined presented new strategy report illustrating ucbs strategy societal responsibility executive committee leading also change labeling sustainability report prepared edited effort move corporate social responsibility csr team conformity sustainability reporting corporate societal responsibility csr aim embrace guideline global reporting initiative gri corporation responsibility towards society broadest sense rather limited social aspect kpmg provided limited assurance number selected indicator refer gri table end section new definition corporate societal responsibility elucidated insight combining data united nation development program global footprint network report countryspecific data health wealth education country ecological footprint published enable bridge challenge pursuit allow create growth diminishing impact environment ucb adopted patientcentric planetcentric vision figure reconciles two dimension deemed critical sustainability human development index combining health education living standard dimension indicator socioeconomic development ii ecological footprint indicator human demand planet csr focus adopted answering following question ucb contribute help community developing country reach higher human development index ucb continue lowering ecological footprint african country undp threshold high human development global hectare person ecological footprint asian country european country latin american caribbean country north american country oceanian country world average biocapacity per person world average biocapacity per person high human development within earth limit united nation human development index ecological wealth nation earth biocapacity new framework international cooperation global footprint network human development index data human development report overcoming barrier human mobility development undp patient centricity one strength knowledge epilepsy india hope wheel dedicated ability bring treatment patient living establishment hope wheel entity condition today csr activity predominantly indian ucb affiliate pilot project prime objective directed towards patient developed country however serve patient living epilepsy remote area new csr patientcentric strategy aim reach state rajasthan karnataka underprivileged patient living epilepsy developing country ucb want developing three specific mobile clinic shall enable access education diagnosis dimension education awareness diagnosis treatment building creative solution including treatment build increased value patient telemedicine targeted partnership trained shown drawing dedicated colleague regularly tour village community supported state medical colleague address significant social stigma isolation associated value patient epilepsy villager increase awareness education patient family mobile unit van equipped stateoftheart neurological equipment better health care developing integrated resulting improved telemedicine provide realtime consultation health life work care solution social integration local neurology department university hospital building awareness sustainable access community epilepsy community diagnostic equipment china project hope awareness education diagnosis treatment project hope year tradition global health education humanitarian assistance partnership several organisation pharmaceutical company china project today project hope involved several effort improving health community various province china africa brother charity strong partnership ministry health fracarita belgium nongovernmental organization epilepsy child another important project bring ngo development cooperation brother education access adequate diagnosis treatment charity dedicates improving health condition remote community project hope bringing neurology vulnerable people especially child people department ten university hospital together focus disability mental illness ngo strongly anchored need child living epilepsy family local community country partnership bring professional training support ucb ucb focused people living epilepsy lubumbashi democratic republic congo ndera rwanda family planning pregnancy immunology partner want break negative combination time woman men severe chronic disease poverty mental illness including neurological condition immunological condition often receive epilepsy enabling patient living epilepsy optimal consistent medical advice support family return normal life offering sustained come family planning pregnancy cause support appropriate diagnosis treatment key great distress patient due general lack normal life medical paramedical colleague awareness data complex field pregnancy receive neurology education well supportive material occurring severe disease vice versa severe conducting awareness campaign student school disease occurring pregnancy patient family different primary health center fppi family planning pregnancy immunological centre neuropsychiatrique joseph guislain lubumbashi disease medical education partnership initiative provides care patient living epilepsy city launched ucb globally overall goal fppi mobile team neighboring village kipushi initiative improve outcome parent likasi kitumaini brother charity organise immunological disease child bimonthly visit ensure adequate followup adherence increasing awareness understanding issue relating treatment essential aspect wellbeing patient family planning pregnancy immunology centre neuropsychiatrique de ndera kigali reference timulating research order attempt fill knowledge gap hospital psychiatry also newly equipped bed neurology ward hospitalisation patient suffering fppi initiative demonstration patient neurological condition together rwandan league centric leadership vision epilepsy effort underway enhance awareness education well access appropriate diagnosis world health organization treatment partnership ucb contributes within area epilepsy priority within world scientific advanced medical education training health organization mental health gap action medical paramedical colleague programme mhgap ucb agreed collaborate year project reduce treatment gap two developing country identified u c b n n u l r e p rt viii c rp rat e c e ta l r e sp n b l p e r f rma n c e r e p rt planet centricity inevitably activity impact planet directly indirectly ucb colleague share passion excellence directly major contribution waste production energy patient planet driven initiative reflecting profound water consumption greenhouse gas emission come integration customer insight creativity compliance manufacturing research site indirectly daily activity offering sustainable care patient whole value chain including partner supplier contract living severe condition part everything ucb manufacturing operator transporter also contribute ucb colleague critical stakeholder ecological footprint producing waste emitting greenhouse gas ucb relies extended network external consuming water fuel gas electricity stakeholder family ucb colleague patient advocate school institution local community association public ucb strives continuously improve environmental administration nongovernmental organization ngo ecological footprint actively engaging management medium scientific academic community employee stakeholder seven area engagement ensuring legal regulatory compliance recognition responsibly using natural resource enhancing energy efficiency minimizing carbon footprint ecpi sense sustainability promoting green chemistry ecpi independent leading company dedicated controlling emission sustainability research rating index active integrating intangible valuenontraditional risk factor actively managing waste stream preventing sorting research ie environmental social governance esg recycling since ecpi provides simple versatile reliable applying greener lifecycle management principle investment tool solution integrate extrafinancial information investment process detail three year thorough reporting please refer website wwwecpigroupcom strengthening ability tool order improve accuracy december ucb represented two ecpi socially responsible index first ecpi emu ethical next step key performance indicator kpis equity index adjusted capitalizationweighted index defined seven area engagement comprised listed company within euro zone used define local global short long chosen good practice social environmental term objective ethical matter second ecpi euro ethical equity index index selecting top capitalized company csr governance european market eligible investment according ecpi sri screening methodology ecpi index used benchmarking thematic order develop manage policy investment risk management purpose create implementation process csr ucb empowered csr indextracking investment strategy exchange team created csr board csr team traded fund etf primary task managing implementing policy action network engaged ucb colleague different country csr board composed corporate knight functional head senior manager responsible ucb recently ranked global list world setting course design guideline ucbs policy sustainable company corporate knight specialized activity medium financial information product company based csr committee relevant societal toronto canada selection process began topic ucb examined selected based ucbs publicly traded company trimmed fundamental business principle core value evaluated using key environmental social governance handled close involvement main stakeholder within performance indicator finally get list vision shared ucb review process continuously sustainable company ucb ranked th position refines internal external relevance csr topic assess external impact review process equally embrace systematically lesson learned therefore everlasting change relying feedback selected category patient external stakeholder refine improve value patient planet u c b n n u l r e p rt viii c rp rat e c e ta l r e sp n b l p e r f rma n c e r e p rt materiality stakeholder dialogue materiality check performed informally listening concrete initiative engage colleague main contributor telling u significant ucbs strategic decision rise patient standpoint intention formalize ideation campaign materiality check future keeping colleague healthcare expected become personal involved also open external stakeholder forthcoming decade plenty challenge lay ensure ucb initiative bring measurable sustainable ahead although growth healthcare spending must impact patient counterbalanced efficiency saving health although formal report developed yet become individual value decision patient interact concrete example open dialogue main differently healthcare professional payer stakeholder listed considering need embrace change ucb launched first ideageneration campaign june coupling townhall meeting event newsletter power creative culturaldiverse thinking ucbs field report objective progress result csr talent prompting two simple question project shared colleague occasion concrete action ucb undertake trusted colleague emit comment question ucbs partner provides information solution patient csr project keen engage colleague ii concrete action ucb undertake gain csr initiative favor innovative initiative supported actionable insight patient rise patient sponsored colleague csr team explores way ideation campaign resulted idea posted people involve selection process project well covering country seven language implementation execution program comment building idea total vote external world wish learn ucbs casted period three week testimony csr performance action ucb welcome survey engagement commitment trust patient insight interview brings external view ucb partnership performs interaction always opportunity following initial assessment new journey board open constructive informative dialogue member evaluated idea potential strategic impact ucb focus ucb give priority feasibility three pilot project endorsed past year ucb contact several ngo explore define develop way enabling integrated care system underprivileged people living epilepsy create patient liaison role evaluating concept developing country discussion always patient liaison provide support gain actionable conducted within spirit creating launching impactful insight patient sustainable project improved health life work listen customer get comprehensive social integration patient understanding need ucb committed active partner elevate b uild improving patient healthcare professional quality life patient living severe disease relationship close network patient health care professional supplier contractor institution government beyond quality idea generated scientist partner administrator open profound impact exercise came engagement honest dialogue ucb employee carrying connectivity among colleague looking share commitment underprivileged patient build enthusiastic volunteering invaluable insight people part layer organization sometimes hard imagine connection came together focus building solution improve quality patient life u c b n n u l r e p rt viii c rp rat e c e ta l r e sp n b l p e r f rma n c e r e p rt global reporting initiative gri indicator labor practice ucb embracing difference cornerstone embrace diversity thought openness different perspective talent nurture sharing experience competency mind set ucb talent respect trust viewpoint ucbs ability create significant difference life different origin different background gender age race people living severe disease depends talent mentor change everchanging world leverage commitment people end ucb diversity superior performance ucb strives generate employed people worldwide composed opportunity active participation influence inspire nationality almost equity man woman creativity innovation respectively ucb year creating high performance organization leveraging investment talent made ucb present country total ucb past year attracting additional top scientist colleague located europe north america key leadership talent market middle asia pacific australia rest world management layer ratio external hire versus internal ucb foster diversity talent talent fully expressing promotion reflective continuous search skill creativity connectivity critical imperative future competency needed company particularly ucb engage dedicated staff execute rigorously science biotechnology sale drug safety medical affair strategy highly connected collaborative innovative importance developing retaining key talent learning way successfully implement engagement company deliver superior sustainable value patient workforce headcount gender distribution men woman workforce gender region distribution men woman uscanada uk spain italy germany france belgium eu rest world men woman u c b n n u l r e p rt viii c rp rat e c e ta l r e sp n b l p e r f rma n c e r e p rt workforce gender distribution function workforce organization distribution technical admin sale mgr executive admin marketing rd manufacturing operator support force professional sale men woman diversity shared ucb year ucb become mature biotechnology shared culture accepting diversity open aware company order successful future employee cultural intelligence ability understand colleague engagement work culture vital employee engagement way working cultural consistency commitment remains key element progress building living value strategy without boundary building brings people together ucbs dedication patient bind u leveraging diversity ucb people across leadership team made colleague world work culture demand active sharing collecting different nationality seen increasing insight patient customer physician payer participation woman compared last year dictate creative sharing knowledge expertise key v leader aged partnership expanding inspired sharing among year order connect collaborate cocreate future ucbs department continue embrace new sharing platform company putting place new innovative communication approach aimed facilitating sharing collaboration cocreation workforce age pyramid turnover evolution men woman departure recruitment full time part time u c b n n u l r e p rt viii c rp rat e c e ta l r e sp n b l p e r f rma n c e r e p rt training education new training development course training skill improvement initiative key whereas several training development course development ucb colleague prepared implemented course detailed every year ucb training community work designing leadership development program training program target personal technical development need training consists online training concept leadership pipeline introduced module well class room training onthejob refers planned transition preparing emerging leader coaching objective ensuring compliance successful performance future role ensuring achieving improved performance participation sustainable pipeline leader within organization people different responsibility new challenge goal future leader understand act opportunity growth skill behavior required grow ucb invested million continuous new position guaranteeing adopt competence development colleague training expectation transition occurs available ucb colleague four critical transition identified specific program succeeded organize efficient training program designed average number hour training per colleague individual contributor manager others close total represents hour accelerate training hour well distributed men woman respectively manager others manager manager navigate ucb strongly believe working within manager manager managing business biopharmaceutical industry requires everyone orchestrate baseline training platform ensuring patient managing business managing enterprise heart landscape gardener elevate ceo everyone leadership program blended people corporate policy training different function order maximize learning development stimulating individual growth resilience one combine currently three corporatewide policy code classroom training elearning coaching action learning conduct security drug safety compliance delivered several month order incorporate rate respectively proper learning transfer module october compliance rate expressed percentage people taken three corporate program also supporting ucbs strategy value training active internal ucb employee sense purpose end updated version code conduct colleague men woman attended one security completed training module leadership transition training introduced ucb drug discovery development training program miniinternship ucb drug discovery development training program offer colleague opportunity benefit better broader knowledge drug discovery development ucb aim program increase organization skill knowledge base training hour per employee b e important motivator influencer facilitate crossfunctional understanding collaboration training session delivered ucb colleague attending biopharma online training module seven different online training module focusing helping ucb colleague better understand biopharmaceutics created end ucb colleague taken technical admin sale mgr executive operator support force professional least one module u c b n n u l r e p rt viii c rp rat e c e ta l r e sp n b l p e r f rma n c e r e p rt talent organization review wellbeing work ucb driven performance culture annual cycle major priority ucb create positive environment smart objective setting midyear objective review company individual objective met yearend final appraisal complete ongoing performance people express talent wellbeing feedback throughout year process strives keep professional context encompasses area attention organization aligned common goal measurable safety work health employee psychosocial attainable least employee stress caused hygiene ergonomics beautification womenmen ucb population participated workplace environmental management completed cycle employee rewarded many initiative launched different site affiliate recognised individual contribution sense belgium instance initiative create company success environment working condition offer wellbeing talent organization review also designed identify work launched concrete effort regard key talent based performance ability grow communication training coaching set key outcome design implementation action nine wellbeing ambassador identified amongst plan develop retain engage also serf colleague contribute equilibrium way identify prepare successor performance wellbeing everyone encouraged business critical position ucb reviewed management ambassador committed supporting employee population identified top colleague complete confidence talent future newcomer newcomer region age bracket yearend men woman u canada rest world uk spain italy germany france belgium eu departure departure region age bracket yearend men woman u canada rest world uk spain italy germany france belgium eu u c b n n u l r e p rt viii c rp rat e c e ta l r e sp n b l p e r f rma n c e r e p rt convinced programme corresponds perfectly global lost time incident rate ltir care value ucb socially responsible company calculated incident one day absence per one million hour worked global lost time different conference program organised severity rate ltsr calculated day lost per brussels brainelalleud facility following hour worked increase ltir mainly example lecture energy nutrition quality sleep due increased number car accident ucb sophrology attended colleague employee involved working time total weight loss program attended person program repor ted lost time incident occur outside melanoma breast cancer prostate cancer screening ucb premise initiated implementation global health safety dashboard health safety including timely accident investigation reporting corrective preventative action well continued focus workrelated accident slightly increased sharing available hse knowledge competence skill number severity compared clearly enhanced accident awareness important cause lost time incident slip trip continued attention also given fall car accident contact stationary program initiated improving moving object fatal incident occupational hygiene practice research production environment safety performance severity rate safety performance incident rate lost time severity rate ltsr lost time incident rate ltir u c b n n u l r e p rt viii c rp rat e c e ta l r e sp n b l p e r f rma n c e r e p rt employee engagement ucb voice ucb voice global employee engagement survey organized second year september show positive increase staff engagement compared previous year included several question relate directly wellbeing work favorable favorable response response evolution employee engagement proud work ucb overall satisfied ucb place work would recommend ucb great place work rarely think looking new job another company wellbeing work give feeling personal accomplishment job make good use talent skill ability able manage work responsibility way allows maintain healthy balance work home immediate manager treat respect care feel part team survey response rate obtained committee significantly reinforced regular lync mean colleague call scheduled executive committee member recognized value completing survey open employee encouraged open conversation contribution action take place answered question colleague feedback colleague helped shape many mind hundred colleague connected improvement development action taking place across dedicated webcalls company companywide task force established examine example action taken followup survey opportunity implement improvement measure regard global process instill efficiency ligned commitment connect collaborate improve effectiveness several short long term cocreate objective reinforce trust goal established address identified global future interactivity ucb staff executive improvement opportunity u c b n n u l r e p rt viii c rp rat e c e ta l r e sp n b l p e r f rma n c e r e p rt society support ac action contre le spondylarthropathies france human right anticorruption ucb support ac financial grant help association develop therapeutic educationrelated code conduct call performance integrity activity core objective association outlining general principle business conduct ethic expected every ucb colleague third party assist people spondylarthropathies better support acting behalf ucb code revised personal familial socioprofessional disease change content follows encourage research fight new requirement coming u corporate integrity debilitating disease agreement cia added eg topic social represent patient health authority board medium uk antibribery act introduced health facility antitrust section c lear mention corporate societal responsibility running lupus addition ucb integrity line hotline phone following inspirational statement lupus patient run used report compliance concern brussels km run around ucb colleague decided put running shoe connect louvain gift entertainment section rewritten foundation aim participate run quite prohibit use giveaway hot day brussels ucb pledged every kilometer code encompasses critical united nation completed colleague resulting donation global compact ungc principle human right labor runner enjoyed day especially knowledge environment anticorruption supporting lupus patient objective code conduct animal welfare p rovide guidance spirit direction business practice association assessment accreditation p rovide guidance ucb expects colleague laboratory animal care international aaalac third party acting ucbs behalf ucb apply aaalac association p rovide set ethical principle help guide u assessment accreditation laboratory animal care decision making process accreditation brainelalleud research site international nonprofit association promotes responsible treatment code conduct found ucbs external laboratory animal voluntary accreditation program website governance section going beyond legal requirement accreditation represents ucb colleague management label quality high professionalism term animal care nonmanagement successfully completed use also help continuously improving scientific excellence training entailing approximately hour leading animal experimentation research total code compliance level ucb colleague last year team performed preparatory work prior accreditation process help external code also added link contract consultant assessed readiness feasibility external party ensure partner work apply accreditation also invested time spirit written code informing engaging involved colleague involvement local community animal welfare principle rs action european federation pharmaceutical industry part commitment patient association efpia report animal welfare principle understanding severe disease ucb support number rs report elucidates effort pharmaceutical program patient family taking account company ensure high standard animal welfare donation exceeding spent detail three principle replace work without million community sponsorship charitable animal possible reduce animal experimentation donation worldwide excluding product donation cannot avoided use less possible refine patientassistance program use animal respect possible animal first anniversary e keppra japan ucb subscribe animal welfare principle applying r principle instance investing effort meeting attended health care professional introduced field silico toxicology ie science predicting patient empowerment section anniversary event toxic property computational method reduce also first time japanese epilepsy advocate could number animal used framework etox address audience expert epilepsy advocate project imi ucb participates recent advance mentioned heartwarming chance seen gathering unprecedented amount data share thought epilepsy doctor others used new prediction system etoxsys present audience physician remarked attended add dimension current armamentarium many event never heard patient speaking enable decision process mentioned prof trevor think important momentous focus jones director general abpi association british patient event like pharmaceutical industry progress undoubtedly u c b n n u l r e p rt viii c rp rat e c e ta l r e sp n b l p e r f rma n c e r e p rt lead future reduction animal use safety product responsibility assessment pharmaceutical development animal ucb researcher contractor use ucb core strategy bring highest quality product experiment rodent patient living severe disease addition ucb applies strict rule delivering message public relation public authority health care professional within guideline national international regulatory authority many country ucb business law regulating activity corporation political process law set strict limit contribution review promotional scientific corporation political party candidate prohibit press communication altogether also many country act lobbying promotion sale pharmaceutical product highly presenting company position advocating regulated ucb strong commitment comply company interest government employee agency applicable law regulation industry code regulated requires public disclosure ucb employee must comply law ucb fully respect position trust healthcare professional select best treatment option although ucb reporting significant issue formal patient ucb always promotes product based policy position ucb actively connected public approved labeling policy maker regulator stakeholder patient provider advocacy organization example ucbs interaction healthcare professional focus ucb established u fully operational public providing exchanging scientific information policy department includes government relation ultimate objective enabling healthcare professional public affair federal state level u select appropriate treatment patient public policy department responsible representing interaction based standard ethic integrity company interest whole host policy issue fair market value healthcare reform implementation include protection expansion reimbursement government managed promotional press scientific communication relating subsidized healthcare along important policy compound product submitted global consideration patent protectionreform taxation local promotional scientific review committee regulation specific corporation based u total communication reviewed belgium ucb participating group rd investor shown graph order improve local business condition support federal government belgian prime drug safety minister particular ucb member local trade association generally make sense general like biopharmaceutical company ucb receives manager member board country thousand adverse event report every year concerning operates around world u ucb member drug product reviewed internally submitted bio biotechnology industry organization president governing regulatory authority safety team u member board european level ucb use various tool identify potential safety signal could also member board efpia european federation related adverse event may may pharmaceutical industry association colleague associated medicine actively participates various taskforces dealing together department safety team draw current sector issue benefitrisk management plan plan describe potential safety issue necessary action timeline required reduce potential risk patient throughout entire lifecycle medicine review communication ucb provides plan health authority part submission approval market new medicine plan also applied firstinman study regularly reviewed updated new safety data scientific medical knowledge medicine safety profile progress press scientific total promotional u c b n n u l r e p rt viii c rp rat e c e ta l r e sp n b l p e r f rma n c e r e p rt environment energy consumption new reporting tool selected developed million megajoules rolledout team corporate health safety environment corporate societal responsibility new tool allow precise proactive data management data reported validated monthly basis previously reported semester basis tested tool trained user community colleague energy compared last year global energy consumption ucb line reduction electricity fuel consumption respectively increased whilst gas consumption decreased electricity fuell oil gas although energy consumption much linked production volume manufacturing site developing energy saving plan plan resulted energy saving almost million mega joule important individual energy saving realized manufacturing plant shannon ireland water consumption elimination thermal oxidation unit million plume suppression resulted energy saving million mega joule past steam added process order suppress visible plume water water consumption m³ compared last year global water consumption ucb reduced reduction partly linked reduced level activity site monheim germany consumption water almost m³ lower waste waste management ton waste mostly generated production site compared see decrease total waste important fact ratio recovered waste waste management also keep improving waste generated ton ucb recovered ratio respectively recovery mainly organized incineration waste energy recuperation reusing waste secondary liquid fuel third party recycle solvent packaging material incinerated reused liquid solvent recycled rd party packaging recycled rd party recovered u c b n n u l r e p rt viii c rp rat e c e ta l r e sp n b l p e r f rma n c e r e p rt global reporting initiative disclosure table summarises performance indicator economic environmental social performance ucb indicator reported line gri guideline fully partially reported legend indicator fully reported compliant gri indicator definition indicator partially reported partially compliant gri indicator definition reported page general strategy analysis statement ceo letter stakeholder p organisational profile name product service p structure geographical presence market served p operating financial review p scale letter stakeholder p corporate governance p significant change size structure ownership letter stakeholder business perf review p corporate governance p award received csr performane report p report parameter report profile contact point back cover report scope assurance csr performance report p governance commitment engagement structure governance corporate governance p csr performance report p stakeholder engagement letter stakeholder p csr performance report p economic economic performance ec ß economic value generated distributed including revenue operating letter stakeholder p cost employee compensation donation community business perf review p investment retained earnings payment capital provider financial statement p governmentscore ec ß coverage organisation defined benefit plan obligation core financial statement p environmental energy en ß direct energy consumption primary energy source core csr performance report p en ß indirect energy consumption primary source core csr performance report p en ß energy saved due conservation efficiency improvement additional en initiative reduce indirect energy consumption reduction csr performance report p achieved additional u c b n n u l r e p rt viii c rp rat e c e ta l r e sp n b l p e r f rma n c e r e p rt water en ß total water withdrawal source core csr performance report p emission effluent waste en ß total direct indirect greenhouse gas emission weight core csr performance report p en emission ozonedepleting substance weight core en emission volatile organic compound chlorinated non chlorinated weight core en ß total weight waste type disposal method core csr performance report p en weight transported imported exported treated waste deemed csr performance report hazardous term basel convention annex ii iii p viii percentage transported waste shipped internationally additional social performance labor practice decent work employment la ß total workforce employment type employment contract region csr performance report core p la ß total number rate employee turnover age group gender csr performance report region core p occupational health safety la rate injury occupational disease lost day absenteeism csr performance report number workrelated fatality region core p training education la ß average hour training per year per employee employee category core csr performance report p la program skill management lifelong learning support continued employability employee assist managing career ending additional la ß percentage employee receiving regular performance career development review additional csr performance report p diversity equal opportunity la ß composition governance body breakdown employee per csr performance report category according gender age group minority group membership p indicator diversity core social performance human right investment procurement practice hr ß total hour employee training policy procedure concerning csr performance report p aspect human right relevant operation including percentage employee trained additional social performance society corruption ß percentage employee trained organization anticorruption csr performance report p policy procedure core public policy ß public policy position participation public policy development csr performance report p lobbying core social performance product responsibility marketing communication pr ß program adherence law standard voluntary code related csr performance report p marketing communication including advertising promotion sponsorship core ß h ave reviewed year kpmg assurance statement detailing work performed well comment conclusion appears page csr report u c b n n u l r e p rt viii c rp rat e c e ta l r e sp n b l p e r f rma n c e r e p rt human resource environmental data human resource data gri indicator definition unit measure la total workforce workforce december total number employee workforce male female employee number woman gender number men workforce europe belgium number employee area europe asiapacific eu australia north america belgium rest world eu siapacificaustralia north america rest world workforce full time employee fte number fte fte pte parttime employee pte group number pte la recruitment hired number employee hired departure left number employee left company turnover la absenteeism number working day lost day due absenteeism main reported reported reported site excluding u location absenteeism monitored u ltir lost time incident rate number incident resulting lost time one day within month period per million hour worked ltsr lost time severity rate number lost day resulting lost time incident within month period per thousand hour worked u c b n n u l r e p rt viii c rp rat e c e ta l r e sp n b l p e r f rma n c e r e p rt environmental data gri indicator definition unit measure en total total gas fuel oil vehicle fuel megajoules consumption gas gas consumption megajoules fuel oil fuel oil consumption megajoules fuel utilitary vehicle fuel consumption megajoules vehicle en electricity electricity consumption kwh megajoules en energy saved energy saved due conservation kwh efficiency improvement megajoules en water total water m³ main water ground surface water cod chemical oxygen demand ton effluent following internal treatment tss discharge residual total ton suspended solid internal treatment en direct indirect electricity ton co co emission gas scope fuel en od emission ozone depleting cfc equivalent substance ton en chlorinated voc emission chlorinated volatile ton organic compound nonchlorinated emission nonchlorinated ton voc volatile organic compound en waste disposal total waste ton incinerated reused liquid solvent recycled rd party packaging recycled rd party recovered method recovered en hazardous waste hazardous waste product ton defined locally applicable regulation nonhazardous solid waste excluding ton waste emission effluent u c b n n u l r e p rt viii c rp rat e c e ta l r e sp n b l p e r f rma n c e r e p rt scope reporting principle scope people data consolidated ucb company lower heating value applied default emission worldwide globally integrated financial gas reported prior year updated consolidation regardless activity research accordance new method information purpose industrial site sale affiliate headquarters co emission value natural gas reported ton instead ton corporate tool ucb learning consolidating training organised ucb followed ucb employee also accurate method applied exception two site tool place zhuhai calculation coemissions due electricity consumption china saopaolo brazil population covered site reported specific co equivalent tool represents less total population electricity mix consumed taking account growing part electricity generated renewable however compulsory training code conduct source specific ratio available given pharmacovigilance security tracked site used international energy agency iea ratio consolidated ucb employee default result see co equivalence decrease regional split defined following compared last year consumption increased eu france germany italy spain united kingdom eu austria bulgaria czech republic denmark reporting principle finland greece hungary ireland luxemburg netherlands poland portugal romania slovakia sweden order ensure uniformity reliability indicator used entity ucb group implemented global asia pacific australia australia china hongkong india reporting initiative g sustainability reporting guideline japan south korea covering social factor safety environmental impact north america united state canada company performance selfassessed c reporter according gridefined application level rest world row brazil kazakhstan mexico norway russia switzerland turkey ukraine guideline specify methodology used indicator reporting ucb health safety data occupational accident addressed whole ucb employee population excluding affiliate less employee accuracy planet data consolidated ucb corporate health safety environment hse department corporate societal responsibility manufacturing site research site csr team responsible ensuring data sale affiliate china india italy japan mexico u consolidated basis information provided manufacturing research site sale affiliate headquarters belgium administrative headquarters throughout world scope cover ucbs workforce compared hse coordinator perform initial validation safety last year environmental data prior consolidation element state whether ucbs level corporate hse csr also verify data consistency reporting cover requirement fully partially consolidation validation include data comparison previous year well careful analysis significant observation made data validation discrepancy consolidation social data regarding workforce extracted global atlanta monheim rented facility third hr system used management control database party separate meter installed yet ucb worldwide consequence utility consumption overestimated impact overestimation cannot reliably measured reliability braine diesel utilitary vehicle reported order obtain external review data reliability within fuel consumption stored tank thoroughness reporting procedure asked difficult estimate precisely consumption kpmg perform specific verification certain social hse related utilitary vehicle indicator appearing table page assurance statement describing work performed well accurate method applied comment conclusion appears page calculation direct coemissions natural gas consumption however detailed information ucb continue enhance reliability data heating value reported consumption strenghten reporting process u c b n n u l r e p rt viii c rp rat e c e ta l r e sp n b l p e r f rma n c e r e p rt assurance report u c b n n u l r e p rt viii c rp rat e c e ta l r e sp n b l p e r f rma n c e r e p rt assurance report u c b n n u l r e p rt viii c rp rat e c e ta l r e sp n b l p e r f rma n c e r e p rt assurance report u c b n n u l r e p rt viii c rp rat e c e ta l r e sp n b l p e r f rma n c e r e p rt financial calendar april annual general meeting april interim report july halfyear financial result october interim report forwardlooking statement annual report contains forwardlooking statement including without limitation statement containing word belief anticipates expects intends plan seek estimate may continue similar expression forwardlooking statement involve known unknown risk uncertainty factor might cause actual result financial condition performance achievement ucb industry result materially different future result performance achievement expressed implied forwardlooking statement given uncertainty public cautioned place undue reliance forwardlooking statement forward looking statement made date annual report ucb expressly disclaims obligation update forwardlooking statement annual report reflect change expectation regard thereto change event condition circumstance statement based unless statement required pursuant applicable law regulation official report language pursuant belgian law ucb required prepare annual report french dutch ucb also made report available english event difference translation interpretation french version shall prevail availability annual report annual report available website ucb wwwucbcom information website ucb website form part annual report contact investor relation communication corporate societal responsibility antje witte france nivelle isabelle de cambry vp investor relation vp global communication head corporate societal responsibility tel change support tel email antjewitteucbcom tel email csrucbcom email francenivelleucbcom ucb sa design stargraphic allée de la recherche brussels belgium tel fax copyright ucb wwwucbcom photographyves fonck